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The management of most chronic diseases involves a combination of both 
pharmacological and non-pharmacological interventions [1,2]. Pharmacological 
interventions primarily focus on symptom reduction and may have significant side 
effects [3-5]. Non-pharmacological care provided by health professionals such as 
physiotherapists, occupational therapists, nurses, dieticians, podiatrists, psychologists, 
social workers support patients in coping with the consequences of their disease 
and help them to play an active role in the management of their disease. Non-
pharmacological treatment is considered to be a cornerstone in the management of 
many chronic diseases [1]. 
Systemic sclerosis (SSc, or scleroderma) is a chronic rheumatic disease with serious 
consequences in many patients that, in addition to pharmacological treatments, 
require non-pharmacological treatment. The potential importance of psychosocial 
and rehabilitation interventions in the disease management of SSc was emphasised 
by the authors of the European League against Rheumatism (EULAR) and the EULAR 
Scleroderma Trials and Research group (EUSTAR) [6], but the authors of these guidelines 
stated that there was insufficient evidence and a lack of expert consensus for or against 
non-pharmacological interventions for SSc. Indeed, the knowledge about treatment 
targets for non-pharmacological care, the content of care provided in clinical practice, 
and the effectiveness of non-pharmacological care in SSc is limited. The studies in this 
thesis aims at gaining more insight into non-pharmacological care delivered in clinical 
practice to patients with SSc.
SySTEmiC SClErOSiS
Systemic sclerosis is a rare, complex, and chronic connective tissue disease characterised 
by fibrosis of the skin due to increased collagen deposition [7]. In addition to the skin, 
fibrosis can also affect internal organs leading to damage and dysfunction of the lungs, 
heart, kidneys, and gastrointestinal tract. Raynaud’s phenomenon is usually the earliest 
clinical manifestation of SSc, and is reported in 95% of patients. The pathogenesis of 
SSc is complex and poorly understood, but the disease is thought to be caused by an 
interplay between vascular damage and immune dysregulation. 
Due to the heterogeneity of clinical manifestations and prognosis [8], two subtypes 
are widely used to classify patients with SSc based on the degree and location of skin 
involvement; limited cutaneous SSc with skin thickening of distal extremities and/or 
face and diffuse cutaneous SSc with skin thickening of proximal extremities and/or 
trunk. The diffuse subcutaneous subtype is associated with an increased risk of internal 
organ damage [9].
Systemic sclerosis is a relatively rare disease. The prevalence in the Netherlands 
is estimated to be 8.9 per 100,000 adults and the incidence estimated to be 0.77 
patients per 100,000 per year [10], indicating that there are approximately 1500 
patients with SSc in the Netherlands. Systemic sclerosis has a major impact on health 
related quality of life in the majority of patients [11], and far-reaching consequences to 
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perform everyday activities. Compared with other rheumatic diseases, SSc has one of 
the highest mortality rates, with a median survival time from diagnosis of 11 years [12]. 
Involvement of the lungs, both pulmonary fibrosis and pulmonary arterial hypertension, 
are the main causes of SSc-related deaths [13,14].
The majority of patients with SSc are middle-aged women. The onset of SSc is the 
highest between the ages of 30 - 50 years, and the prevalence in females is five times 
higher than in men [12].
CONSEquENCES Of SySTEmiC SClErOSiS
To describe and understand the consequences of SSc, the International Classification 
of Functioning, Disability and Health (ICF) is a useful and widely accepted model 
[15]. As is displayed in Figure 1, the ICF consists of the following categories: (1) body 
functions which are physiological and psychological functions of the body; (2) body 
structures which are anatomic parts of the body; (3) activities that refer to individual 
tasks or actions; (4) participation that refers to societal involvement; (5) environmental 
factors which are factors that are not within the person’s control, such as climate, access 
to care, etc.; and (6) personal factors (e.g. gender, race, age, educational level). The 
ICF categories that are addressed in this thesis are body functions, body structures, 
activities, and environmental factors (health care use).
Body functions and structures - impairments and impact
As a consequence of the complexity of the disease, patients with SSc report impairments 
in their physical as well as mental health related quality of life [11, 16]. Fatigue is the most 
frequently reported symptom in patients with SSc, but commonly overlooked by health 
Systemic sclerosis 
Body functions and 
body structures 
Activity Participation 
Environmental 
factors Personal factors 
Figure 1: Health status in systemic sclerosis according to the International Classification of Functioning, Disability and Health (ICF). 
figure 1. Health status in systemic sclerosis according to the International Classification of Functioning, 
Disability and Health (ICF).
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care providers and researchers [17]. Amongst 464 Canadian patients with SSc, fatigue 
was the most frequently reported symptom that was experienced by 89% of patients 
at least some of the time in the past year, and it had a moderate to severe impact on 
daily activities in 72% of the patients [18]. Similarly, 92% out of 123 Dutch patients with 
SSc rated fatigue as the most bothersome symptom [19]. Increased work disability [20], 
poorer sleep quality, greater pain, more depressive symptoms, and decreased physical 
functioning have been found to be associated with fatigue [17]. In a longitudinal cohort 
study including 256 SSc patients, levels of fatigue fluctuated in some individuals but 
the overall cohort did not show change during a mean follow-up period of 3.8 years 
[21]. Levels of fatigue in SSc were similar to fatigue experienced by cancer patients in 
active treatment, and higher compared to cancer patients in remission [22].
The range of problems that patients with SSc face, apart from fatigue, is quite 
extensive. A Canadian study with 464 patients assessed the frequency and impact of 
69 SSc related problems and showed that fatigue, Raynaud’s phenomenon, stiffness of 
hands, joint pain, and difficulty sleeping, were the five highest rated symptoms in terms 
of frequency [18]. These symptoms also affected the performance of daily activities. 
In addition to these mainly physical problems, patients with SSc often experience 
psychological problems such as depressive symptoms, anxiety, uncertainty about 
future outcomes, and concerns with physical appearance [16,19,23,24]. Due to the 
broad range of symptoms that patients with SSc experience and their impact on daily 
life, the disease has a high clinical burden [23].
Activities
Reduced ability to perform daily activities is common in patients with SSc [25], and more 
prevalent than activity limitations reported by patients with other chronic rheumatic 
conditions such as osteoarthritis [26]. Activity limitations in patients with SSc were most 
often identified in the following components of the Health Assessment Questionnaire- 
Disability Index (HAQ-DI): dressing, eating, hygiene, grip, and reach [25]. Furthermore, 
strong evidence has been found that limitations in activities increase over time; 
however, the course of activity limitations varies considerably across individuals [27]. 
Female sex, older age, the diffuse cutaneous subtype, higher skin score, poorer hand 
mobility, tendon rubs, joint involvement, breathing problems, and muscle involvement 
have been associated with the severity of limitations in activities [25,27,28]. The most 
important contributor to overall disability in SSc is reported to be limitations in hand 
function [28-30].
societal participation
The ICF defines participation as a person’s involvement in a life situation, such as 
interpersonal relations/interactions, major life areas, and community/ social/ civic 
life [15]. Participation is decreased in patients with SSc, including participation in 
domestic chores, household maintenance, services to others, and social activities. 
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Reduced participation is associated with higher disability, depression, and severity of 
disease symptoms such as Raynaud’s phenomenon, ulcers, fatigue, and gastrointestinal 
involvement [31]. Participation restrictions related to work status are well documented 
in a recent systematic review that shows that work disability is substantial in SSc and 
is associated with more functional disability, more disease-specific symptoms, and 
decreased quality of life. In addition, inconsistent results were found regarding other 
predictors of work disability, such as education level, other demographic and job 
characteristics, and disease duration [32].
Environmental factors – health care usage
Studies in Canada and Hungary showed that with respect to medical consultations, 
the rheumatologist (70-90%) and the general practitioner (80%) were contacted 
most frequently by patients with SSc [33-35]. Other medical specialists, such as 
pulmonologists (40 - 67%), gastroenterologists (32- 54%), cardiologists (22 - 51%), 
dermatologists (33 - 42%), and nephrologists (6 - 13%) were frequently involved in the 
care of patients with SSc as well. Higher physician service use in SSc was associated 
with a higher income, more skin involvement, more comorbidities, and lower physical 
health status [33]. It is unclear to what extent occupational therapists, nurses, dieticians, 
podiatrists, social workers, and psychologists are involved in the care for patients with 
SSc. In contrast, it is known that a considerable proportion of patients with SSc (31-61%) 
yearly contact a physiotherapist [34,35]. This is probably the reason that research about 
non-pharmacological health care use is mainly restricted to the use of physiotherapy.
ThE NON-pharmaCOlOgiCal maNagEmENT Of 
SySTEmiC SClErOSiS
Describing non-pharmacological care 
In this thesis, we aim to describe the non-pharmacological care in SSc. For this purpose, 
the Scandinavian Team Arthritis Register-European Team Initiative for Care Research 
(STAR-ETIC) framework was used (Figure 2) [36]. This theoretical framework provides 
a common structure to describe the content of rehabilitation, in particular arthritis 
rehabilitation, and facilitate comparing, transferring, and implementing research 
evidence into clinical practice. The STAR-ETIC framework is based on Donabedian’s 
healthcare model that defines quality of care [37], the ICF [15], and the rehabilitation 
model by Wade [38,39]. It defines four domains of health care: context, structure, 
process, and outcome. Key elements of the domains structure, process, and outcome 
are addressed in this thesis.
Structure
The composition of the rehabilitation team and patient involvement are the elements we 
focus on regarding the structure domain. Given the complexity of SSc, multidisciplinary 
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treatment is often required and involves a wide range of medical specialists and 
health professionals [33-35]. Health professionals provide support and can play an 
important role in care provision. It is a challenge to integrate a patient’s care among 
multiple independent care providers. Health professionals need to be available 
and establish a shared basis of knowledge and common goals in the treatment of 
a patient. Care delivered by multiple care providers must be aligned to prevent the 
occurrence of inconsistent treatment plans, wasteful duplication of diagnostic testing, 
and contradictory advices [40,41]. In this thesis, we assessed the extent of health care 
utilisation among people with SSc and patients’ perceptions on the quality of the 
delivered care such as communication among health care providers.
Furthermore, it is important that patients’ needs are well aligned with the provided 
care. Patient-centred health care is a useful concept to ensure that patients’ needs 
and preferences are at the centre of all aspects of health care. Previous studies found, 
however, that unmet health care and information needs are common among patients 
with SSc, suggesting that patients were not completely satisfied with the current 
care provided [42-44]. Therefore, a comprehensive evaluation of the prevalence of 
experienced symptoms, their impact on daily functioning and their course is necessary 
to select and prioritize interventions targeting those symptoms and problems that are 
important to patients.
Process
The health care process comprises a description of the content of referrals, targets of 
treatment, and interventions. These elements need to be properly aligned with one 
another in order to provide high quality care. In SSc it is especially important to set 
and prioritize treatment goals considering the broad range of symptoms that patients 
with SSc can experience. A wide variety of non-pharmacological treatment options in 
SSc is available to relieve symptoms that patients with SSc experience. For instance, 
paraffin wax, range of motion and stretching exercises, joint manipulation, splints, and 
connective tissue massage are being used to target hand function problems in patients 
with SSc [45]. However, to date, it is still unclear how non-pharmacological care for 
patients with SSc is organised in clinical practice in terms of content of referrals, targets 
of treatment established by health professionals, and the content of interventions. 
Knowledge about the current state of the provided non-pharmacological care in clinical 
practice can provide starting points to improve and optimize the quality of care in SSc 
in the future.
Outcome
Outcome refers to changes, both desirable and undesirable, in patients that 
can be attributed to health care. Research regarding the effectiveness of non-
pharmacological interventions in SSc is scarce, despite the increasing awareness 
concerning the need to use psychometrically valid outcome measures and rigorously 
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test the effectiveness of non-pharmacological interventions in SSc [46]. An overview 
of the effectiveness of non-pharmacological interventions in patients with SSc helps 
to identify the current level of evidence for or against these types of interventions, 
and may guide future research.
To assess patients’ health, well-being, and response to treatment based on 
patient perspectives, health related patient-reported outcome (HR-PRO) measures 
are often used. In addition to validity, reliability, sensitivity to treatment effects, the 
cross-language measurement equivalence in the target population is an important 
psychometric feature of HR-PROs. Cross-language measurement equivalence means 
that patients across language groups with similar levels of a certain concept, for instance 
fatigue, will have similar scores on the measure and respond similarly to individual items 
of the measure. It is important to know whether results from measures administered 
in different linguistic or cultural settings can validly be pooled so that results are not 
influenced by linguistic or cultural differences. This is especially important for SSc, for 
which high-quality research with sufficient sample sizes often requires international 
and multicentre research, including the pooling of outcomes that are obtained across 
nations and languages [47,48].
National 
context: 
 
• Welfare-  
  and health 
  care system 
Structure: 
 
• Criteria for admission  
  and discharge 
• Funding 
• Clinical setting 
• Rehabilitation team 
• Rehabilitation  
  management 
• Patient involvement 
• Family involvement 
• Length of team care 
  rehabilitation 
 •Follow-up 
Process: 
 
• Goals 
• Interventions 
• Assessment and 
  evaluation 
 
Outcome: 
 
• Body functions (ICF) 
• Activity (ICF) 
• Participation (ICF) 
• Health related quality of  
  life 
• Self management skills 
• Goal attainment 
• Patient satisfaction 
• Harms/ adverse effects 
• Cost 
Figure 2: The STAR-ETIC framework. 
STAR-ETIC: The Scandinavian Team Arthritis Register-European Team Initiative for Care Research.  ICF: International Classification of 
Function, Disability and Health.  figure 2. The STAR-ETIC framework. STAR-ETIC: The Scandinavian Team Arthritis Register-European 
Team Initiative for Care Research. ICF: International Classification of Function, Disability and Health.
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aimS aNd OuTliNE Of ThiS ThESiS
In sum, before guidelines regarding the non-pharmacological care in SSc can be 
developed, the consequences of SSc that require non-pharmacological care and the 
extent to which health professionals are involved in the care for patients with SSc must be 
assessed. Furthermore, it is important to know which non-pharmacological interventions 
are provided and which symptoms are addressed by health professionals in clinical 
practice to treat patients with SSc. In addition to the provided non-pharmacological 
care, it must be determined whether there is sufficient evidence for the effectiveness of 
non-pharmacological interventions in SSc. Therefore, the main objective of this thesis 
is to gain more insight into the management of non-pharmacological care in SSc to 
provide recommendations for future research and clinical practice, a first step towards 
optimising non-pharmacological care in SSc.
Chapter 2, provides insight into patients’ needs in terms of highly prevalent and 
debilitating symptoms of SSc that health care providers should target in the treatment 
of patients with SSc. The frequency of 40 SSc symptoms and the impact on everyday 
activities is assessed and compared among patients from France, the Netherlands, 
Spain, Switzerland, and the United Kingdom.
The cross-language measurement equivalence of the English, French, and Dutch 
versions of the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) 
is assessed in patients with SSc in Chapter 3.
In Chapter 4, a longitudinal observational study examines the progression of 
physical functioning measured with the HAQ-DI and fatigue measured with the SF-36 
vitality scale over three years. Homogeneous subgroups with distinct trajectories of 
disability and fatigue over time are identified in patients with SSc and the characteristics 
of these subgroups are described.
Chapter 5 is a cross-sectional study that examines health care utilisation in Dutch 
patients with SSc and its association with demographic characteristics and health 
related quality of life. Patients’ perspectives on quality of care and the association 
between quality of care and health care use is also explored.
In Chapter 6, a survey is conducted to provide an initial description of the non-
pharmacological care provided by European health professionals in clinical practice 
to treat patients with SSc including referrals, treatment targets, and interventions. 
Considering the substantial involvement of multiple health professionals in the care 
for patients with SSc, it is remarkable that it is still unclear what types of interventions 
patients with SSc receive in clinical practice.
The evidence regarding the effectiveness of non-pharmacological interventions in 
SSc is systematically reviewed in Chapter 7.
Finally in Chapter 8, the main results of the present thesis are summarized, and 
recommendations and directions for future research and clinical practice are discussed.
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aBSTraCT
Objective
Knowledge about the nature and impact of symptoms faced by patients with systemic 
sclerosis (SSc) is needed to identify targets for research and treatment. The aim of this 
study was to assess and compare the frequency and impact on everyday activities of 
SSc symptoms among patients from five European countries.
Methods
European patients with SSc were invited through announcements by patient associations 
to complete an online survey. The survey included items assessing the frequency of 
40 SSc symptoms and the impact on daily activities, if present. Chi-square tests were 
utilized to assess the differences in frequency and impact of symptoms across countries.
Results
In total, 537 patients were included from France (n=111), the Netherlands (n=229), Spain 
(n=61), Switzerland (n=50), and the United Kingdom (n=86). Symptoms experienced 
by ≥ 70% of patients in all countries were fatigue, Raynaud’s phenomenon, joint pain, 
and muscle pain. Twenty symptoms were experienced by ≥ 50% of patients in all 
countries. Thirty symptoms had an impact on daily activities in ≥ 50% of patients 
who reported that the symptom was present in all countries. There were significant 
differences among countries in the prevalence of 17 out of 40 symptoms. Furthermore, 
in 24 out of 40 symptoms significant differences in the proportion of patients reporting 
impact of a specific symptom on everyday activities were observed.
Conclusion
European patients with SSc experience a broad range of symptoms that have an 
impact on everyday activities. International research initiatives should target common 
SSc symptoms cooperatively. Further research is needed to better understand the 
differences in SSc symptoms among countries.
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iNTrOduCTiON
Systemic sclerosis (SSc, or scleroderma) is a rare, clinically heterogeneous, autoimmune 
connective tissue disease. The disease is characterized by thickening and fibrosis of the 
skin, fibrosis of internal organs, and vascular damage [1]. SSc has an important impact 
on physical functioning and health-related quality of life [2-16].
Several studies have used qualitative or survey methods to identify the most 
frequently experienced and impactful physical and emotional symptoms in patients 
with SSc, including pain, fatigue, functional limitations, stiffness of joints, concerns with 
physical appearance, and uncertainty about future outcomes [17-19]. These studies 
generally assessed only a relatively narrow range of potential problems, even though 
SSc is a highly heterogeneous disease with a wide range of potentially problematic 
symptoms that vary across patients [20].
Only two studies have examined a broader range of symptoms and their impact 
on daily functioning [3,21]. A Canadian study, in which 464 SSc patients participated, 
assessed the frequency and impact on daily activities of 69 possible symptoms of 
SSc and showed that fatigue, Raynaud’s phenomenon, stiffness of hands, joint pain, 
and difficulty sleeping were the most frequently present symptoms, and that these 
symptoms impacted the ability to carry out everyday activities in the vast majority of 
patients [3]. The authors also identified symptoms that had an important role in patients’ 
daily lives, but that have been overlooked in research, including, for instance, sleep 
problems. Among 128 Brazilian SSc patients, using the same survey as the Canadian 
study, the five most commonly reported symptoms were joint pain, skin tightening, 
heartburn, difficulty concentrating, and difficulty with memory [21].
No studies have examined the frequency and impact of a broad range of SSc 
symptoms in Europe. Patient-oriented research that involves international collaboration, 
however, depends on understanding the frequency and impact of problems faced by 
patients with SSc in order to prioritize problems for future research and intervention. 
Geographic and national differences in disease severity and manifestation have been 
reported [22], but the frequency and impact of problems faced by patients have not 
been compared across countries. 
The aim of this study was to describe similarities and differences in prevalence 
of symptoms and their impact on everyday activities among patients with SSc from 
five European countries: France, the Netherlands, Spain, Switzerland, and the United 
Kingdom (UK).
paTiENTS aNd mEThOdS
Patients and procedure
An anonymous survey was distributed through patient organizations in 16 European 
countries (Belgium, Cyprus, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, 
the Netherlands, Norway, Poland, Portugal, Spain, Switzerland, and the UK). The current 
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study included data from the five countries with at least 50 respondents (France, the 
Netherlands, Spain, Switzerland, and the UK). Data were collected between December 
2010 and November 2011. Two different methods were used for the recruitment of 
SSc patients. In the Netherlands, the Dutch organization for patients with systemic 
autoimmune diseases (Nationale Vereniging voor Lupus, APS, Sclerodermie en MCTD; 
NVLE) mailed members with SSc an invitation to complete the survey. Patients in 
the other European countries were invited to participate through the Federation of 
European Scleroderma Associations and national scleroderma associations, which 
advertised the survey on their websites, in their newsletters and via information 
e-mailed to their members. The survey was administered via the internet in all countries, 
and patients in the Netherlands and Switzerland also had the opportunity to receive 
a paper version on request.
To be included in the current study, survey respondents had to be 18 years or older 
and diagnosed with SSc by a physician (self-report). Possible duplicate surveys, based 
on matching demographic data, were removed, and patients who did not complete 
≥ 10% of the survey items on symptom frequency and impact (8 of 80 items) were 
excluded.
Patients did not provide signed informed consent due to the anonymous nature of 
the survey. Ethical approval was obtained from the local medical ethics board of the 
Radboud University Medical Center for the Dutch part of the study (CMO 2011/203), and 
from the ethics committee of the Centre for Research in Psychology at the University 
of Minho in Portugal for the other European countries.
Questionnaire
The English and French versions of the Canadian Scleroderma Patient Survey of Health 
Concerns and Research Priorities [3] were provided by the Canadian research group. 
The survey was translated into Spanish, German, and Dutch by qualified translators. For 
each translation, patient representatives from the given country reviewed the survey to 
ensure that items were understandable, unambiguous, and acceptable.
Demographic variables included sex, age, education, marital status, current 
employment status, self-reported disease subtype and time since diagnosis. Of the 
69 symptoms included in the Canadian survey [3], the 30 most frequently experienced 
symptoms and the 30 symptoms with the highest impact in that study were included 
in the European survey (33 items), as well as 7 additional items (persistent coughing, 
dilated face vessels, nausea, medication side effects, difficulty opening mouth, open 
sores, weight loss). Patients rated each symptom on frequency, “How frequently have 
you experienced (insert symptom) in the past year?”  with the response options never, 
rarely, sometimes, most of the time, always. If a symptom was at least rarely present, 
the impact on daily activities was assessed: “Please specify the degree of impact that 
(insert symptom) has had on your ability to carry out everyday activities in the past year.” 
with the response options no impact, minimal, moderate, severe, extremely severe.
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statistical analysis
Differences in demographic and disease characteristics across countries were assessed 
using the chi-square statistic for categorical variables and the Kruskal-Wallis test for 
continuous variables.
Symptom frequency and impact were recoded into dichotomous variables, with 
‘never or rarely’ versus ‘sometimes, most of the time, or always’ for frequency and 
‘no impact or minimal impact’ versus ‘moderate, severe, or extremely severe impact’ 
for impact [3]. The proportion of patients reporting that a symptom was present was 
calculated, as well as the proportion of patients reporting an impact on everyday 
activities (only for those patients reporting the given symptom was present). Responses 
on the items for vaginal dryness and erectile dysfunction were included only from 
women and men, respectively.
We used the chi-square statistic to assess possible differences in frequency and 
impact across countries for each symptom. We used α = 0.05 and the Benjamini-
Hochberg method to adjust for multiple tests since there were 40 frequency analyses 
and 40 impact analyses. We did not conduct post-hoc tests within symptoms to 
attempt to identify specific differences between countries, given the number of 
potential tests this would involve, beyond the 80 tests already conducted. As a 
sensitivity-analysis to examine the robustness of the differences in frequency and 
impact of symptoms, differences in median scores were also assessed with the 
Kruskal-Wallis test, similarly adjusting with the Benjamini-Hochberg method. Finally, 
we tested for differences across countries in the median number of symptoms and 
the median number of symptoms with an impact per patient using the Kruskal-Wallis 
test. All statistical analyses were conducted using Stata/IC 10.1 software (StataCorp 
LP, College Station, TX).
rESulTS
sample characteristics
In total, 537 European patients with SSc were included, from France (n = 111), the 
Netherlands (n = 229), Spain (n = 61), Switzerland (n = 50), and the UK (n = 86). 
Demographics and disease characteristics for each country are displayed in Table 1. 
In total, 68 men and 469 women were included, with a median age of 57 (interquartile 
range [IQR] = 48-64) years. About half of the respondents completed more than 
12 years of education, and approximately 70% were married or living as married. The 
majority of the patients (55%) had limited SSc, 36% had diffuse SSc, and 9% did not 
know their disease subtype. The mean time since diagnosis was 8 (IQR = 4-14) years.
There were some notable differences in sample characteristics between countries. 
The percentage of female participants was highest in France (96%) and lowest in Spain 
(80%). Patients in the Netherlands were the oldest (median age = 60, IQR = 51-66 years) 
and least likely to be employed (21%), whereas patients in Spain were the youngest 
25
2FR
E
Q
U
E
N
C
Y
 A
N
D
 IM
PA
C
T O
F SSC
 SY
M
P
TO
M
S
Table 1. Demographics and disease characteristics of 537 patients with systemic sclerosis per country.
Characteristics
France 
(n = 111)
Netherlands 
(n = 229)
spain 
(n = 61)
switzerland 
(n = 50)
uK  
(n = 86)
Female, %* 96.4 83.8 80.3 88.0 89.5
Age, years; median (IQR)* 55 (45-62) 60 (51-66) 49 (43-56) 56.5 (49-67) 57.5 (48-63)
> 12 years education, %* 53.8 46.3 62.3 38.0 34.9
Living with partner, % 67.3 72.6 65.6 64.0 72.1
Paid employment, % * 33.6 20.7 52.5 42.0 37.2
Disease subtype, %*
   Limited 52.3 63.8 52.4 30.0 54.7
   Diffuse 35.1 32.3 27.9 62.0 37.2
   Subtype unknown 12.6 3.9 19.7 8.0 8.1
Time since diagnosis, years; median (IQR)* 8 (4-15) 9 (4-15) 8 (3-13) 5 (3-11) 6 (3-12)
Number of symptoms, median (IQR)* 24 (18-29) 22 (18-27) 18 (13-25) 21 (16-29) 26 (19-31)
Number of symptoms with impact if 
present, median (IQR)*
20 (12-23)a 14 (8-18)b 14 (11-21)c 14 (9-21)d 18 (11-26)e
UK = United Kingdom; IQr = interquartile range; * p < 0.05; a n = 102; b n = 225; c n = 35; d n = 30; e n = 78
(median age = 49, IQR = 43-56 years) and most likely to report paid employment (53%). 
The median time since diagnosis ranged from 5 (IQR = 3-11) years in Switzerland to 9 
(IQR = 4-15) years in the Netherlands. Overall, approximately half of the patients were 
diagnosed with limited SSc and one-third of the patients with diffuse SSc, except 
in Switzerland where 30% reported having limited SSc and 62% diffuse SSc. The 
proportion of patients with more than 12 years of education ranged from 35% in the 
UK to 62% in Spain.
Comparisons among countries
Frequency
The percentages of patients in each country who experienced each symptom are 
shown in Table 2 (detailed country-level results in Appendices 1-5). The symptoms 
fatigue, Raynaud’s phenomenon, joint pain, and muscle pain were experienced by 
≥ 70% of the patients in each country. In the five countries, each of the 40 symptoms was 
experienced by at least 22% of the patients and 20 of 40 symptoms were experienced 
by at least half of the patients in all countries.
Statistically significant differences across countries were found for 17 of the 
40 symptoms. Of these 17 symptoms there were very large differences (>30%) in 
reported symptoms between countries for persistent coughing (37% in the Netherlands 
vs. 76% in Spain), skin color change (40% in Switzerland vs. 78% in Spain), difficulty 
making a fist (41% in Spain vs. 76% in the UK), difficulty holding objects (51% in Spain 
vs. 85% in the UK), and stiffness of hands (59% in Spain vs. 91% in the UK). When 
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Table 2. Frequency of 40 symptoms experienced by patients with systemic sclerosis in Europe (n=537).
symptoms¹
France
(n = 111)
%
Netherlands
(n = 229)
%
spain
(n = 61)
%
switzerland
(n = 50)
%
uK
(n = 86)
%
Fatigue* 96 95 76 85 93
Raynaud’s phenomenon 85 90 84 83 98
Joint pain 84 80 81 83 92
Stiffness of hands* 76 83 59 73 91
Muscle pain 74 70 76 79 86
Skin tightening 68 75 73 79 79
Erectile dysfunction 75 75 50 100 100
Difficulty sleeping 76 69 71 80 84
Shortness of breath* 73 65 86 84 76
Tender joints* 77 71 49 69 79
Difficulty holding objects* 70 72 51 63 85
Dry mouth 74 69 55 69 79
Difficulty climbing stairs 69 68 62 73 68
Heartburn* 71 59 73 74 76
Difficulty making fist* 63 67 41 49 76
Difficulty concentrating* 61 55 75 77 75
Dry eyes 62 62 53 66 67
Difficulty walking 56 61 60 66 63
Skin color change* 55 59 78 40 73
Vaginal dryness 68 53 62 76 58
Difficulty swallowing* 53 56 56 77 70
Dilated hand vessels* 66 55 49 44 74
Difficulty remembering* 59 49 62 79 70
Swollen joints* 68 48 70 57 65
Itching* 61 48 70 69 67
Diarrhoea 54 56 53 60 67
Numbness 60 52 69 63 54
Skin pain 53 58 45 53 58
Difficulty opening hand 54 51 40 41 60
Constipation* 52 42 54 65 64
Difficulty in/out car 42 51 49 61 59
Persistent coughing* 49 37 76 73 45
Nausea 44 46 34 55 47
Dilated face vessels 49 42 45 24 48
Side effects 49 41 43 41 41
Difficulty opening mouth 39 44 40 39 44
Difficulty dressing* 41 32 56 41 55
Finger ulcers 36 37 56 50 37
Open sores 22 31 40 39 35
Weight loss 26 28 31 37 25
¹Symptoms are ordered in the table by the overall frequency among all patients from the five countries; 
UK = United Kingdom; * p < 0.05 for differences in proportion of patients among countries based on chi-
square test with Benjamini-hochberg correction
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ordinal item data were compared across countries, there were differences in Raynaud’s 
phenomenon, dry mouth, dilated face vessels, difficulty with sleeping, difficulty fully 
opening the hand, and erectile dysfunction, in addition to the 17 items identified via 
analysis of dichotomous data. 
Impact
As shown in Table 3 (see also Appendices 1-5 for detailed country-level results), in 
each country all 40 symptoms, when present, had an impact on daily functioning for ≥ 
20% of the patients and 30 out of 40 symptoms had an impact ≥ 50% of patients in all 
countries. Difficulty walking, swollen joints, joint pain, difficulty holding objects, and 
muscle pain impacted daily functioning for ≥ 70% of the patients in all countries. In 
addition, symptoms related to decreased hand function, including difficulty opening 
hand (66%-89%), difficulty making a fist (65%-94%), stiffness of hands (63%-96%), and 
Raynaud’s phenomenon (62%-91%) impacted the ability to carry out everyday activities 
in the majority of patients.
Statistically significant differences among countries in the proportion of patients 
who reported an impact on everyday activities once a symptom was present were 
found in 24 out of 40 symptoms (Table 3). Of these 24 symptoms, symptoms with 
at least 25 respondents with differences of > 30% between countries included 
itching (25% in the Netherlands vs. 87% in Spain), dilated hand vessels (39% in 
the Netherlands vs. 85% in France), finger ulcers (46% in France vs. 97% in the 
UK), constipation (47% in the Netherlands vs. 81% in France), dry eyes (50% in the 
Netherlands vs. 84% in France), heartburn (52% in the Netherlands vs. 97% in Spain), 
difficulty getting in/out a car (52% in Switzerland vs. 87% in France), stiffness of hands 
(63% in Switzerland vs. 96% in Spain), and fatigue (63% in Switzerland vs. 94% in 
France). When ordinal item data were compared across countries, there were also 
differences in weight loss, difficulty opening the mouth, dry mouth, and difficulty 
swallowing. However, there were eight symptoms (stiffness of hands, joint pain, 
difficulty sleeping, Raynaud’s phenomenon, tender joints, difficulty opening the 
hand, difficulty climbing stairs, vaginal dryness) not significantly different compared 
to the analysis of dichotomous data.
Number of symptoms
The median number of symptoms experienced in the past year differed significantly 
across countries (χ2 (4) = 28.5, p < 0.05), and ranged from 18 in Spain to 26 in the UK 
(Table 1). The median number of symptoms with an impact on the ability to carry out 
everyday activities in the past year also differed significantly across countries (χ2 (4) = 
23.3, p < 0.05), and ranged from 14 in the Netherlands, Spain, and Switzerland to 20 
in France.
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Table 3. Impact on everyday activities of 40 systemic sclerosis symptoms if present.
symptoms¹
France
%
Netherlands
%
spain
%
switzerland
%
uK
%
Difficulty walking 92 83 96 79 84
Fatigue* 94 84 76 63 92
Swollen joints* 96 74 83 81 85
Finger ulcers* 46 86 96 76† 97
Stiffness of hands* 94 82 96 63 75
Joint pain* 95 74 85 80 81
Raynaud’s phenomenon* 91 79 78 62 78
Difficulty holding objects 89 76 87† 74 75
Muscle pain* 91 70 94 71 78
Difficulty climbing stairs* 88 73 86 63 78
Difficulty sleeping* 89 70 81 62 81
Difficulty opening hand* 89 66 83† 83† 80
Difficulty making fist* 94 65 94† 67† 81
Open sores* 96† 70 55† 57† 90
Erectile dysfunction 67† 67† 83† 100† 89†
Tender joints* 88 66 81† 70 75
Side effects 87 65 77† 80† 71
Skin tightening* 85 63 81 63 83
Shortness of breath NA 76 55 71† 69
Difficulty concentrating 85 66 64 64 70
Heartburn* 87 52 97 73 67
Difficulty swallowing 79 65 72† 53 73
Difficulty dressing 76 67 75† 71† 56
Skin pain 73 60 89† 65† 73
Diarrhoea* 86 56 64† 52† 77
Vaginal dryness* 83 58 62† 61† 65
Difficulty in/out car* 87 58 86† 52 60
Difficulty opening mouth 84 60 67† 50† 61
Dry eyes* 84 50 88† 68 64
Numbness* 77 47 70 74 67
Difficulty remembering 71 58 72 51 61
Constipation* 81 47 62 36† 76
Nausea 71 52 53† 56† 66
Dilated hand vessels* 85 39 57† 50† 61
Weight loss 79 47 43† 58† 62†
Dry mouth 69 50 64† 46 53
Persistent coughing NA 50 52† 42† 68
Itching* 55 25 87 41 41
Skin color change 39 34 53 38† 50
Dilated face vessels* 52 23 70† 20† 43
¹Symptoms are ordered in the table by the overall impact among all patients from the five countries; UK = 
United Kingdom; * p < 0.05 for differences in proportion of patients among countries based on chi-square 
test with Benjamini-hochberg correction; Na = not administered in the French version of the survey due to 
technical failure; † based on ≤ 25 respondents
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diSCuSSiON
This was the first study that examined the frequency and impact of a broad range of 
symptoms experienced by patients with SSc in Europe. Overall, European patients with 
SSc experienced many different symptoms, often simultaneously. Fatigue, Raynaud’s 
phenomenon, joint pain, and muscle pain were experienced by at least 70% of patients 
in all five countries. These symptoms also frequently had an impact on the ability to 
carry out everyday activities.
The results of our study confirm findings among Canadian and Brazilian patients 
regarding the high prevalence of symptoms faced by patients with scleroderma [3,21]. 
In line with these studies, fatigue and symptoms related to hand function were highly 
prevalent in our sample, and had an impact on daily functioning in the majority of 
patients.
Although fatigue and problems related to functional disabilities in SSc are increasingly 
recognised in the literature [3,12,13,23-26], non-pharmacological interventions 
targeting these symptoms in SSc are scarce [27]. There have been studies that have 
evaluated interventions to improve hand function in patients with SSc, but none have 
included a sufficiently large number of patients to robustly assess the effectiveness 
of these interventions [28-32]. Beyond hand function, at least 80% of the patients 
in each country reported difficulty walking, which commonly impacted the ability to 
carry out everyday activities. Currently, however, there are no studies that describe 
interventions to address problems with walking in patients with SSc. Consistent with 
this, authors of recent EULAR guidelines for the treatment of SSc indicated that no 
recommendations could be made for or against non-pharmacological interventions 
that address functional problems because of a lack of evidence, despite the potential 
of these interventions to help patients [33]. Thus, there is an urgent need to develop 
and rigorously test non-pharmacological interventions that focus on reducing fatigue 
and improving hand function and mobility in SSc.
In addition, differences across countries in the frequency and the impact of SSc 
symptoms were identified as well. Further research is warranted to better understand 
and explain these differences, since it is not clear whether differences may be attributed 
to different disease profiles or to different access to services, such as physical or 
occupational therapy, or assistive devices.
In a rare disease context, international collaborations play an important role, and 
large international consortia will be needed to better understand the nature and impact 
of symptoms in SSc and to develop and test interventions addressing these symptoms. 
Currently, multiple international consortia, including the Scleroderma Patient-centered 
Intervention Network [27,34] and the EULAR Scleroderma Health Professionals Network 
(EUSHNet) [35] have been established to address this important care gap.
This study has limitations that should be considered when interpreting the results. 
First, the generalizability of our results may be limited because the study was conducted 
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in a convenience sample, and the survey was distributed through patient associations. 
As a consequence, it was not possible to verify the patient-reported diagnosis and 
medical information. However, patients rarely report a diagnosis that is incompatible 
with their clinical diagnosis [36]. Second, it is unclear to what extent the observed 
differences in the frequency and impact of SSc symptoms reflect actual differences 
in disease presentation, or whether it is a consequence of sampling differences, 
differences in climate, culture, or the management of SSc. Finally, the survey did not 
include mental health problems in the symptom list, and was limited by single-item 
assessment of symptoms and the lack of open-ended response options for symptoms 
that were not listed.
In conclusion, European patients with SSc experienced a broad range of symptoms, 
many of which had an impact on the ability to carry out everyday activities. Differences 
as well as similarities in disease presentation exist among European patients with SSc. 
International research initiatives should target common symptoms of SSc cooperatively, 
for instance to develop and evaluate non-pharmacological interventions to reduce 
fatigue, limitations in hand function, and difficulty walking.
aCKNOWlEdgEmENTS
This research project was supported by the Dutch patient organization for patients with 
systemic autoimmune diseases (NVLE). The funder had no role in study design, data 
collection and analysis, decision to publish, or preparation of the manuscript. There 
were no conflicts of interest for any of the authors. Dr. Kwakkenbos is supported by a 
Fonds de la Recherche en Santé Québec (FRSQ) postdoctoral fellowship. Dr. Thombs 
is supported by an Investigator Salary Award from the Arthritis Society.
rEfErENCES
1. Katsumoto TR, Whitfield ML, Connolly MK. 
The pathogenesis of systemic sclerosis. Annu 
Rev Pathol 2011;6:509-37.
2. Schnit zer M, Hudson M, Baron M, 
Canadian Scleroderma Research Group, 
Steele R. Disability in systemic sclerosis 
– A longitudinal observational study. J 
Rheumatol 2011;38:685-92.
3. Bassel M, Hudson M, Taillefer SS, Schieir O, 
Baron M, Thombs BD. Frequency and impact 
of symptoms experienced by patients with 
systemic sclerosis: Results from a Canadian 
national survey. Rheumatology (Oxford) 
2011;50:762-7.
4. Hudson M, Thombs BD, Steele R, Panopalis 
P, Newton E, Baron M, et al. Health-related 
quality of life in systemic sclerosis: a systematic 
review. Arthritis Rheum 2009;61:1112-20.
5. Bussone G, Mouthon L. Interstitial lung 
disease in systemic sclerosis. Autoimmunity 
Reviews 2011;10:248–55.
6. Randone SB, Guiducci S, Cerinic MM. 
Musculoskeletal involvement in systemic 
sclerosis. Best Pract Res Clin Rheumatol 
2008;22:339-50.
7. Haythornthwaite JA, Heinberg LJ, McGuire 
L. Psychologic factors in scleroderma. Rheum 
Dis Clin North Am 2003;29:427-39.
8. Thombs BD, Taillefer SS, Hudson M, Baron 
M. Depression in patients with systemic 
sclerosis: A systematic review of the evidence. 
Arthritis Rheum 2007;57:1089-97.
9. Thombs BD, Hudson M, Taillefer SS, Baron 
M, Canadian Scleroderma Research 
Group. Prevalence and clinical correlates 
31
2FR
E
Q
U
E
N
C
Y
 A
N
D
 IM
PA
C
T O
F SSC
 SY
M
P
TO
M
S
of symptoms of depression in patients 
with systemic sclerosis. Arthritis Rheum 
2008;59:504-9.
10. Schieir O, Thombs BD, Hudson M, Boivin 
JF, Steele R, Bernatsky S, et al. Prevalence, 
severity, and clinical correlates of pain in 
patients with systemic sclerosis. Arthritis 
Care Res (Hoboken) 2010;62:409-17.
11. Benrud-Larson LM, Haythornthwaite JA, 
Heinberg LJ, Boling C, Reed J, White B, 
et al. The impact of pain and symptoms of 
depression in scleroderma. Pain 2002;95:267-
75.
12. Sandusky SB, McGuire L, Smith MT, Wigley 
FM, Haythornthwaite JA. Fatigue: an 
overlooked determinant of physical function 
in scleroderma. Rheumatology (Oxford) 
2009;48:165-9.
13. Thombs BD, Bassel M, McGuire L, Smith MT, 
Hudson M, Haythornthwaite JA. A systematic 
comparison of fatigue levels in systemic 
sclerosis with general population, cancer and 
rheumatic disease samples. Rheumatology 
(Oxford) 2008;47:1559-63.
14. Golemat i  CV, Mout sopoulos HM, 
Vlachoyiannopoulos PG. Psychological 
characteristics of systemic sclerosis patients 
and their correlation with major organ 
involvement and disease activity. Clin Exp 
Rheumatol 2013;31:37-45.
15. Ennis H, Herrick AL, Cassidy C, Griffiths CE, 
Richards HL. A pilot study of body image 
dissatisfaction and the psychological impact 
of systemic sclerosis-related telangiectases. 
Clin Exp Rheumatol 2013;31:12-7.
16. Tedeschini E, Pingani L, Simoni E, Ferrari D, 
Giubbarelli C, Giuggioli D, et al. Correlation of 
articular involvement, skin disfigurement and 
unemployment with depressive symptoms in 
patients with systemic sclerosis: a hospital 
sample. Int J Rheum Dis 2014;17:186-94.
17. Suarez-Almazor ME, Kallen MA, Roundtree 
AK, Mayes M. Disease and symptom  burden 
in systemic sclerosis: a patient perspective. J 
Rheumatol 2007;34:1718-26.
18. Van Lankveld WGJM, Vonk MC, Teunissen 
H, van den Hoogen FHJ. Appearance 
self-es teem in sys temic sclerosis— 
subjective experience of skin deformity 
and its relationship with physician-assessed 
skin involvement, disease status and 
psychological variables. Rheumatology 
(Oxford) 2007;46:872–6.
19. Richards HL, Herrick AL, Griffin K, Gwilliam 
PDH, Loukes J, Fortune DG. Systemic 
sclerosis: patients’ perceptions of their 
condition. Arthritis Rheum 2003;49:689-96.
20. Gu YS, Kong J, Cheema GS, Keen CL, Wick 
G, Gershwin ME. The immunobiology of 
systemic sclerosis. Semin Arthritis Rheum 
2008;38:132-60.
21. Leite CC, Maia AC. Symptoms of disease 
and psychological adaptation in Brazilian 
scleroderma patients. Rev Bras Reumatol 
2013;53:405-11.
22. Walker UA, Tyndall A, Czirják L, Denton 
CP, Farge-Bancel D, Kowal-Bielecka O, 
et al. Geographical variation of disease 
manifestations in systemic sclerosis: a report 
from the EULAR Scleroderma Trials and 
Research (EUSTAR) group database. Ann 
Rheum Dis 2009;68:856-62.
23. Thombs BD, Hudson M, Bassel M, Taillefer 
SS, Baron M, Canadian Scleroderma 
Research Group. Sociodemographic, 
disease, and symptom correlates of fatigue 
in systemic sclerosis: Evidence from a sample 
of 659 Canadian Scleroderma Research 
Group Registry patients. Arthritis Rheum 
2009;61:966-73.
24. Sandqvist G, Scheja A, Hesselstrand R. 
Pain, fatigue and hand function closely 
correlated to work ability and employment 
status in systemic sclerosis. Rheumatology 
2010;49:1739-46.
25. Sandqvist G, Hesselstrand R, Eberhardt K. A 
longitudinal follow-up of hand involvement 
and activities of daily living in early systemic 
sclerosis. Scand J Rheumatol 2009;18:1-7.
26. Sandqvist G, Eklund M, Åkesson A, 
Nordenskiöld U. Daily activities and 
hand function in women with limited and 
diffuse scleroderma. Scand J Rheumatol 
2004;33:102-7.
27. Thombs BD, Jewett LR, Assassi S, Baron M, 
Bartlett SJ, Maia AC, et al. New directions 
for patient-centred care in scleroderma: the 
Scleroderma Patient-centred Intervention 
Network (SPIN). Clin Exp Rheumatol 
2012;30(2 Suppl 71):S23-9.
28. Mancuso T, Poole JL. The effect of paraffin 
and exercise on hand function in persons with 
scleroderma: a series of single case studies. J 
Hand Ther 2009;22:71-7.
29. Antonioli CM, Bua G, Frigè A, Prandini K, 
Radici S, Scarsi M, et al. An individualized 
32
2FR
E
Q
U
E
N
C
Y
 A
N
D
 IM
PA
C
T O
F SSC
 SY
M
P
TO
M
S
rehabilitation program in patients with 
systemic sclerosis may improve quality 
of life and hand mobility. Clin Rheumatol 
2009;28:159-65.
30. Bongi SM, Del Rosso A, Galluccio F, Sigismondi 
F, Miniati I, Conforti ML, et al. Efficacy of 
connective tissue massage and Mc Mennell 
joint manipulation in the rehabilitative 
treatment of the hands in systemic sclerosis. 
Clin Rheumatol 2009;28:1167-73.
31. Maddali Bongi S, Del Rosso A, Passalacqua 
M, Miccio S, Cerinic MM. Manual lymph 
drainage improving upper extremity edema 
and hand function in patients with systemic 
sclerosis in edematous phase. Arthritis Care 
Res 2011;63:1134-41.
32. Sandqvist G, Åkesson A, Eklund M. 
Evaluation of paraffin bath treatment in 
patients with systemic sclerosis. Disabil 
Rehabil 2004;26:981-7.
33. Kowal-Bielecka O, Landewé R, Avouac J, 
Chwiesko S, Miniati I, Czirjak L, et al. EULAR 
recommendations for the treatment of 
systemic sclerosis: a report from the EULAR 
Scleroderma Trials and Research group 
(EUSTAR). Ann Rheum Dis 2009;68:620-8.
34. Kwakkenbos L, Jewet t LR, Baron M, 
Bar tlett SJ, Furst D, Gottesman K, et 
al. The Scleroderma Patient-centered 
Inter vention Network (SPIN) Cohor t: 
protocol for a cohort multiple randomised 
controlled trial (cmRCT) design to support 
trials of psychosocial and rehabilitation 
interventions in a rare disease context. BMJ 
Open 2013;3:e003563.
35. Redmond A. EUSHNet- the EUL AR 
sc le roder ma hea l th p rofes s iona ls ’ 
network. EULAR HP news. http://www.
eular.org/myUploadData/f i les/HP%20
Newsletter_0212.pdf
36. Rasooly I, Papageorgiou AC, Badley EM. 
Comparison of clinical and self-reported 
diagnosis for rheumatology outpatients. Ann 
Rheum Dis 1995;54:850-2.
33
2FR
E
Q
U
E
N
C
Y
 A
N
D
 IM
PA
C
T O
F SSC
 SY
M
P
TO
M
S
appendix 1. France (n =111)
symptoms n
Frequency ≥ sometimes Impact ≥ moderate Impact ≥moderate 
and frequency ≥ 
sometimes (%) Rank n (%) Rank n (%)
Fatigue 111 1 107 (96) 1 99 (91) 94
Raynaud’s phenomenon 110 2 94 (85) 3 85 (78) 91
Joint pain 111 3 93 (84) 2 86 (79) 95
Tender joints 108 4 83 (77) 6 73 (68) 88
Difficulty sleeping 110 5 84 (76) 5 74 (68) 89
Stiffness of hands 107 6 81 (76) 4 76 (71) 94
Erectile dysfunction 4 7 3 (75) 20 2 (50) 67
Muscle pain 107 8 79 (74) 7 72 (67) 91
Dry mouth 107 9 79 (74) 19 54 (50) 69
Shortness of breath 107 10 78 (73) NA NA NA
Heartburn 110 11 78 (71) 10 68 (62) 87
Difficulty holding objects 108 12 76 (70) 9 67 (63) 89
Difficulty climbing stairs 109 13 75 (69) 11 64 (60) 88
Skin tightening 110 14 75 (68) 13 63 (58) 85
Vaginal dryness 103 15 70 (68) 15 50 (54)¹ 83
Swollen joints 106 16 72 (68) 8 69 (65) 96
Dilated hand vessels 106 17 70 (66) 14 58 (56) 85
Difficulty making fist 107 18 67 (63) 12 63 (59) 94
Dry eyes 109 19 68 (62) 16 56 (52) 84
Itching 108 20 66 (61) 30 35 (33) 55
Difficulty concentrating 109 21 66 (61) 18 55 (51) 85
Numbness 111 22 67 (60) 22 51 (46) 77
Difficulty remembering 107 23 63 (59) 27 44 (42) 71
Difficulty walking 109 24 61 (56) 17 56 (51) 92
Skin color change 110 25 60 (55) 35 23 (21) 39
Diarrhoea 107 26 58 (54) 23 49 (46) 86
Difficulty opening hand 108 27 58 (54) 21 50 (47) 89
Skin pain 105 28 56 (53) 28 40 (38) 73
Difficulty swallowing 107 29 57 (53) 26 44 (42) 79
Constipation 110 30 57 (52) 25 46 (42) 81
Side effects 108 31 53 (49) 24 45 (42) 87
Persistent coughing 109 32 53 (49) NA NA NA
Dilated face vessels 107 33 52 (49) 34 27 (25) 52
Nausea 108 34 48 (44) 32 34 (31) 71
Difficulty in/out car 110 35 46 (42) 29 39 (36) 87
Difficulty dressing 110 36 45 (41) 33 34 (31) 76
Difficulty opening mouth 110 37 43 (39) 31 36 (33) 84
Finger ulcers 110 38 40 (36) 38 12 (13)¹ 46
Weight loss 110 39 29 (26) 37 23 (21) 79
Open sores 110 40 24 (22) 36 23 (21) 96
¹ > 5% missing; Na = not administered in the French version of the survey due to technical failure
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appendix 2. The Netherlands (n = 229)
symptoms n
Frequency ≥ sometimes Impact ≥ moderate Impact ≥moderate 
and frequency ≥ 
sometimes (%) Rank n (%) Rank n (%)
Fatigue 226 1 214 (95) 1 180 (80) 84
Raynaud’s phenomenon 227 2 205 (90) 2 160 (71) 79
Stiffness of hands 226 3 187 (83) 3 153 (68) 82
Joint pain 228 4 182 (80) 4 134 (59) 74
Erectile dysfunction 28 5 21 (75) 7 14 (50) 67
Skin tightening 229 6 171 (75) 12 108 (47) 63
Difficulty holding objects 227 7 164 (72) 5 124 (55) 76
Tender joints 226 8 161 (71) 13 106 (47) 66
Muscle pain 227 9 160 (70) 9 112 (49) 70
Dry mouth 226 10 157 (69) 18 78 (35) 50
Difficulty sleeping 226 11 155 (69) 11 109 (48) 70
Difficulty climbing stairs 227 12 154 (68) 10 111 (49) 73
Difficulty making fist 227 13 151 (67) 14 98 (43) 65
Shortness of breath 226 14 148 (65) 8 112 (50) 76
Dry eyes 226 15 139 (62) 23 70 (31) 50
Difficulty walking 227 16 139 (61) 6 115 (51) 83
Heartburn 226 17 134 (59) 24 70 (31) 52
Skin color change 228 18 134 (59) 35 46 (20) 34
Skin pain 229 19 132 (58) 19 78 (35) 60
Diarrhoea 225 20 127 (56) 22 71 (32) 56
Difficulty swallowing 227 21 127 (56) 15 83 (37) 65
Difficulty concentrating 226 22 125 (55) 16 83 (36) 66
Dilated hand vessels 228 23 125 (55) 32 49 (21) 39
Vaginal dryness 180 24 95 (53) 25 55 (31) 58
Numbness 225 25 116 (52) 30 54 (24) 47
Difficulty opening hand 227 26 116 (51) 20 77 (34) 66
Difficulty in/out car 227 27 115 (51) 26 66 (29) 58
Difficulty remembering 226 28 110 (49) 27 64 (28) 58
Itching 229 29 111 (48) 39 28 (12) 25
Swollen joints 227 30 110 (48) 17 81 (36) 74
Nausea 227 31 104 (46) 31 54 (24) 52
Difficulty opening mouth 226 32 99 (44) 29 59 (26) 60
Constipation 224 33 95 (42) 36 44 (20) 47
Dilated face vessels 229 34 96 (42) 40 22 (10) 23
Side effects 225 35 93 (41) 28 60 (27) 65
Finger ulcers 227 36 85 (37) 21 73 (32) 86
Persistent coughing 225 37 84 (37) 37 42 (19) 50
Difficulty dressing 227 38 72 (32) 34 48 (21) 67
Open sores 229 39 70 (31) 33 49 (21) 70
Weight loss 227 40 64 (28) 38 30 (13) 47
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appendix 3. Spain (n = 61)
symptoms n
Frequency ≥ sometimes Impact ≥ moderate Impact ≥moderate 
and frequency ≥ 
sometimes (%) Rank n (%) Rank n (%)
Shortness of breath 49 1 42 (86) 17 16 (44)¹ 55
Raynaud’s phenomenon 51 2 43 (84) 4 32 (65) 78
Joint pain 42 3 34 (81) 3 29 (69) 85
Skin color change 45 4 35 (78) 22 18 (41) 53
Persistent coughing 51 5 39 (76) 29 12 (34)¹ 52
Muscle pain 42 6 32 (76) 1 30 (71) 94
Fatigue 50 7 38 (76) 8 29 (58) 76
Difficulty concentrating 51 8 38 (75) 15 23 (47) 64
Heartburn 45 9 33 (73) 2 32 (71) 97
Skin tightening 44 10 32 (73) 6 26 (59) 81
Difficulty sleeping 49 11 39 (80) 10 30 (58) 81
Itching 43 12 30 (70) 5 26 (60) 87
Swollen joints 43 13 30 (70) 7 25 (58) 83
Numbness 51 14 35 (69) 14 23 (47) 70
Difficulty climbing stairs 45 15 28 (62) 12 24 (53) 86
Difficulty remembering 50 16 31 (62) 19 21 (44) 72
Vaginal dryness 42 17 26 (62) 28 13 (35)¹ 57
Difficulty walking 45 18 27 (60) 9 26 (58) 96
Stiffness of hands 44 19 26 (59) 11 25 (57) 96
Finger ulcers 50 20 28 (56) 13 26 (53) 96
Difficulty swallowing 45 21 25 (56) 24 18 (40) 72
Difficulty dressing 45 22 25 (56) 23 18 (41) 75
Dry mouth 44 23 24 (55) 30 14 (33) 64
Constipation 50 24 27 (54) 34 16 (33) 62
Dry eyes 45 25 24 (53) 16 21 (47) 88
Diarrhoea 51 26 27 (53) 33 16 (33) 64
Difficulty holding objects 45 27 23 (51) 18 20 (44) 87
Erectile dysfunction 12 28 6 (50) 21 5 (42) 83
Difficulty in/out car 45 29 22 (49) 20 19 (42) 86
Dilated hand vessels 45 30 22 (49) 36 12 (27) 57
Tender joints 43 31 21 (49) 25 17 (40) 81
Dilated face vessels 44 32 20 (45) 35 14 (32) 70
Skin pain 42 33 19 (45) 26 16 (39) 89
Side effects 51 34 22 (43) 31 17 (33) 77
Difficulty making fist 41 35 17 (41) 27 16 (39) 94
Difficulty opening mouth 52 36 21 (40) 37 12 (24)¹ 67
Difficulty opening hand 45 37 18 (40) 32 15 (33) 83
Open sores 45 38 18 (40) 39 6 (16)¹ 55
Nausea 50 39 17 (34) 38 8 (17) 53
Weight loss 51 40 16 (31) 40 6 (12) 43
¹ > 5 % missing
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appendix 4. Switzerland (n = 50)
symptoms n
Frequency ≥ sometimes Impact ≥ moderate Impact ≥moderate 
and frequency ≥ 
sometimes (%) Rank n (%) Rank n (%)
Erectile dysfunction 1 1 1 (100) 1 1 (100) 100
Fatigue 48 2 41 (85) 5 26 (54) 63
Shortness of breath 44 3 37 (84) 4 17 (55)¹ 71
Raynaud’s phenomenon 47 4 39 (83) 8 21 (50)¹ 62
Joint pain 46 5 38 (83) 2 28 (65)¹ 80
Difficulty sleeping 49 6 39 (80) 9 24 (49) 62
Difficulty remembering 48 7 38 (79) 21 19 (40) 51
Skin tightening 43 8 34 (79) 11 20 (49) 63
Muscle pain 42 9 33 (79) 3 22 (55) 71
Difficulty concentrating 48 10 37 (77) 10 23 (49) 64
Difficulty swallowing 43 11 33 (77) 20 17 (40) 53
Vaginal dryness 29 12 22 (76) 19 9 (41)¹ 60
Heartburn 43 13 32 (74) 6 22 (54) 73
Persistent coughing 45 14 33 (73) 34 5 (21)¹ 42
Difficulty climbing stairs 44 15 32 (73) 16 20 (45) 63
Stiffness of hands 44 16 32 (73) 18 17 (44)¹ 63
Itching 42 17 29 (69) 31 11 (28) 41
Dry mouth 42 18 29 (69) 28 13 (31) 46
Tender joints 45 19 31 (69) 12 21 (48) 70
Difficulty walking 44 20 29 (66) 7 23 (52) 79
Dry eyes 44 21 29 (66) 17 19 (44) 68
Constipation 43 22 28 (65) 33 9 (23)¹ 36
Numbness 46 23 29 (63) 15 20 (45) 74
Difficulty holding objects 43 24 27 (63) 13 20 (47) 74
Difficulty in/out car 44 25 27 (61) 27 14 (32) 52
Diarrhoea 45 26 27 (60) 29 13 (30) 52
Swollen joints 46 27 26 (57) 14 21 (46) 81
Nausea 44 28 24 (55) 32 10 (26)¹ 56
Skin pain 45 29 24 (53) 23 15 (34) 65
Finger ulcers 38 30 19 (50) 22 13 (36)¹ 76
Difficulty making fist 45 31 22 (49) 26 14 (32) 67
Dilated hand vessels 43 32 19 (44) 35 8 (20)¹ 50
Difficulty dressing 44 33 18 (41) 30 12 (28) 71
Difficulty opening hand 44 34 18 (41) 24 15 (34) 83
Side effects 49 35 20 (41) 25 16 (33) 80
Skin color change 43 36 17 (40) 39 6 (14) 38
Difficulty opening mouth 44 37 17 (39) 38 8 (19) 50
Open sores 44 38 17 (39) 36 8 (20)¹ 57
Weight loss 38 39 14 (37) 37 7 (19)¹ 58
Dilated face vessels 42 40 10 (24) 40 2 (5) 20
¹ > 5 % missing
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appendix 5. United Kingdom (n = 86)
symptoms n
Frequency ≥ sometimes Impact ≥ moderate Impact ≥moderate 
and frequency ≥ 
sometimes (%) Rank n (%) Rank n (%)
Erectile dysfunction 9 1 9 (100) 1 9 (89) 89
Raynaud’s phenomenon 83 2 81 (98) 3 62 (76) 78
Fatigue 85 3 79 (93) 2 72 (86) 92
Joint pain 83 4 76 (92) 4 61 (74) 81
Stiffness of hands 82 5 75 (91) 5 56 (68) 75
Muscle pain 81 6 70 (86) 7 54 (68) 78
Difficulty holding objects 81 7 69 (85) 9 52 (64) 75
Difficulty sleeping 85 8 71 (84) 6 57 (68) 81
Tender joints 82 9 65 (79) 11 48 (59) 75
Dry mouth 82 10 65 (79) 26 34 (41) 53
Skin tightening 85 11 67 (79) 8 54 (65) 83
Heartburn 84 12 64 (76) 19 42 (51) 67
Shortness of breath 83 13 63 (76) 15 43 (52) 69
Difficulty making fist 83 14 63 (76) 10 51 (61) 81
Difficulty concentrating 84 15 63 (75) 16 44 (52) 70
Dilated hand vessels 85 16 63 (74) 22 38 (45) 61
Skin color change 84 17 61 (73) 28 30 (36) 50
Difficulty remembering 84 18 59 (70) 23 36 (43) 61
Difficulty swallowing 80 19 56 (70) 17 41 (51) 73
Difficulty climbing stairs 75 20 51 (68) 13 40 (53) 78
Dry eyes 82 21 55 (67) 24 35 (43) 64
Itching 84 22 56 (67) 37 22 (27) 41
Diarrhoea 84 23 56 (67) 18 43 (51) 77
Swollen joints 84 24 55 (65) 12 46 (55) 85
Constipation 85 25 54 (64) 20 41 (48) 76
Difficulty walking 81 26 51 (63) 14 43 (53) 84
Difficulty opening hand 82 27 49 (60) 21 39 (48) 80
Difficulty in/out car 82 28 48 (59) 31 29 (35) 60
Vaginal dryness 65 29 38 (58) 27 24 (38) 65
Skin pain 84 30 49 (58) 25 35 (42) 73
Difficulty dressing 83 31 46 (55) 34 25 (30) 56
Numbness 84 32 45 (54) 30 30 (36) 67
Dilated face vessels 85 33 41 (48) 39 17 (20) 43
Nausea 83 34 39 (47) 33 25 (30) 66
Persistent coughing 84 35 38 (45) 35 25 (30) 68
Difficulty opening mouth 85 36 37 (44) 38 22 (26) 61
Side effects 85 37 35 (41) 36 25 (29) 71
Finger ulces 83 38 31 (37) 29 30 (36) 97
Open sores 83 39 29 (35) 32 26 (31) 90
Weight loss 84 40 21 (25) 40 13 (15) 62
38


Chapter
THE COMPARABILITY OF ENGLIsH, 
FRENCH AND DuTCH sCOREs ON 
THE FuNCTIONAL AssEssMENT 
OF CHRONIC ILLNEss THERAPY-
FATIGuE (FACIT-F): AN AssEssMENT 
OF DIFFERENTIAL ITEM 
FuNCTIONING IN PATIENTs WITH 
sYsTEMIC sCLEROsIs
Kwakkenbos L, Willems LM, Baron M, Hudson M, 
Cella D, van den Ende CHM, Thombs BD, 
and the Canadian scleroderma Research Group. 
Published in PLoS ONE 9(3):e91979. doi:10.1371/ 
journal.pone.0091979.
3
3M
e
a
su
r
e
M
e
n
t e
q
u
iva
le
n
c
e
 o
f th
e
 fa
c
it-f
aBSTraCT
Objective
The Functional Assessment of Chronic Illness Therapy- Fatigue (FACIT-F) is commonly 
used to assess fatigue in rheumatic diseases, and has shown to discriminate better 
across levels of the fatigue spectrum than other commonly used measures. The aim of 
this study was to assess the cross-language measurement equivalence of the English, 
French, and Dutch versions of the FACIT-F in systemic sclerosis (SSc) patients.
Methods
The FACIT-F was completed by 871 English-speaking Canadian, 238 French-speaking 
Canadian and 230 Dutch SSc patients. Confirmatory factor analysis was used to assess 
the factor structure in the three samples. The Multiple-Indicator Multiple-Cause 
(MIMIC) model was utilized to assess differential item functioning (DIF), comparing 
English versus French and versus Dutch patient responses separately.
Results
A unidimensional factor model showed good fit in all samples. Comparing French 
versus English patients, statistically significant, but small-magnitude DIF was found for 
3 of 13 items. French patients had 0.04 of a standard deviation (SD) lower latent fatigue 
scores than English patients and there was an increase of only 0.03 SD after accounting 
for DIF. For the Dutch versus English comparison, 4 items showed small, but statistically 
significant, DIF. Dutch patients had 0.20 SD lower latent fatigue scores than English 
patients. After correcting for DIF, there was a reduction of 0.16 SD in this difference.
Conclusions
There was statistically significant DIF in several items, but the overall effect on fatigue 
scores was minimal. English, French and Dutch versions of the FACIT-F can be reasonably 
treated as having equivalent scoring metrics.
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iNTrOduCTiON
Chronic fatigue from medical illness can be characterized as persistent exhaustion that 
is disproportionate to exertion and not relieved by rest. Fatigue is common and often 
persistent in rheumatic diseases and can have a major impact on health-related quality 
of life (HRQL)[1,2]. Patients with systemic sclerosis (SSc, or scleroderma), a chronic, multi-
system connective tissue disorder characterized by thickening and fibrosis of the skin, 
involvement of internal organs, substantially reduced HRQL, and significant morbidity 
and mortality [3-5] report that fatigue impacts HRQL as much or more than any other 
symptom [6-8]. Fatigue was reported to be present in 89% of 464 Canadian SSc patients 
who responded to a national survey, with an impact on the ability to carry out daily 
activities in 72% [9]. A Dutch study found that 92% of 123 patients were bothered 
by fatigue [8]. Fatigue in SSc is independently associated with reduced capacity to 
carry out daily activities, work disability and impaired physical function [10-13]. Fatigue 
ratings by SSc patients are similar to those of patients with other rheumatic diseases 
and cancer patients currently undergoing treatment, and substantially worse than in 
the general population or among cancer patients in remission [14].
Several instruments have been used to assess fatigue in rheumatic diseases [15,16]. 
Compared to other measures, the Functional Assessment of Chronic Illness Therapy- 
Fatigue (FACIT-F) has been found to provide better coverage of the full range of the 
fatigue spectrum in SSc [17] and rheumatoid arthritis [18]. This is important because SSc 
patients are in the moderate to severe range of fatigue, but the SF-36 vitality subscale, 
for instance, targets the healthy end of the spectrum and does not differentiate 
between patients with moderate versus severe fatigue [17,18]. The Multidimensional 
Assessment of Fatigue (MAF) scale, on the other hand, best discriminates between 
patients in the middle of the spectrum, but does not differentiate well between 
patients with moderately high versus severe fatigue or moderately low versus very 
low fatigue [18].
The FACIT-F has been translated into more than 50 languages, which is important 
when outcomes are reported in multiple languages, including in countries with more 
than one common language, such as Canada (French/English) or the United States 
(Spanish/English), as well as in international multi-center collaborations, which are 
utilized frequently in rare diseases, such as SSc. However, to pool results from the 
FACIT-F among study participants from different countries or to compare results 
between patients from different cultural or linguistic groups, it is necessary to establish 
measurement equivalence, meaning that patients across language groups with 
similar levels of fatigue will have similar scores on FACIT-F items [19]. Differential item 
functioning (DIF) is said to occur when patients with different diseases, but with similar 
levels of a construct such as fatigue, score differently on an item assessing fatigue. 
DIF in cross-linguistic comparisons may occur because translations shift meanings, 
formats, or severity of items used in patient-reported outcome measures, which can 
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lead to responses that differ across groups even when levels of the outcome being 
measured are similar [20].
The objective of the present study was to assess the cross-language measurement 
equivalence of the English, French, and Dutch versions of the FACIT-F scale in SSc 
patients.
mEThOdS
Ethics statement
The English-speaking and French-speaking samples of this study consisted of patients 
with SSc enrolled in the Canadian Scleroderma Research Group Registry (CSRG). The 
study was approved by the Institutional Review Board of McGill University and all 
patients provided written consent for their information to be stored in a computer 
database and used for research. The Dutch sample consisted of members of the 
Dutch organization for patients with systemic autoimmune diseases (NVLE). The 
organization mailed members with SSc an invitation to complete the online survey 
or a paper version on request. Ethical approval was obtained from the Institutional 
Review Board of the Radboud University Medical Center Nijmegen. According to 
Dutch regulations, signed informed consent was not required because of the non-
invasive nature of the study.
Patients and Procedures
English- and French-speaking samples
The English and French-speaking samples consisted of patients who completed the 
FACIT-F from November 2007 through March 2013 in the Canadian Scleroderma 
Research Group (CSRG) Registry. Patients with a diagnosis of SSc confirmed by a CSRG 
rheumatologist, who are at least 18 years of age and fluent in English or French are 
recruited for the Registry from 15 centers across Canada. Patients in the Registry 
undergo extensive physical evaluations at annual visits and complete a series of self-
report questionnaires in their preferred language (English or French). For patients who 
completed the FACIT-F at multiple annual visits, the first available visit with complete 
FACIT-F data was used.
Dutch sample
The Dutch sample consisted of members of the Dutch patient organization for patients 
with systemic autoimmune diseases (NVLE). The NVLE mailed members with SSc an 
invitation to complete an anonymous online survey, or a paper version on request, 
between June and August 2011. The survey consisted of a series of self-report 
questionnaires related to fatigue, health care utilization, and HRQL. Patients with a 
self-reported diagnosis of limited or diffuse SSc who were 18 years of age or older 
were included in this study.
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Measures
Demographics and disease characteristics
Demographic variables available in all three samples included age, sex, marital status, 
education, current employment status, time since diagnosis, and SSc subtype. In the 
English and French samples, time since diagnosis and a patient’s classification as having 
limited or diffuse SSc were provided by a CSRG rheumatologist. Limited SSc was 
defined as skin involvement distal to the elbows and knees only, whereas diffuse SSc 
was defined as skin involvement proximal to the elbows and knees, and/or the trunk [21]. 
In the Dutch sample, both time since diagnosis and SSc subtype were patient-reported.
Functional Assessment of Chronic Illness Therapy- Fatigue (FACIT-F)
The FACIT-F consists of 13 items that assesses tiredness, weakness and difficulty 
conducting everyday activities due to fatigue in the past 7 days [22]. Items are scored 
on a 5-point scale (0 = not at all, 4 = very much). All items except items 7 (I have energy) 
and 8 (I am able to do my usual activities) are reverse-scored before item scores are 
summed to obtain a total score (range 0-52). Higher scores reflect less fatigue. The 
FACIT has been shown to have excellent internal consistency (Cronbach’s alpha >0.90) 
and very good concurrent, divergent and predictive validity across several patient 
populations [18]. The original English, French and Dutch versions of the FACIT-F were 
used [23].
statistical analyses
For all comparisons, the English-speaking sample was used as the reference group. 
Demographics and disease characteristics were compared between the English and 
French samples, and between the English and Dutch samples using the chi-square 
statistic for categorical variables and t-tests for continuous variables.
The factor structure of the FACIT-F was assessed for each sample separately using 
confirmatory factor analysis (CFA). Ideally for DIF assessment, the simplest structure 
with reasonable fit is used. The FACIT-F has shown to have a single-dimensional factor 
structure across diverse samples [24]. Thus, a single-dimensional CFA model was 
constructed to determine whether this structure could be reasonably used in the DIF 
analysis. Item responses for the FACIT-F were ordinal Likert data and were therefore 
modeled using the weighted least squares estimator with a diagonal weight matrix, 
robust standard errors, and a mean- and variance-adjusted chi-square statistic with 
delta parameterization [25]. The chi-square test, the Tucker-Lewis Index (TLI) [26], the 
Comparative Fit Index (CFI) [27] and the Root Mean Square Error of Approximation 
(RMSEA) [28] were used to assess model fit. Good fitting models are indicated by a TLI 
and CFI ≥ 0.95 and RMSEA ≤ 0.06 [29], although a CFI of .90 or above [30] and a RMSEA 
of .08 or less [31] are often regarded as indicators of acceptable model fit. Since the 
chi-square test is highly sensitive to sample size, it can lead to the rejection of well-
fitting models [32]. Therefore, the TLI, CFI and RMSEA fit indices were emphasized. 
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Modification indices were used to identify pairs of items for which model fit would 
improve if error estimates were freed to covary and for which there appears to be 
theoretically justifiable shared method effects (e.g., similar wording) [33]. Once the 
factor structure was established for each sample separately, a CFA model was fit that 
included patients from English and French samples and English and Dutch samples 
combined, respectively.
To determine if items of the FACIT-F exhibited DIF for French versus English and 
Dutch versus English, the Multiple-Indicator Multiple-Cause (MIMIC) model was 
utilized. MIMIC models for DIF assessment are based on structural equation models, 
in which the grouping variable (language) is added to the basic CFA model as an 
observed variable. The base MIMIC model consists of the CFA factor model, to which 
the additional direct effect of group on the latent factors is added. This serves to 
control for group differences on the level of the latent factors. An important strength 
of the MIMIC model is that it allows for adjustment for important covariates that may 
differ between comparison groups, by adding a direct effect of these variables on 
the latent factors. We controlled for differences between samples in age, sex, marital 
status, education, current employment status, SSc subtype, and disease duration.
Each FACIT-F item was regressed separately on the language variable to assess 
potential DIF. Statistically significant DIF is represented by a statistically significant 
association in the model from language to the item, while controlling for any differences 
in the overall level of the latent factor between groups (by regressing the latent factor on 
language). If there was DIF for one or more items, the item with the largest magnitude 
of DIF was considered to have DIF, and the association between the linguistic group 
variable and that item was included in the model. This procedure was repeated until 
none of the remaining items show significant DIF. Once all items with significant DIF 
were identified, the potential magnitude of DIF items collectively was evaluated by 
comparing the difference on the latent factor between groups in the baseline CFA 
model and after controlling for DIF. The magnitude of this difference was interpreted 
following Cohen’s effect sizes, with ≤ 0.20 SD indicating small, 0.50 SD = moderate 
and 0.80 SD = large differences [34,35,36].
For the English versus French and English versus Dutch comparisons, separately, 
Hommels’ correction for multiple testing was applied [37]. CFA and DIF analyses were 
conducted using Mplus 7 [25] and all other analyses were conducted using IBM SPSS 
Statistics 20 (Chicago, IL).
rESulTS
sample characteristics
Demographic and disease characteristics for the three samples are displayed in Table 1.
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English sample
The English sample consisted of 871 patients who completed the FACIT-F, with a mean 
age of 56.6 years (SD=12.1) and mean time since diagnosis of 9.2 years (SD=8.4). The 
majority (86.7%) were female and most patients were married or living as married 
(83.6%). The mean FACIT-F score was 32.5 (SD=12.1).
French sample
In total, 238 patients completed the FACIT-F in French. The mean age was 57.8 years 
(SD=10.4) and the mean time since diagnosis was 8.2 years (SD=8.6). The majority 
(88.7%) were female and had a partner (79.0%). The mean FACIT-F score was 31.5 
(SD=12.2). Patients in the French sample were less likely to have >12 years of education 
than patients in the English sample (P<0.05).
Dutch sample
A total of 230 patients completed the FACIT-F in Dutch. The mean age was 58.3 years 
(SD=11.1) and mean time since diagnosis was 11.0 years (SD=9.3). Most patients were 
female (83.9%) and married or living as married (71.7%). The mean FACIT-F score was 
29.1 (SD=10.4). Dutch patients were less likely to be currently working or to be married 
than patients in the English sample. Furthermore, patients in the Dutch sample had 
significantly longer time since diagnosis and lower (worse) mean FACIT-F scores than 
the English sample (P<0.05).
Confirmatory factor analysis
A single-factor structure was initially assessed in all three samples separately (English: 
Χ2(65)=1416.5, P<0.001, CFI=0.97, TLI=0.97, RMSEA=0.16; French: Χ2(65)=325.2, 
P<0.001, CFI=0.98, TLI=0.98, RMSEA=0.13; Dutch: Χ2(65)=345.6, P<0.001, CFI=0.97, 
TLI=0.96, RMSEA=0.14). Inspection of the modification indices indicated that freeing 
error terms to covary for items 5 (‘trouble starting things’) and 6 (‘trouble finishing 
Table 1. Demographic and disease characteristics for the three SSc samples.
Variable English (N=871) French (N=238) Dutch (N=230)
Female (%) 755 (86.7) 211 (88.7) 193 (83.9)
Mean age, years (SD) 56.6 (12.1) 57.8 (10.4) 58.3 (11.1)a
Higher education (% > 12 years) 433 (49.8)b 101 (42.4)* 106 (46.5)a
Currently working (%) 355 (40.8)c 91 (38.2) 48 (21.1)a **
Married or living as married (%) 728 (83.6) 188 (79.0) 165 (71.7) **
Limited disease (%) 568 (69.1)d 149 (63.9) 147 (66.5)e
Time since diagnosis, mean (SD) 9.2 (8.4)f 8.2 (8.6) 11.0 (9.3)g*
FACIT-F score, mean (SD) 32.5 (12.1) 31.5 (12.2) 29.1 (10.4)**
Due to missing values: aN=228, bN=869, cN=868, dN=822, eN=221, fN=861, gN=225 
Difference with english sample: *p<0.05; **p<0.001
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things’), items 7 (‘energy’) and 8 (‘ability to do usual activities’), and items 1 (‘fatigued’) 
and 4 (‘tired’) would improve model fit, and there was clearly recognizable overlap in 
the item’s content for items 5 and 6, as well as 1 and 4. Items 7 and 8 are the two only 
reverse-scored items of the FACIT-F and may therefore have more shared method 
effects compared to other items. This change resulted in a model with good enough 
fit in all three samples to be treated as a unidimensional construct for the purpose of 
DIF assessment (English: Χ2(62)=873.3, P<0.001, CFI=0.98, TLI=0.98, RMSEA=0.12; 
French: Χ2(62)=193.5, P<0.001, CFI=0.99, TLI=0.99, RMSEA=0.09; Dutch: Χ2(62)=152.81, 
P<0.001, CFI=0.99, TLI=0.99, RMSEA=0.08).
Differential Item Functioning
French versus English
The single-factor structure was fit to the combined English and French sample, including 
a direct effect of language (English/French) on the latent fatigue factor and direct effects 
of covariates on the latent fatigue factor, to correct for differences in latent fatigue 
levels between the samples and differences in sample characteristics, respectively. 
The single-factor model showed good fit (Χ2(158)=1197.6, P<0.001, CFI=0.98, TLI=0.98, 
RMSEA=0.08). Prior to accounting for possible DIF, French patients had 0.04 SD lower 
latent factor scores (more fatigue) than English patients, although this difference was 
not statistically significant (95% confidence interval [CI] -0.15 to 0.11, P=0.63) Three 
items showed statistically significant DIF: item 1 (z=9.34, P<0.001), item 4 (z=4.46, 
P<0.001), and item 8 (z=7.38, P<0.001). Items 1 and 8 had higher scores (less fatigue) 
in the French sample compared with the English sample, while item 4 had lower scores 
in the French sample compared with the English sample (Table 2).
As shown in Table 2, after correcting for DIF, compared with the base model, 
there was an increase of only 0.03 SD on the latent fatigue factor in the difference 
between English and French samples, for a between-groups difference of 0.07 (95% 
CI -0.22 to 0.08, P=0.79). Thus, although there was statistically significant DIF on 3 
items, this did not influence the overall latent factor scores of French versus English 
scores substantially.
Dutch versus English
The single-factor structure was fit to the combined English and Dutch sample, along 
with a direct effect of language (English/Dutch) and the covariates on the latent factor, 
showing good fit (Χ2(158)=1107.5, P<0.001, CFI=0.98, TLI=0.98, RMSEA=0.08). Prior 
to accounting for possible DIF, Dutch patients had 0.20 SD lower latent factor scores 
(more fatigue) than English patients, and this difference was statistically significant 
(95% CI -0.36 to -0.04, P=0.01). Four items showed statistically significant DIF: item 
7 (z=10.0, P<0.001), item 8 (z=6.40, P<0.001), item 9 (z=3.51, P<0.001), and item 13 
(z=3.81, P<0.001). All four items had lower scores (more fatigue) in the Dutch sample 
compared with the English sample.
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After correcting for DIF, compared with the base model, there was a reduction of 
0.16 SD in the difference between English and Dutch samples as shown in Table 3, and 
between-group differences were no longer significant (-0.04 SD, 95% CI -0.21 to 0.08, 
P=0.17). The magnitude of the difference, however, in overall fatigue was small, even 
though 4 items had statistically significant DIF.
As a sensitivity analysis, we ran the MIMIC model with the 9 items that had no 
statistically significant DIF, yielding virtually the same results as the 13-item model 
corrected for the 4 DIF items, with a factor loading for language on the latent factor 
of -0.04.
Table 2. Factor loadings for the FACIT-F in English and French samples and influence on the overall 
estimates of fatigue latent factor scores.
Base modela DIF corrected modelb
Factor  
loading
95% 
Confidence 
Interval
Factor  
loading
95% 
Confidence 
Interval
FACIT-F items:
1. I feel fatigued 0.87 [0.85, 0.89] 0.87 [0.85, 0.89]
2. I feel weak all over 0.85 [0.83, 0.87] 0.85 [0.83, 0.87]
3. I feel listless (“washed out”) 0.90 [0.89, 0.92] 0.90 [0.89, 0.92]
4. I feel tired 0.91 [0.89, 0.92] 0.91 [0.89, 0.92]
5. I have trouble starting things because  
I am tired
0.92 [0.90, 0.93] 0.92 [0.90, 0.93]
6. I have trouble finishing things because  
I am tired
0.90 [0.88, 0.91] 0.90 [0.88, 0.91]
7. I have energy 0.69 [0.66, 0.72] 0.69 [0.66, 0.72]
8. I am able to do my usual activities 0.59 [0.55, 0.63] 0.59 [0.55, 0.63]
9. I need to sleep during the day 0.66 [0.62, 0.70] 0.66 [0.62, 0.70]
10. I am too tired to eat 0.71 [0.66, 0.75] 0.71 [0.66, 0.75]
11. I need help doing my usual activities 0.71 [0.67, 0.74] 0.71 [0.67, 0.74]
12. I am frustrated by being too tired to do the 
things I want to do
0.89 [0.87, 0.90] 0.89 [0.87, 0.90]
13. I have to limit my social activity because  
I am tired
0.88 [0.86, 0.90] 0.88 [0.86, 0.90]
Direct effects on items attributable to French 
language:
Item 1 0.42 [0.33, 0.52]
Item 4 -0.47 [-0.60, -0.34]
Item 8 0.20 [0.11, 0.28]
structural effect of English language of latent 
factors
-0.04 [-0.19, 0.11] -0.07 [-0.22, 0.08]
a Not corrected for DIF, b Corrected for DIF for item 1, 4 and 8
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diSCuSSiON
The main finding of this study was that, although there were some items with statistically 
significant DIF, the magnitude of the DIF was small, and there were not substantive 
differences in measurement between French and English, and Dutch and English 
version of the FACIT-F. There was statistically significant DIF for 3 of 13 items in French 
and 4 items in Dutch compared with the original English version. French patients had 
higher FACIT-F scores (less fatigue) on items 1 and 8, and lower scores on item 4. 
Dutch patients had lower scores (more fatigue) on items 7, 8, 9, and 13 compared to 
Table 3. Factor loadings for the FACIT-F in English and Dutch samples and influence on the overall 
estimates of fatigue latent factor scores.
Base modela DIF corrected modelb
Factor  
loading
95% 
Confidence 
Interval
Factor  
loading
95% 
Confidence 
Interval
FACIT-F items:
1. I feel fatigued 0.86 [0.84, 0.88] 0.86 [0.84, 0.88]
2. I feel weak all over 0.84 [0.82, 0.86] 0.84 [0.82, 0.86]
3. I feel listless (“washed out”) 0.88 [0.87, 0.90] 0.88 [0.87, 0.90]
4. I feel tired 0.90 [0.88, 0.92] 0.90 [0.89, 0.92]
5. I have trouble starting things because  
I am tired
0.91 [0.90, 0.93] 0.91 [0.90, 0.93]
6. I have trouble finishing things because  
I am tired
0.88 [0.87, 0.90] 0.88 [0.87, 0.90]
7. I have energy 0.68 [0.64, 0.71] 0.68 [0.64, 0.71]
8.I am able to do my usual activities 0.55 [0.51, 0.59] 0.55 [0.51, 0.59]
9. I need to sleep during the day 0.63 [0.58, 0.67] 0.63 [0.58, 0.67]
10. I am too tired to eat 0.68 [0.63, 0.72] 0.68 [0.63, 0.72]
11. I need help doing my usual activities 0.69 [0.65, 0.72] 0.69 [0.65, 0.72]
12.I am frustrated by being too tired to do  
the things I want to do
0.87 [0.85, 0.89] 0.87 [0.85, 0.89]
13.I have to limit my social activity because  
I am tired
0.86 [0.84, 0.88] 0.86 [0.84, 0.88]
Direct effects on items attributable to Dutch 
language:
Item 7 -0.74 [-0.87, -0.64]
Item 8 -0.57 [-0.73, -0.40]
Item 9 -0.28 [-0.42, -0.13]
Item 13 -0.24 [-0.36, -0.04]
structural effect of English language on latent 
factors:
-0.20 [-0.36, -0.04] -0.04 [-0.21, 0.13]
a Not corrected for DIF, b Corrected for DIF for item 7, 8, 9, and 13
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the English sample. The influence of DIF on the overall fatigue estimates, however, was 
negligible for the French-English comparison. For the Dutch translation, the influence of 
DIF on latent fatigue factor levels was larger, but still small (i.e., ≤ 0.20 SD), suggesting 
that FACIT-F scores from English- and Dutch-speaking samples can also be validly 
compared and assumed to measuring fatigue using substantively the same metric.
Where there is differential item functioning, it may be related to translational 
differences. For the French items that were identified with DIF, only item 1 appeared 
to have a potentially meaningful difference from the English version. In item 1, the 
English ‘fatigued’ is translated as the French ‘épuisée’, which may be interpreted as 
‘exhausted’. Exhaustion, however, is generally considered a more severe case of fatigue 
[38], which may have influenced the higher (reflecting less fatigue) scores of French 
SSc patients for this item.
In the English-Dutch comparison, the amount of DIF was largest for items 7 and 8. 
For item 7 (I have energy), the Dutch translation might be best understood as ‘I feel 
energetic’ (Ik voel me energiek). Feeling energetic, however, may be suggestive of 
having a high amount of energy, and people who have energy may not necessarily feel 
energetic. This distinction may have played a role in the lower fatigue scores (worse) 
on this item in the Dutch sample.
It has been previously noted that FACIT-F item 8 (I am able to do my usual activities) 
could be misinterpreted as a measure of fatigue in rheumatic diseases [16]. Because 
the item includes no direct reference to fatigue, ‘ability’ could be interpreted as a 
consequence of, for instance, physical limitations due to SSc, rather than fatigue. Item 
8 was found to have a very low factor loading in our Dutch sample (0.35), which was 
much lower than any other factor loadings (0.56 to 0.90). This was not the case, however, 
for the English and French models, where the factor loading for item 8 in the English 
(0.61) and French (0.61) samples was similar to the range of factor loadings for other 
items (English, 0.66 to 0.92; French 0.65 to 0.96). It is not known why this item was 
differentially associated with fatigue in the Dutch sample, but, again, translation may be 
a factor. The Dutch word (‘gewone’) that was chosen to translate ‘usual’ is more closely 
related to the English ‘normal’. Normal activities, however, may suggest activities done 
by people not confronted with a disease, such as SSc, whereas ‘usual’ in English, may 
be interpreted as ‘everyday activities.’
Despite these item differences, overall, there was no evidence that the DIF items 
for the Dutch translation influenced fatigue scores in any more than a trivial magnitude. 
Therefore, scores generated with the FACIT-F in English, French, and Dutch SSc 
patients can be reasonably treated as comparable without adjustment for linguistic 
differences. Nonetheless, if our findings are replicated, the translations of some items, 
particularly the Dutch translations of items 7 and 8, might be reconsidered, especially 
given the influence of the FACIT system in other approaches to measure fatigue in 
chronic diseases, including the development of different item banks for Computer 
Adaptive Testing [39-41].
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Effective research often requires international collaboration to include a sufficient 
number of patients for adequately powered studies, particularly in rare diseases. 
In SSc, for instance, the Scleroderma Clinical Trials Consortium [42] and the EULAR 
Scleroderma Trials and Research group [43] routinely conduct multicenter drug trials 
involving patients who complete outcome measures in multiple different languages. In 
addition, the Scleroderma Patient-centered Intervention Network (SPIN) was recently 
organized to test psychosocial and rehabilitation interventions in patients from across 
Canada, the US, and Europe [44,45]. Improvement of fatigue management will be 
an important target for SPIN interventions. The current study supports the use of 
the FACIT-F in the different languages included in SPIN, and future studies should 
extend this assessment of the FACIT-F into other languages. In addition, measurement 
equivalence should also be assessed for other frequently used patient-reported 
outcome measures central to research in rheumatic diseases.
There are limitations that should be considered in interpreting the results of this 
study. Because of the difference in sample size between the samples, the core model 
used to assess DIF relied more on data from English-speaking patients than French 
and Dutch patients. However, since the initial factor analysis yielded the same results 
in all three samples, it does not seem likely that this would have influenced results 
substantially. It should be noted that in all three samples, the RMSEA exceeded 
the commonly used 0.06 threshold. This is similar to what has been found in other 
samples in which the factor structure of the FACIT-F was assessed [24]. The excellent 
CFI and TLI parameters in our samples, on the other hand, suggest the essential 
unidimensionality of the FACIT-F. In addition, when improving model fit by identifying 
pairs of items for which error estimates were freed to covary, there is no objective 
standard to assess whether there are theoretically justifiable shared method effects, 
such as similar wording. Other limitations relate to differences in sample recruitment 
between the Dutch and Canadian English and French samples. Whereas the English-
speaking patients were recruited from 15 centers from across Canada, Dutch patients 
were recruited through the Dutch patient organization. Therefore, medical data in the 
English and French samples were based on medical records, in contrast to the Dutch 
sample for which these were self-reported, and there were large differences in disease 
duration. However, the analysis correcting for differences in demographics and disease 
characteristics between samples yielded virtually the same results as the non-corrected 
model, which suggests that differences in sampling did not likely influence the results 
substantially. In addition, our English-speaking and French-speaking data were both 
collected from Canadian patients. Both language and cultural differences related to 
the construct being measured may affect measurement, and thus, DIF. Therefore, 
it remains to be elucidated to which extend our results generalize to other French-
speaking countries. Finally, a potential disadvantage of the MIMIC model, that was 
used in the present study, compared with other models to assess DIF is, that MIMIC 
does not test for non-uniform DIF. Non-uniform DIF means that the amount of DIF is 
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unequal for different levels of the outcome of interest, in our case fatigue. On the other 
hand, MIMIC models do allow for adjustment for important covariates that may differ 
between comparison groups, which is an important strength of the model, especially 
given the differences in sampling in the present paper.
In conclusion, the English, French and Dutch versions of the FACIT-F, despite minor 
DIF, can be reasonably treated as essentially equivalent measures. If our results are 
replicated, the translations of several items, particularly the Dutch translation of items 
7 and 8, should be reconsidered, especially given the influence of the FACIT system in 
other approaches to measure fatigue in chronic diseases.
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aBSTraCT 
Objective
Functional disability and fatigue are important consequences of systemic sclerosis 
(SSc), but little is known about their course over time. The aim of this study was to 
identify and characterize homogeneous subgroups with distinct 3-year trajectories of 
disability and fatigue, separately.
Methods
A 3-year cohort study including 215 patients with SSc was conducted. Functional 
disability was assessed using the Health Assessment Questionnaire-Disability Index 
(HAQ-DI). Fatigue was assessed using the SF-36 Vitality subscale. Longitudinal 
trajectories were identified using latent class growth analyses (LCGA). Baseline patient 
characteristics were compared across classes using multivariable logistic regression.
Results
Two disability classes were identified: a ‘low’ group (n = 133) with low baseline HAQ-DI 
scores (intercept = 0.48) and slight, statistically non-significant deterioration over time 
(slope = 0.01), and a ‘high’ group (n = 82) with high baseline HAQ-DI scores (intercept 
= 1.63) and also slight, statistically non-significant deterioration over time (slope = 
0.01). Patients in the high disability group were more likely to be female, have higher 
fatigue, more helplessness, and less emotion-focused coping. Two fatigue classes were 
identified: an ‘average’ group (n = 99) with average baseline Vitality scores (intercept 
= 53.9) and slight, statistically non-significant deterioration over time (slope = -0.23), 
and a ‘high’ fatigue group (n = 116) with low baseline Vitality scores (intercept = 39.8) 
and also slight, but non-significant deterioration over time (slope = -0.15). Patients 
in the high fatigue group were more likely to be female, report more impact of lung 
involvement, and less acceptance.
Conclusion
Functional disability and fatigue trajectories in SSc were relatively stable over a 3-year 
period, and differences in baseline scores, but not slopes, defined classes.
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iNTrOduCTiON
Systemic sclerosis (SSc, or scleroderma) is a rare chronic connective tissue disease, 
characterized by vascular damage and collagen deposition in the skin and internal 
organs [1]. SSc may cause dysfunction of the lungs, heart, kidneys, gastrointestinal tract, 
and the musculoskeletal system, and patients experience a broad range of symptoms, 
with fatigue, Raynaud’s phenomenon, joint pain, stiffness of hands, muscle pain and 
difficulty sleeping being reported most frequently [2,3]. The clinical manifestations of 
SSc and progression of the disease is highly variable among patients, and can vary 
widely over time [4]. However, little is known about the course over time of problems 
important to patients with SSc, such as disability and fatigue.
In two longitudinal studies, evidence was found that, overall, disability in patients 
with SSc increases slightly over time [5,6], and disease characteristics found to be 
most strongly associated with the course of disability were diffuse disease, breathing 
problems, and more skin thickening. The course of disability varied widely across 
individuals in these studies, however, suggesting that subgroups of patients may exist 
with a distinct disability progression over time, that may warrant different treatment 
approaches. In other rheumatic diseases, the course of disability over time was found 
to be associated with sociodemographic characteristics, e.g. age and education level; 
clinical variables including body mass index, pain, number of comorbidities, and fatigue; 
and psychosocial characteristics such as activity avoidance, depressive symptoms, and 
perceived self-efficacy [7-9].
In addition to functional disabilities, patients with SSc have rated fatigue amongst 
their most prevalent symptoms, and have reported that fatigue has a major impact 
on the ability to carry out everyday activities [2,3,10-13]. Levels of fatigue in SSc were 
similar to fatigue experienced by cancer patients in active treatment and patients 
with other rheumatic diseases, and higher compared with the general population and 
cancer patients in remission [14]. To date, only one study has examined the course of 
fatigue in patients with SSc [15] and reported that levels of fatigue fluctuated in some 
individuals, but that the overall cohort did not show a significant trend of change in 
fatigue over time. In this study, fatigue severity over time was associated with pain, 
severity of gastrointestinal and lung involvement, and psychological variables [15]. 
No studies, however, have examined the possibility of the existence of homogeneous 
subgroups with distinct trajectories of fatigue in SSc. Identifying these subgroups may 
help health care providers to target therapy to high-risk groups that are most likely to 
benefit from interventions addressing fatigue.
The aim of the present study was to examine change in disability and fatigue 
in patients with SSc over time, to identify homogeneous subgroups with distinct 
trajectories of disability and fatigue, and to assess differences in baseline demographic, 
disease, and psychosocial characteristics of these subgroups.
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mEThOdS
Patients and procedure
Data were collected between June 2008 and August 2013 in a cohort study including 
patients with a diagnosis of SSc according to the American College of Rheumatology 
classification criteria [16] undergoing treatment in the Sint Maartenskliniek or Radboud 
University Medical Center Nijmegen in the Netherlands. At baseline, medical data 
were recorded by the attending rheumatologist, and patients completed sets of 
questionnaires every 6 months for 3 years. Exclusion criteria for participation in the 
cohort were a life expectancy of less than one year, acute serious complications 
(e.g., acute renal crisis), severe psychiatric comorbidity (e.g., severe substance abuse, 
psychosis or dementia), other serious comorbidities (e.g., cancer), and insufficient 
knowledge of the Dutch language. The attending rheumatologist in each hospital 
invited eligible patients to participate in the study during a patient’s regular visit to the 
outpatient clinic. All patients provided informed consent, and the local medical ethics 
board (CMO 2008/109) approved the study.
Measures
Outcome measures
Functional disability was measured with the Health Assessment Questionnaire- 
Disability Index (HAQ-DI) [17]. The HAQ-DI includes 20 items covering 8 dimensions 
of functioning: dressing and grooming, arising, eating, walking, hygiene, reach, grip, 
and activities. Patients are asked to rate their abilities to perform specific tasks in each 
domain over the past week on a scale that ranges from 0 (without any difficulty) to 
3 (unable to do). For each domain the highest (worst) score is used to calculate the 
HAQ-DI total score, with each of the domains valued equally. Thus, the total HAQ-DI 
score ranges from 0 (no disability) to 3 (severe disability). The HAQ-DI showed good 
validity and responsiveness to change in patients with SSc [6,18,19].
Fatigue was assessed with the Vitality subscale of the Medical Outcomes Study 
Short Form 36 (SF-36), which includes four Likert items that assess a patient’s level of 
fatigue during the previous four weeks [20]. Items are scored on a 5-point Likert scale 
(1 = all the time, 5 = none of the time) and the total SF-36 Vitality scores are normalized 
based on US population data (M = 50, SD = 10), with higher scores indicating less 
fatigue. The SF-36 is a reliable and valid measure in patients with SSc [19].
Baseline characteristics
Demographic variables included age, gender, marital status (married vs. not married), 
and education (≤12 years vs. >12 years of education).
Disease variables were provided by the attending rheumatologist and included 
disease subtype (limited SSc vs. diffuse SSc), disease duration (defined as the time since 
onset of the first non-Raynaud’s symptom), antibody profile (anticentromere antibody 
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(ACA) and antitopomerase antibody (anti-TOPO); positive vs. negative). In addition, 
patients rated the impact of disease symptoms (Raynaud’s phenomenon, digital ulcers, 
gastrointestinal symptoms, breathing problems, and pain) on a 10 cm Visual Analogue 
Scale (VAS). Answers ranged from 0 “does not interfere” to 100 “very severe limitation”.
Because previous research has shown that psychosocial factors were related to 
physical disability and fatigue cross-sectionally and over time, measures of cognitions, 
coping, and social support were recorded. The Illness Cognition Questionnaire (ICQ) 
[21] consists of 18 items that assess disease cognitions of helplessness, acceptance, 
and disease benefits. Participants rated their agreement with the statements on a 
4-point Likert scale, ranging from 1 (not at all) to 4 (completely). Higher scores on the 
subscales represented higher level of agreement with a particular disease cognition. 
The questionnaire showed good psychometric properties in chronic diseases [21]. In this 
study we only used the subscales acceptance and helplessness. The Coping Inventory 
Stressful Situations (CISS) [22] includes 48 items that assess three coping strategies 
including problem-focused coping, emotion-focused coping, and avoidance. Items were 
scored on a 5-point Likert scale, ranging from 1 (not at all) to 5 (very much). Higher scores 
indicate a greater use of that particular coping style. The CISS scales demonstrated good 
reliability and validity in diverse samples [22,23]. The Personal Resources Questionnaire 
85 Part 2 (PRQ-85) [24] includes 25 items that assess patients’ perceived level of social 
support using a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly 
agree). Higher scores indicating greater availability of and satisfaction with social 
support. There is strong evidence for the validity and reliability [25].
statistical analysis
Identification of classes 
Descriptive statistics are provided as means and standard deviations (SD) for continuous 
variables and percentages for categorical variables. Latent class growth analysis (LCGA) 
was conducted using MPlus to identify trajectories (classes) over time for disability and 
fatigue separately, following the guidelines described by Jung and Wickrama [26]. 
LCGA estimates individual differences (variability) in parameters reflecting participants’ 
change in outcome over time. Individuals are classified into latent classes based upon 
similar patterns in the outcome of interest (i.e., disability and fatigue, respectively). LCGA 
assumes no within-class variation on the growth factors (i.e., the rate of change or slope 
of the longitudinal trajectories). By fixing the within-class variances to zero, all individual 
longitudinal trajectories within a subgroup are considered to be homogeneous, leading 
to a clearer identification of classes. The full information maximum likelihood (FIML) 
estimation for handling missing data was applied.
Following the guidelines, a single-class growth curve model was specified, as well 
as a three-class model. To determine the number of classes in the sample, the three-
class model was compared with a two-class and four-class model. In total, the fit of four 
unconditional latent class models (i.e., models with no covariates) were estimated, with 
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one to four linear trajectories, for both fatigue and disability. Determining the number 
of trajectories was based on fit indices, model parsimony, and clinical interpretability. 
The model with the best fit has the smallest Bayesian Information Criterion (BIC), and 
significant p-values (p<0.05) for the Vuong-Lo-Mendell Ruben Likelihood Ratio Test 
(LMR-LRT) and the Bootstrap Likelihood Ratio Test (BLRT), which indicate that a model 
with a k number of classes has a better fit than a model with k-1 number of classes. Other 
considerations regarding the best fitting model include a higher entropy statistic (near 
1.0) indicating the degree to which latent trajectories may be clearly distinguished, and 
higher posterior probabilities of group membership (near 1.0) indicating the degree to 
which individuals have been correctly classified into a class. For clinical interpretability, 
we also considered the number of participants (no less than 10% of total sample) of 
the identified classes.
After LCGA was conducted, we proceeded to fit a growth mixture model (GMM) 
that freely estimates the within-class variances. However, by allowing this variation 
in covariance matrices, the model did not reach convergence. Therefore, the results 
provided by the LCGA regarding the number of classes of trajectories were used in 
further exploratory analyses. For each individual patient in the database, the predicted 
class of the best fitting model (i.e., with the optimal number of subgroups) was obtained.
Baseline characteristics of classes
We compared baseline demographic, disease, clinical and psychosocial characteristics 
between the identified classes using univariate and multivariate logistic regression 
analyses, for functional disability and fatigue separately. Multivariate Imputation by 
Chained Equation (MICE) was used to produce 20 complete datasets, using 15 cycles 
for each dataset [27]. Results of the imputed datasets were combined following Rubin’s 
rules [28].
First, univariate associations of baseline characteristics with the classes of disability 
and fatigue were calculated. Next, to understand the independent contribution of 
the baseline characteristics, multivariate logistic regression analyses were conducted. 
Because the number of variables in the regression models would lead to overfitting of 
the model, we were not able to enter all the variables that were univariately associated 
into the multivariable regression analysis. Therefore, we pre-selected characteristics 
before fitting the final model. For this selection procedure, we divided the variables 
of interest in four blocks: one block included the demographic variables (age, 
gender, education, employment, marital status); another block included the disease 
characteristics (time since onset first non-Raynaud symptom, subtype SSc, ACA, anti-
TOPO); the third block included the self-reported clinical characteristics (VAS for 
impact of gastrointestinal involvement, lung involvement, Raynaud’s phenomenon, 
and digital ulcers, SF-36 Vitality subscale (in the disability model), and HAQ-DI (in 
the fatigue model)); and the final block included the psychosocial characteristics 
(helplessness (ICQ), acceptance (ICQ), problem-focused coping (CISS), emotion-
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focused coping (CISS), avoidance coping (CISS), social support (PRQ-85)). For each 
block, we used a backward stepwise regression (in each step, a variable was removed if 
p>0.10) to determine which variables could be included in the final logistic regression 
model. All variables that were not excluded during the backward selections were 
entered simultaneously in the final regression model. As pain may have substantial 
conceptual overlap with fatigue and disability, it was not included in the primary 
analyses. A sensitivity analysis was conducted to examine the association of pain 
with disability and fatigue, respectively. A second sensitivity analysis was conducted 
where we ran the final regression model with complete cases only. Finally, we assessed 
the frequency distributions between the classes of disability and fatigue using a chi-
squared test.
LCGA was performed in Mplus7 and the logistic regression analyses in Stata 13.
rESulTS
sample characteristics
In total, 279 patients were invited to participate in the cohort study, of whom 215 
completed the baseline questionnaire (response rate 77.1%). After 3 years, 54 
participants (25.1%) had dropped out. The most frequently reported reasons for 
dropout were death and severe medical problems (Figure 1). At baseline, the mean 
age (SD) of the 215 participants was 56.4 (12.0) years, 67.9% were women, and most 
participants were married or cohabiting (76.3%). The mean disease duration measured 
from the first non-Raynaud’s symptom to baseline was 9.2 (8.0) years, and 75.1% of 
participants had limited SSc. Baseline characteristics are presented in Table 1. The 
total number of missing values among the 22 baseline characteristics was 50 (1.1%), 
corresponding to 36 participants.
Course of disability
For the complete sample, the intercept of the HAQ-DI score generated with Mplus was 
0.92 (95% confidence interval [CI] 0.83 to 1.01), indicating mild to moderate disability. 
There was a slight increase in HAQ-DI score (more disability) over time (slope 0.02; 95% 
CI 0.01 to 0.03), equivalent to an average increase in HAQ-DI score of 0.04 per year, 
or 0.12 over 3 years. The number of participants with a missing HAQ-DI score was 1 
(0.5%) at baseline, and increased to 76 (35.3%) after 3 years.
Identification of classes
For disability, a two-class model was identified as most appropriate based on fit 
indices, internal reliability, and interpretability (Table 2). In the three-class model, 
compared with the two-class model, the BIC was better, but the entropy was lower 
and the LMR-LRT was non-significant. The posterior probabilities were also better in 
the two-class model.
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T0 (baseline): n=215  
signed informed consent 
Invited: n=279 
6 month follow-up 
(T1): n=186 
1 year follow-up 
(T2): n=165 
1.5 years follow-up 
(T3): n=167 
2 years follow-up 
(T4): n=153 
2.5 years follow-up 
(T5): n=138 
3 years follow-up 
(T6): n=142 
Missing: n=14 
Missing: n=28 
Missing: n=17 
Missing: n=20 
Missing: n=25 
Missing: n=19 
Loss to follow-up  (n=15): 
Death ( n=5) 
Medical problems (n=3) 
Personal circumstances (n=1) 
Moved (n=1) 
Survey too confronting (n=1) 
Unknown (n=4)  
Loss to follow-up  (n=7): 
Death (n=2) 
Medical problems (n=2) 
Survey too difficult or takes too 
much time (n=2) 
Unknown (n=1) 
Loss to follow-up  (n=9): 
Death (n=2) 
Medical problems (n=4) 
Survey takes too much time (n=1) 
No longer receiving treatment (n=1) 
Unknown (n=1) 
Loss to follow-up  (n=11): 
Death (n=4) 
Medical problems (n=2) 
Improved health (n=1) 
Old age (n=1) 
Survey too difficult or takes too 
much time (n=2) 
Unknown (n=1) 
Loss to follow-up  (n=10): 
Death (n=5) 
Medical problems (n=2) 
Changed hospital (n=1) 
Survey takes too much time (n=1) 
Survey too confronting (n=1) 
Loss to follow-up  (n=2): 
Death (n=1) 
Medical problems (n=1) 
Figure 1. Study flowchart. 
figure 1. Study flowchart.
The two subgroups differed in the baseline values (intercepts) of the HAQ-DI and 
there were only small, statistically non-significant, changes in disability over time; both 
classes showed trajectories of slight worsening of disability. The first subgroup consisted 
of 133 participants and was defined as ‘low disability’, as participants reported low 
baseline disability scores (intercept 0.48; 95% CI 0.38 to 0.58) and the slope was 0.01 
(95% CI 0.00 to 0.02). The second subgroup was defined as ‘high disability’, as the 82 
participants showed high baseline disability scores (intercept 1.63; 95% CI 1.45 to 1.82) 
and the slope was 0.01 (95% CI -0.01 to 0.03).
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Table 1. Baseline characteristics of the identified subgroups of disability and fatigue. 
Total 
n =215
subgroup 1
Low 
disability 
n=133
subgroup 2
High 
disability 
n=82 
subgroup 1
Average 
fatigue
n=99
subgroup 2 
High  
fatigue
n=116
Demographics
Age, mean (SD), years 56.4 (12.0) 55.1 (12.4)* 58.7 (11.0) 57.0 (11.5) 56.0 (12.4)
Female, n (%) 146 (67.9) 82 (61.7)* 64 (78.0) 53 (53.5)* 93 (80.2)
Higher education (> 12 years), n (%) 88 (41.1) 65 (49.2)* 23 (28.0) 45 (45.9) 43 (37.1)
Currently employed, n (%) 71 (32.9) 59 (44.1)* 12 (14.6) 40 (40.1)* 31 (26.7)
Married/ cohabiting, n (%) 164 (76.3) 107 (80.5) 57 (69.5) 80 (80.9) 84 (72.4)
Disease characteristics
Time since onset first non-
Raynaud symptom, mean (SD), years
9.2 (8.0) 9.1 (8.3) 9.3 (7.5) 8.4 (6.8) 9.8 (8.9)
Patients with limited SSc, n (%) 162 (75.1) 102 (76.4) 60 (73.0) 73 (73.6) 89 (76.4)
ACA positive, n (%) 54 (25.1) 34 (25.6) 20 (24.4) 25 (25.3) 29 (25.0)
Anti-TOPO positive, n (%) 57 (26.5) 40 (30.1) 17 (20.7) 34 (34.3)* 23 (19.8)
Clinical factors
VAS gastrointestinal involvement, 
mean (SD)
18.8 (24.6) 15.1 (22.4)* 24.8 (26.8) 9.8 (16.4)* 26.4 (27.7)
VAS lung involvement, mean (SD) 26.2 (26.4) 17.8 (21.3)* 39.9 (28.2) 12.5 (15.1)* 37.9 (28.4)
VAS Raynaud’s phenomenon, 
mean (SD)
41.2 (28.8) 37.5 (27.9)* 47.2 (29.4) 30.7 (26.7)* 50.2 (27.6)
VAS digital ulcers, mean (SD) 23.7 (29.9) 20.2 (27.4)* 29.3 (32.6) 14.2 (22.2)* 31.8 (32.9)
VAS pijn, mean (SD) 28.4 (24.7) 21.8 (21.5)* 39.2 (25.7) 19.1 (19.6)* 36.4 (25.8)
HAQ-DI, mean (SD) 0.91 (0.70) 0.47 (0.38)* 1.61 (0.51) 0.57 (0.56)* 1.19 (0.69)
SF-36 Vitality subscale, mean (SD) 46.8 (10.0) 49.8 (9.9)* 42.1 (8.4) 55.0 (7.4)* 39.9 (6.0)
Psychosocial factors
Helplessness (ICQ), mean (SD) 12.7 (4.3) 11.6 (3.8)* 14.5 (4.5) 10.5 (3.5)* 14.5 (4.0)
Acceptance (ICQ), mean (SD) 16.4 (4.1) 16.7 (3.8) 15.8 (4.6) 18.1 (3.6)* 14.9 (4.0)
Problem-focused coping (CISS), 
mean (SD)
50.6 (11.0) 50.9 (10.6) 50.1 (11.6) 50.0 (11.2) 51.1 (10.8)
Emotion-focused coping (CISS), 
mean (SD)
34.0 (11.7) 34.7 (12.2) 32.9 (10.8) 30.2 (10.0)* 37.3 (12.1)
Avoidance coping (CISS), mean (SD) 40.4 (9.9) 40.7 (10.1) 39.9 (9.7) 40.4 (10.6) 40.4 (9.3)
Social support (PRQ-85), mean (SD) 131.5 (20.6) 135.3 (19.5)* 125.4 (21.0) 136.4 (18.2)* 127.3 (21.7)
SSc, systemic sclerosis; aCa, anticentromere anitbody; anti-tOpO, antitopomerase antibody; VaS, Visual 
analog Scale; haQ-DI, health assessment Questionnaire- Disability Index; SF-36, Short-Form 36 health 
Survey; ICQ, Illness Cognition Questionnaire; CISS, Coping Inventory Stressful Situations; prQ-85, personal 
resources Questionnaire 85. *p<0.05.
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Table 3. Final model of baseline characteristics associated with subgroup membership for fatigue and 
disability, multivariable logistic regression analysis.
Fatigue 
high fatigue (n=116) vs. 
average fatigue (n=99)
Disability 
high disability (n=82) vs. 
low disability (n=133)
OR 95% CI P OR 95% CI P
Demographics
   Female sex 4.59 1.87-11.30 <0.01 2.21 1.01-4.85 0.05
   Higher education (> 12 years) 0.51 0.24-1.09 0.08
   Currently employed 1.41 0.57-3.47 0.46 0.50 0.22-1.16 0.11
Disease characteristics
   Anti-TOPO positive 0.53 0.21-1.36 0.19
Clinical factors
   VAS gastrointestinal involvement (0-100) 1.01 0.99-1.03 0.15
   VAS lung involvement (0-100) 1.05 1.02-1.07 <0.01 1.01 1.00-1.03 0.06
   VAS Raynaud’s phenomenon (0-100) 1.01 1.00-1.03 0.07
   HAQ-DI (0-3) 1.79 0.86-3.71 0.12
   SF-36 Vitality subscale (0-100) 0.94 0.90-0.99 0.02
Psychosocial factors
   Helplessness (ICQ) (6-24) 1.14 0.99-1.30 0.06 1.12 1.01-1.25 0.04
   Acceptance (ICQ) (6-24) 0.84 0.74-0.95 <0.01
   Emotion-focused coping (CISS) (16-80) 0.95 0.91-0.98 <0.01
   Social support (PRQ-85) (25-175) 0.99 0.97-1.01 0.26 0.98 0.97-1.00 0.07
anti-tOpO, antitopomerase antibody; VaS, Visual analog Scale; haQ-DI, health assessment Questionnaire- 
Disability Index; SF-36, Short-Form 36 health Survey; ICQ, Illness Cognition Questionnaire; CISS, Coping 
Inventory Stressful Situations; prQ-85, personal resources Questionnaire 85; Or, odds ratio; CI, confidence 
interval.
Table 2. Fit indices, entropy and average posterior probabilities across models with different number 
of subgroups with distinct trajectories of disability.
No. of 
subgroups BIC LMR-LRT BLRT Entropy n
Posterior 
probabilities
Intercept 
(95% CI)
slope linear 
(95% CI)
2 1532.53 0.015 <0.0001 0.921 133
82
0.98
0.97
0.48 (0.38, 0.58)
1.63 (1.45, 1.82)
0.01 (0.00, 0.02)
0.01 (-0.01, 0.03)
3 1154.35 0.31 <0.0001 0.897 59
82
74
0.95
0.95
0.95
1.84 (1.56, 2.11)
0.27 (0.19, 0.36)
0.91 (0.61, 1.20)
0.01 (-0.02, 0.03)
0.01 (-0.01, 0.02)
0.02 (0.00, 0.04)
4 964.13 0.16 <0.0001 0.920 73
56
13
73
0.97
0.96
0.94
0.94
0.25 (0.17, 0.33)
1.59 (1.39, 1.79)
2.40 (2.15, 2.64)
0.82 (0.67, 0.97)
0.01 (-0.01, 0.02)
0.02 (0.00, 0.04)
0.03 (-0.04, 0.10)
0.02 (0.00, 0.05)
BIC, Bayesian Information Criterion; LMr-Lrt, Vuong-Lo-Mendell rubin Likelihood ratio test; BLrt, Bootstrap 
Likelihood ratio test; CI, confidence interval
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Baseline characteristics of classes
The results of the univariate and multivariate regression analyses comparing baseline 
characteristics of the participants between the two disability classes are shown in 
Tables  1 and 3. Eight variables were selected to be included in the final model. 
Participants in the high disability class, compared with participants in the low disability 
class were characterized by: female gender, more fatigue, more helplessness, and less 
emotion-focused coping.
The results from the complete cases sensitivity analysis differed slightly from the 
model with imputed data, in the model with complete cases female gender was not 
a significant characteristic of the high disability subgroup. In the sensitivity analysis, 
adding pain to the final model, results were different from those from the model 
without pain (data not shown): in the model with pain, emotion-focused coping and 
pain were significant characteristics of disability classification, but not female gender, 
fatigue, and helplessness.
Course of fatigue
The intercept of the SF-36 Vitality score for the complete sample was 46.42 (95% CI 
45.15 to 47.69), and the course showed a slight decrease (more fatigue) over time (slope 
-0.23; 95% CI -0.41 to -0.05), equivalent to an average decrease in SF-36 Vitality score 
of 0.46 per year, or 1.38 over 3 years. The number of participants with missing SF-36 
Vitality scores was 3 (1.4%) at baseline and increased to 74 (34.4%) after 3 years.
Identification of classes
For fatigue, a two-class model was identified as most appropriate based on fit indices, 
internal reliability, and interpretability (Table 4). In the three-class model, compared 
with the two-class model, the BIC and entropy were better, but the LMR-LRT was 
non-significant. The posterior probabilities were also better in the two-class model.
The two fatigue subgroups differed in their baseline values (intercepts) of the 
SF-36 Vitality subscale and both subgroups showed small, statistically non-significant, 
worsening of fatigue over time. The first subgroup consisted of 99 participants and 
was defined as ‘average fatigue’, as participants fatigue levels were virtually similar to 
a US norm population (intercept 53.94; 95% CI 51.44 to 56.45) and the slope was -0.23 
(95% CI -0.49 to 0.04). The second subgroup was defined as ‘high fatigue’, as the 116 
participants showed high baseline fatigue (intercept 39.81; 95% CI 38.30 to 41.32) and 
the slope was -0.15 (95% CI -0.47 to 0.17).
Baseline characteristics of classes
The results of the univariate and multivariate regression analyses comparing baseline 
characteristics of the participants in the two identified subgroups are shown in Tables 
1 and 3. Ten variables were selected for the final model. Participants in the high fatigue 
class, compared with participants in the average fatigue class, were characterized by: 
female gender, more impact of lung involvement, and less acceptance.
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In both sensitivity analyses, adding pain to the final model and only including 
complete cases, results were virtually similar to those from the model without pain, with 
female gender, more impact of lung involvement, and less acceptance as significant 
characteristics of fatigue classification (data not shown).
Distribution of disability and fatigue classes
About one third (31%) of the patients could be classified to both the high disability and 
high fatigue groups, whereas 39 percent (n=83) of the cohort was classified to both the 
low disability and average fatigue groups (Table 5). There was a statistically significant 
association between the disability subgroups and the fatigue subgroups (p<0.01).
Table 4. Fit indices, entropy and average posterior probabilities across models with different number 
of subgroups with distinct trajectories of fatigue.
No. of 
subgroups BIC LMR-LRT BLRT Entropy n
Posterior 
probabili-
ties
Intercept 
(95% CI)
slope linear
(95% CI)
2 8068.14 0.003 <0.0001 0.852 99
116
0.96
0.96
53.94 (51.44, 56.45)
39.81 (38.30, 41.32)
-0.23 (-0.49, 0.04)
-0.15 (-0.47, 0.17)
3 7853.00 0.095 <0.0001 0.862 90
28
97
0.94
0.92
0.94
49.41 (46.57, 52.26)
62.27 (56.38, 68.16)
38.81 (37.35, 40.28)
-0.06 (-0.33, 0.21)
-0.39 (-0.81, 0.03)
-0.29 (-0.60, 0.02)
4 7812.30 0.051 <0.0001 0.821 16
80
41
78
0.93
0.85
0.85
0.95
64.73 (62.24, 67.23)
46.71 (43.75, 49.66)
55.36 (53.12, 57.61)
38.07 (36.06, 40.08)
-0.22 (-0.74, 0.30)
 0.02 (-0.34, 0.39)
-0.36 (-0.80, 0.08)
-0.30 (-0.61, 0.01)
BIC, Bayesian Information Criterion; LMr-Lrt, Vuong-Lo-Mendell rubin Likelihood ratio test; BLrt, Bootstrap 
Likelihood ratio test; CI, confidence interval
Table 5. Frequency distributions between the classes of disability and fatigue.
Average fatigue, n (%) High fatigue, n (%) Total, n (%)
Low disability, n (%) 83 (38.6) 50 (23.3) 133 (61.9)
High disability, n (%) 16 (7.4) 66 (30.7) 82 (38.1)
Total, n (%) 99 (46.0) 116 (54.0) 215 (100)
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diSCuSSiON
The main finding of our 3-year observational study was that disability and fatigue are 
relatively stable consequences of SSc over time. Overall, both disability and fatigue 
deteriorated slightly over time; HAQ-DI scores increased on average with 0.04 points 
per year, and SF-36 Vitality scores decreased with 0.46 points per year. We identified, 
a low and a high subgroup for disability, and an average and high subgroup for fatigue. 
Classes differed in baseline characteristics, but had similar trajectories over time, with 
small, statistically non-significant worsening of symptoms over time. Thus, differences 
in baseline scores, but not slopes, defined classes.
Our findings are in line with previous studies that have examined change in disability 
over time in patients with SSc [5,6]. Schnitzer et al. [5] in a cohort of 745 Canadian SSc 
patients, similarly found an increase in HAQ-DI score that ranged from 0.12 to 0.21 
over 3 years. The minimum clinically important difference (MCID), which defines the 
smallest change in a score of a health measure that patients identify as important 
[29], for the HAQ-DI has been suggested to be up to 0.14 in patients with SSc [30,31]. 
Thus, the change over 3 years that we found in our cohort is in the range of a clinically 
meaningful change for patients with SSc.
Patients in the high disability group were more likely to be female, have higher 
fatigue, more helplessness, and less emotion-focused coping. However, when pain 
was entered in the model, emotion-focused coping and pain were the only significant 
characteristics of disability classification, indicating that pain is an important factor in 
relation to disability, which role needs to be further explored.
In line with the study of Assassi et al. [15] that included 256 SSc patients with early 
SSc, fatigue levels in our study changed only slightly over time in the overall sample 
and in the two classes separately. The MCID for the SF-36 Vitality scale is unknown 
for SSc, but has been suggested to be 14.8 for patients with RA [32]. Thus, our finding 
that the SF-36 Vitality score decreases by 1.38 over 3 years indicates that this change 
is not clinically meaningful.
Self-reported impact of lung problems was an important characteristic of the 
patients with high baseline fatigue in our study. This was in line with the cohort of Assassi 
et al., where diffuse capacity of the lung for carbon monoxide (DLco) was predictive 
of change in fatigue severity [15], suggesting that patients with more extensive lung 
involvement are more likely to experience worse fatigue.
The results of our study have implications for clinical practice. Remarkably, SSc 
subtype and disease duration were not identified as characteristics of the high disability 
and high fatigue group, whereas cognitions and coping were associated with these 
groups. This implies that these psychosocial factors could be considered targets 
for treatment that focuses on reducing disability and fatigue and its impact on daily 
activities. Therapy should ideally be targeted to those who are most likely to benefit, 
thus preferably to patients experiencing both high disability and high fatigue, which 
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is approximately one-third of the patients in our study. Further research should focus 
specifically on these patients and need to identify the best strategy to target these 
consequences of SSc. An important research question might be, whether it is more 
effective to provide an intervention that targets both disability and fatigue at the 
same time or whether addressing the most bothersome symptom would also result in 
improvements of the other symptom.
The main limitation of our study relates to the relatively small sample size. As a 
consequence of this, we were not able to conduct GMM analyses. GMM is a more 
flexible approach compared to LCGA and allows assessment of parameters that can 
vary both within and between classes. Furthermore, there may have been different 
reasons for drop out in our study, and in some instances, the missingness itself may be 
informative, such as when patients drop out as a consequence of disease worsening 
or death [33]. We were not able to account for this informative dropout due to the 
small sample size. As a consequence, our results concerning the deterioration over 
time may be underestimated, because the remaining cohort may appear to be doing 
better over time simply because the sicker patients have dropped out. Furthermore, 
our cohort was a convenience sample of patients in two centers specialized in SSc 
treatment, and there was no information available about the received treatments 
during the 3-year follow-up.
In conclusion, functional disability and fatigue trajectories in SSc were relatively 
stable over a 3-year period, and difference in baseline scores, but not slopes, defined 
classes. More than half of the patients with SSc in our sample are relatively little affected 
by disability in daily functioning, whereas the vast majority of patients report to be 
consistently impacted by fatigue. In addition, our findings imply that psychosocial 
factors such as coping and cognitions could be considered as targets for treatment 
in particular in those patients who experience both high disability and high levels 
of fatigue.
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Objectives
To assess health care utilization in Dutch patients with systemic sclerosis (SSc) and 
its associated factors. To evaluate patients’ perspectives on quality of care and its 
association with health care use.
Methods
In a cross-sectional design, 198 Dutch patients with SSc completed an anonymous 
survey concerning health care utilization, quality of care (CQ Index), and quality of life 
(SF-36).
Results
In the last 12 months, 95% of the patients had contact with at least one medical specialist 
and two-thirds contacted at least one health professional (HP). The median numbers 
of visits to medical specialists and HPs were 7 and 7.5, respectively. Having a partner 
and reduced physical health status (SF-36 Role-Physical) were significantly associated 
with more visits to medical specialists and HPs. The median numbers of disciplines 
contacted since the onset of SSc and in the last 12 months were 8 and 4, respectively. 
Patients with less fatigue (SF-36 vitality) and more pain (SF-36 bodily pain) contacted 
more disciplines. A higher number of disciplines involved in the care was significantly 
associated with less satisfaction with the coordination of care (r = -0.14, P = 0.03).
Conclusion
Health care utilization in Dutch patients with SSc is substantial, as is reflected in the high 
number of visits and the number of disciplines. Patients’ rating of care coordination 
was lower if more disciplines were involved in their care.
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Systemic sclerosis (SSc, scleroderma) is a rare, multisystem, autoimmune disease 
characterized by fibrosis of the skin. SSc often also affects internal organs such as the 
kidneys, lungs, heart and gastro-intestinal tract [1]. Physical functioning is impaired 
in most patients with SSc, and disability increases over time [2]. As a consequence of 
this complex disease, patients report impairments in their physical as well as mental 
health-related quality of life (HRQL) [3] and often receive treatment from a variety of 
health care providers [4,5].
To date, little is known about the extent to which patients with SSc use health care 
services and how they evaluate the quality of care. Moreover, insight into health care 
utilization in Western European countries is lacking. Research so far has been restricted to 
three studies (two Canadian and one Hungarian study), however those studies assessed 
a limited range of health care providers [4,5,6]. Identified factors associated with more 
frequent visits to physicians in SSc included a higher income, more skin involvement, 
more comorbidities, and lower physical health status [4]. The generalizability of those 
studies to Western European countries is limited, due to differences in health care 
system and the accessibility of health care services (e.g. health insurance or travel 
distance). In addition, disease presentation might differ among countries, since more 
severe SSc cases have been reported in Eastern European countries than in Western 
European countries [7]. Therefore, it is important to assess health care utilization by 
patients with SSc in Western European countries, such as the Netherlands as well.
High quality care implies that care among multiple health care providers is 
coordinated into a coherent whole. Recent studies strongly suggests that failures 
in the coordination of care are common and can cause serious quality concerns [8]. 
The definition of care coordination is “the deliberate integration of patient care 
activities between two or more participants involved in a patient’s care to facilitate 
the appropriate delivery of health care services” [9]. Exchange of information and 
communication are basic elements of coordinated care.
Various studies show that lack of coordination may result in inconsistent treatment 
plans, wasteful duplication of diagnostic testing, and contradictory advices [8,10]. 
Therefore, good care coordination and communication between health care providers 
are regarded as imperative in chronic disease management [11,12]. Since SSc is a 
complex disease and multiple health care providers are involved in the treatment of 
SSc, it might be a challenge to coordinate care. Although poor coordination of care 
among health care providers may have serious consequences, it has never been studied 
how patients with SSc perceive the  coordination of their care.
Therefore, the aims of this study were 1) to assess health care use in a Dutch 
sample of patients with SSc and its association with demographic characteristics and 
HRQL, and 2) to evaluate patients’ perspectives on quality of care and to examine the 
association between quality of care and health care use.
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Patients and procedure
Between June and August 2011, the Dutch patient organization for patients with 
systemic autoimmune diseases (NVLE) invited 501 members with SSc and 198 members 
with mixed connective tissue disease (MCTD) to complete an anonymous online survey 
or a paper version on request. Invitations to members of the NVLE were based on their 
diagnosis at registration with the patient organization. Because MCTD could have been 
evolved into SSc [13] after registration, members with MCTD at registration were invited 
as well. Only those patients with a self-reported current diagnosis of SSc were included 
in the study. Patients with a diagnosis of SSc (self-report) and age 18 years or older were 
included in this study. The response rate was 69% (N = 481), of which 82% (N = 396) 
answered the survey online and 18% (N = 85) used the paper version (see flowchart in 
Figure 1). Based on a comparison of demographic variables, 28 questionnaires were 
classified as duplicates. Furthermore, 25 patients were excluded from the analyses 
because they failed to complete more than the demographic questions of the survey 
and 33 patients were excluded because they did not report a diagnosis. Only patients 
with systemic sclerosis were included in this study; patients with MCTD and other 
diseases were excluded. Of the 240 potentially eligible patients, 42 patients answered 
inconsistently that they had never visited a medical specialist while also reporting 
that a medical specialist had confirmed the diagnosis. Therefore, these patients were 
excluded from this study. Thus, a total of 198 SSc patients (28%) were included in the 
analyses. Ethical approval was obtained from the local medical ethics board (CMO 
2011/203).
The Dutch survey was partly based on a Canadian survey [14], which was jointly 
developed by a panel of Canadian Scleroderma Research Group and Scleroderma 
Society of Canada members, based on the Listening to Patients Survey and the CARE III 
online patient survey [15] created by the Arthritis Society. The core objective of the 
Canadian survey was to assess a broad range of symptoms and experiences of Canadian 
SSc patients, including quality of life, psychological and social aspects, employment, 
ability to obtain appropriate care, and interactions with health professionals. The 
Canadian survey was translated and adjusted for the Dutch health care system. 
Questions about health care utilization relating to SSc, quality of care, and quality of 
life were added to the original Canadian survey. Data on health care utilization and 
quality of care were used for the current study. Draft versions of the questionnaire were 
commented on by two patient representatives and adjusted accordingly.
Measures
Demographic variables assessed were: sex, age, education, marital status, current 
employment status, self-reported disease subtype (limited SSc, diffuse SSc, unknown), 
and the time since diagnosis.
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  108 MCTD 
  33 unknown diagnosis 
  28 localized scleroderma/ morphea 
  28 possible duplicates  
  19 other diagnosis 
  16 blank surveys 
  9 uncompleted surveys 
42 no visit to medical specialist 
A self-reported diagnosis of 
MCTD (n=198) or SSc (n=501) 
at registration with the patient 
organization 
Total: n=699 (100%) 
218 (31%) 
non-responders 
481 (69%) 
respondents 
241 (35%) 
excluded 
240 (34%) 
SSc respondents 
42 (6%) 
excluded 
198 (28%) 
SSc respondents 
Figure 1. Study flow chart figure 1. Study flow chart
Health care use related to SSc was assessed using a list of 26 health care providers, 
with the possibility to indicate other health care providers. Patients were asked 
whether they had had contact with a health care provider because of their SSc since 
the onset of the disease (yes/no) and during the last 12 months (yes/no). Health care 
use was classified according to four categories (see Table 1): medical specialists, 
health professionals, complementary therapists (manual therapist, touch therapist, 
acupuncturist, homeopathist, anthroposophist, hypnotherapist), and home care (home 
help, domestic help, community nurse). If patients indicated that they had contacted 
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a health care provider during the last year, they were asked how often they had visited 
this health care provider during the past year.
Perceived quality of care was assessed with two subscales of the Consumer 
Quality Index (CQ Index), which has been found to be a reliable measure of patients’ 
experiences with the quality of rheumatic health care [16]. The subscale “cooperation 
and alignment” (6 items) measures patients’ perspectives on how well health care 
providers transfer information and communicate with each other to coordinate care 
(e.g., “Were parallel treatments aligned with one another?”). This subscale was 
assessed on a five-point Likert scale (never, sometimes, most of the time, always, and 
I don’t know/ inapplicable) except for the question “Did you make appointments with 
the caregivers about what to do when the disease worsens?” (yes/no). The subscale 
“visit to most important health care provider” (5 items) measures how patients evaluate 
the interaction with their most important health care provider during appointments 
Table 1. Health care utilization by 198 patients with SSc.
Health care service
Contacted since  
onset ssc 
N (%)
Contacted in 
last 12  months¹ 
N (%)
Number of visits,
if at least one
Median (p25-p75)
Medical specialists 198 (100) 187 (95) 7 (4-11)²
   Rheumatologist 184 (93) 164 (83) 4 (2-4)
   General practitioner 177 (89) 99 (50) 3 (2-5)
   Cardiologist 143 (72) 92 (47) 1 (1-2)
   Lung specialist 139 (70) 90 (46) 1 (1-2)
   Dermatologist 115 (58) 50 (25) 2 (1-3.5)
   Internist 102 (52) 42 (21) 2 (2-4)
   Gastroenterologist 81 (41) 37 (19) 2 (1-3)
   Nephrologist 11 (6) 4 (2) 4 (1-4)
   Other medical specialists 22 (11) 26 (12) 3 (2-5)
Health professionals 175 (88) 132 (67) 7.5 (0-52)²
   Physical therapist 149 (75) 106 (53) 52 (22-55)
   Nurse specialist 89 (45) 30 (15) 1 (1-3)
   Occupational therapist 72 (36) 26 (13) 3 (1-6)
   Dietician 45 (23) 17 (9) 3 (1-4)
   Psychologist 38 (19) 14 (7) 3 (2-4)
   Social worker 35 (18) 8 (4) 4 (3-6)
   Exercise therapist 12  (6)  3 (2) 52 (5-52)
   Other health professionals 4 (2) 9 (5) 5 (3-17.5)
Complementary therapists 60 (30) 30 (15) 0 (0-0)²
Home care 75 (38) 59 (30) 0 (0-10)²
¹ missing value; ² number of visits including patients with no visits
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(e.g., “Did the health care provider explain things clearly?”). The subscale was assessed 
on a four-point Likert scale (1 = never to 4 = always). Higher scores on the CQ Index 
indicate higher satisfaction with the received health care. In addition, patients were 
asked to rate the quality of care by their most important health care provider on an 
11-point scale (0 = very poor to 10 = excellent). The CQ Index showed good internal 
consistency in our sample, with a Cronbach’s α of 0.87, and the subscales Cronbach’s 
α was 0.80 for “cooperation and alignment” and 0.89 for “visit to most important 
health care provider”.
The Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) is a 
generic questionnaire measuring HRQL [17]. The questionnaire consists of 36 items 
that measure 8 domains of health status: physical functioning, role-physical, bodily pain, 
general health, vitality, social functioning, role-emotional, and mental health. Lower 
scores indicate lower HRQL. The SF-36 has shown to be a valid measure of HRQL across 
diverse samples, including SSc [18-20]. The SF-36 showed excellent internal consistency 
in our sample, with a Cronbach’s α of 0.94.
statistical analysis
Descriptive statistics were used to describe demographic characteristics and health care 
use. Univariate linear regression analyses were performed to examine the association of 
sociodemographic and disease characteristics with health care use (number of different 
disciplines and number of visits). The variables that showed a univariate association 
(P < 0.20) with health care use were entered into multiple regression analyses, adjusted 
for sex, age, and time since diagnosis. Tolerance values were calculated to check for 
multicollinearity. In the final analyses, all tolerance values were between 0.39 and 0.97, 
indicating multicollinearity was not an issue.
Associations between perceived quality of care (including the mean scores of the 
CQ-Index subscales and the rating of the most important health care provider), the 
number of different disciplines and the number of visits in the last 12 months were 
investigated using partial Kendall’s tau, corrected for sex, age, educational level, 
employment status, marital status, disease subtype, and time since diagnosis. All 
statistical analyses were conducted using Stata/IC 10.1 software (StataCorp LP, College 
Station, TX).
rESulTS
Demographics and disease characteristics
Demographics and disease characteristics are displayed in Table 2. In total, 27 men and 
171 women were included, with a mean age of 58.1 years (SD = 11.3) and a mean time 
since diagnosis of 11.1 years (SD = 9.5). About half of the respondents had received 
higher education and most respondents were married or cohabiting. The majority of 
patients (65%) had limited SSc, and 31% had diffuse SSc.
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Medical specialists
Health care use is displayed in Table 1. Since the onset of the disease, the majority 
of the patients had contacted a rheumatologist (93%), general practitioner (89%), 
cardiologist (72%), lung specialist (70%), dermatologist (58%) or an internist (52%). Most 
patients (95%) had contact with at least one medical specialist in the last 12 months. 
Patients reported a median of 7 visits to medical specialists in the last year. In terms 
of medical specialists, patients who had at least one contact most frequently visited 
nephrologists and rheumatologists.
Health professionals
Most patients (88%) had contact with at least one health professional since the onset 
of the disease, and 67% of the patients visited a health professional in the last 12 
months, with the physical therapist being mentioned most frequently. About half of 
the patients (45%) had contacted a nurse specialist at some point. In total, patients 
reported a median of 7.5 visits to health professionals per year, and a mean of 32 visits. 
If only counted for patients with at least one visit, the mean visits per patient per year 
was 46. In terms of health professionals, patients who had at least one contact most 
frequently visited physical therapists and exercise therapists.
Complementary therapists and home care
Besides contacts with medical specialists and health professionals since the onset of 
the disease, 30% of the patients had contact with at least one complementary therapist, 
and home care had been used by 38% of the patients.
Table 2. Demographic and disease characteristics of 198 patients with SSc.
Characteristics
Female, N (%) 171 (86.4)
Age, years; mean (SD), range 58.1 (11.3), 29-85
Education level, N (%)
   0-12 years 101 (51.5)
   > 12 years 95 (48.5)
Living with partner, N (%) 139 (70.9)
Paid employment, N (%) 37 (18.9)
Disease subtype, N (%)
   Limited SSc 129 (65.2)
   Diffuse SSc 61 (30.8)
   Subtype unknown 8 (4.0)
Time since diagnosis, years; mean (SD), range 11.1 (9.5), 0-64
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In total, patients visited a median of 8 different disciplines (range 0-14) since the 
onset of their disease, including 5 medical specialists and 2 health professionals. In 
the last 12 months, involvement of a median of 4 different disciplines was reported, 
including 3 medical specialists and 1 health professional.
Associated factors of health care use
Univariate and multiple regression analyses are shown in Table 3, both for the number 
of visits and the number of different disciplines in the last 12 months. The multivariate 
analyses show that a higher SF-36 vitality score (Beta = 0.26, P < 0.05) and lower 
SF-36 bodily pain score (Beta = -0.21, P < 0.05) were significantly associated with the 
involvement of a higher number of disciplines. Thus, patients with less fatigue (SF-36 
vitality) or more pain visited more different disciplines. Having a partner (Beta = 0.16, 
P < 0.05) and lower SF-36 role physical score (Beta = -0.31, P < 0.01), meaning more 
problems with daily activities due to physical functioning, were found to be significantly 
associated with a higher number of visits. 
Perceived quality of care
Table 4 shows the perceived quality of care and its correlations with health care use. The 
mean scores for the subscales “cooperation and alignment” and “visit to most important 
health care provider” were 2.9 (SD = 0.8) and 3.6 (SD = 0.5), respectively. On average, 
patients gave their most important health care provider an 8.4 (SD = 1.4) on a scale of 0 to 
10. More than 90% of the patients reported that the most important health care provider 
took him/her seriously, listened carefully, explained things clearly, and spent enough 
time during appointments, and were satisfied about the opportunity to ask questions 
(Figure 2). Approximately 60% of the patients reported that treatments and advices were 
aligned with one another, and 53% felt that health care providers communicated well with 
each other. 12% of the patients reported to be dissatisfied with at least one aspect of 
the care provided by their most important health care provider, and 64% of the patients 
were dissatisfied about at least one aspect of care coordination. Scores on the subscale 
“cooperation and alignment” correlated significantly with the number of different health 
care providers (r = -0.14, P = 0.03), but not with number of visits.
diSCuSSiON
Our findings demonstrate that health care use in Dutch patients with SSc is substantial 
and involves multiple care providers. Physical health status and having a partner were 
found to be the most important factors associated with health care utilization. In 
addition, our results show that two-thirds of the patients was dissatisfied with at least 
one aspect of care coordination.
To date, there are few studies that have assessed the use of health care services in 
SSc, and none of these studies was conducted in a West-European country. In our study, 
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Table 3. Results of univariate and multiple regression analysis of the association of sociodemographic 
and disease variables with the number of disciplines and the number of visits to health care providers 
in the last 12 months (N = 197).
Characteristic
Number of disciplines¹ Number of visits¹
univariate regression
B (Beta) 
95% CI for B
Multiple regression
B (Beta) 
95% CI for B
univariate regression
B (Beta) 
95% CI for B
Multiple regression 
B (Beta) 
95% CI for B
Age -0.01 (-0.06)
-0.04, 0.02
-0.02 (-0.07)
-0.05, 0.02
-0.40 (-0.09)
-1.08, 0.28
-0.26 (-0.06)
-1.02, 0.51
Gender, female -0.22 (-0.03)
-1.20, 0.77
-0.01 (-0.00)
-0.99, 0.96
0.10 (-0.00)
-21.58, 21.77
1.62 (0.01)
-20.07, 23.31
> 12 years education 0.51 (0.11)
-0.17, 1.19γ
0.65 (0.14)
-0.06, 1.36
-2.57 (-0.03)
-18.10, 12.97
Paid employment -0.42 (-0.07)
-1.28, 0.44
-0.57 (-0.00)
-20.60, 19.46
Living with partner -0.08 (-0.02)
-0.83, 0.66
12.22 (0.11)
-4.53, 28.98γ
17.97 (0.16)
0.67, 35.27*
Diffuse SSc 0.10 (0.02)
-0.62, 0.83
2.28 (0.02)
-14.50, 19.06
Subtype unknown 0.25 (0.02)
-1.44, 1.94
4.35 (0.02)
-34.96, 43.65
Time since diagnosis - 0.03 (-0.13)
-0.07, 0.00γ
-0.03 (-0.11)
-0.07, 0.01
-0.76 (-0.14)
-1.58, 0.07γ
-0.81 (-0.15)
-1.66, 0.05
SF-36 Scales 
Physical functioning -0.06 (-0.25)
-0.09, -0.02∞
-0.04 (-0.16)
-0.08, 0.01
-1.11 (-0.23)
-1.83, -0.40∞
-0.90 (-0.18)
-1.92, 0.13
Role-physical -0.07 (-0.28)
-0.11, -0.03∞
-0.06 (-0.22)
-0.11, 0.00
-1.80 (-0.31)
-2.66, -0.94∞
-1.81 (-0.31)
-3.15, -0.46∞
Bodily pain -0.07 (-0.28)
-0.10, -0.03∞
-0.05 (-0.21)
-0.10, -0.00*
-1.07 (-0.20)
-1.88, -0.25*
-0.20 (-0.04)
-1.30, 0.90
General health -0.04 (-0.15)
-0.08, -0.00*
-0.02 (-0.08)
-0.07, 0.03
-0.72 (-0.12)
-1.64, 0.21γ
-0.05 (-0.01)
-1.21, 1.10
Vitality -0.03 (-0.11)
-0.07, 0.01γ
0.07 (0.26)
0.01, 0.12*
-0.85 (-0.15)
-1.74, 0.03γ
0.72 (0.12)
-0.53, 1.97
Social functioning -0.04 (-0.17)
-0.07, -0.01*
0.01 (0.06)
-0.03, 0.06
-0.63 (-0.13)
-1.37, 0.11γ
0.37 (0.07)
-0.64, 1.38
Role-emotional 0.00 (0.01)
-0.02, 0.03
0.14 (0.04)
-0.45, 0.73
Mental health 0.01 (0.04)
-0.03, 0.05
-0.39 (-0.07)
-1.23, 0.44
∞ p < 0.01, * p < 0.05, γ p < 0.20, ¹Medical specialists and health professionals
Dutch patients with SSc reported many visits to health care providers. In concordance 
with the existing literature [5,6], the rheumatologist and general practitioner were the 
most frequently visited physicians. The reported number of visits to medical specialists 
was similar to that in a Canadian study of SSc patients [4] and a Dutch study of patients 
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with systemic lupus erythematosus (SLE) [21], another chronic systemic autoimmune 
disease. However, the number of visits in the last 12 months to health professionals in 
our study was considerably higher than that reported in the study of Dutch SLE patients, 
with an average of 32 for SSc patients versus 13 visits for SLE visits [21].
Among health professionals, physical therapists are visited most frequently by 
patients with SSc. This finding suggests that physical therapists have a prominent role in 
the management of SSc. Problems may be jointly addressed in combined rehabilitation 
programs [22-25] and some evidence exist on their effectiveness. However, studies 
so far involve only small numbers of patients. The lack of accessible, evidence-based 
non-pharmacological interventions is an important gap in care for patients with SSc, 
and there is a need to establish recommendations for these interventions and to reduce 
variability in the management of SSc [26]. To address this gap, Scleroderma Patient-
centered Intervention Network (SPIN) was recently established to develop, test, and 
disseminate a set of accessible psychosocial rehabilitation interventions, designed to 
complement standard medical care in SSc [27].
Less than half of the participants in our study reported ever having visited a nurse 
specialist in secondary care, and only one out of six patients had contact with a nurse 
specialist during the last year. This is not concordant with the European League Against 
Rheumatism (EULAR) recommendations on the role of the nurse in the management 
of rheumatic diseases, which states that all patients should have access to a nurse 
specialist throughout the course of the disease [28]. This result may to some extent be 
due to underreporting of visits, because visits to a nurse specialist are usually planned 
in conjunction with a visit to a rheumatologist. Therefore, this could be regarded by 
patients as being part of a visit to a second care unit instead of a separate visit. Despite 
the good accessibility of health professionals like psychologists, occupational therapists, 
and social workers, who are skilled to target psychological well-being and physical 
functioning, patients reported relatively few visits to those health professionals. This 
might suggest that the provided care is not yet properly tuned to the patients’ needs.
Table 4. Perceived quality of health care rated by patients with SSc and correlation coefficients (r) 
between CQ Index, number of different disciplines and number of visits (N = 197).
CQ Index CQ Index
Number of different 
disciplines¹
Number  
of visits ¹
range mean (sD) r r
Cooperation and alignment 1-4 2.9 (0.8) -0.14* -0.07
Care from your most important
health care provider
1-4 3.6 (0.5) -0.01 0.01
Score 0-10 8.4 (1.4) -0.06 -0.03
* p < 0.05
¹ Kendall’s tau correlation corrected for: sex, age, level of education, employment status, marital status, disease 
subtype, time since diagnosis
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In concordance with results from studies conducted in the UK [29] and Germany [30], 
patients in our sample were satisfied with their most important health care provider. 
However, patients were not very satisfied with the coordination of care, as about two-
thirds of the patients were dissatisfied with at least one aspect of the coordination of 
care. In addition, we found that a greater number of health care providers involved 
in the care was associated with more dissatisfaction with coordination of care. These 
findings underline the need for further improvement in the coordination of care in the 
complex disease SSc. Our research findings warrant further research like qualitative 
studies to identify barriers in the coordination of care from health care providers’ and 
patients’ perspectives in order to obtain starting points to improve coordination of 
care in SSc.
An interesting finding in our study was that having a partner was correlated with 
more visits to health care providers, even after controlling for demographic and 
disease-related characteristics. A possible explanation for this finding is that married 
individuals are more likely to be subject to health-related social control than unmarried 
individuals [31] and receive more encouragement from their partners to visit a health 
care provider. Existing literature is, however, inconclusive regarding the association 
between marital status and health care use [32]. Although the majority of the published 
studies found that marital status had no impact on health care utilization [32], other 
studies found that being unmarried or living alone is associated with greater health 
care utilization. Possibly, in rare diseases like SSc, the encouragement and involvement 
of partners might have an influence on health care use, since information about the 
disease and its treatment is not readily available [33].
Another unexpected finding was that higher levels of fatigue (SF-36 vitality) were 
significantly associated with the involvement of fewer different disciplines in the 
patient’s care. This indicates that tired patients are less likely to seek treatment from 
various care providers less often, even though such treatment might be more necessary. 
This finding suggests that health care use might not yet be properly attuned to the 
patients’ needs in SSc. Possibly, fatigue may prevent certain patients from seeking the 
treatments they need for their SSc symptoms. Since fatigue has been found to be one 
of the main symptoms of SSc [14], our findings warrant specific attention to the impact 
of fatigue on visits to health care providers.
This study has certain limitations that should be taken into account when interpreting 
the results. First, the level of health care use was based on a patient-reported outcome, 
potentially leading to recall bias. According to the literature [34,35], self-reported 
physician visits in the last year are less precise than computerized provider records 
and are inaccurate due to underreporting, which is likely to increase as the number 
of visits increases. Thus, health care use in SSc might be even higher than described 
in this study. Furthermore, due to the use of patient-reported outcomes and the 
anonymous nature of the survey, it was not possible to verify the patient-reported 
diagnosis. However, previous data show that patients with rheumatic diseases rarely 
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report a diagnosis that is incompatible with their clinical diagnosis [36]. A potential 
limitation of the generalizability of our results is selection bias. Characteristics of 
the non-responders in this study are unknown and the sample in this study included 
only members of the patient organization. However, with regard to demographic and 
disease characteristics, the patients in our study were comparable to another large 
and well-described Dutch sample of patients with SSc [37].
A strength of the present study was the inclusion of a relatively large number of 
patients from all regions of the Netherlands, thereby avoiding geographical differences 
such as access to care influencing our results. In addition, a broad range of health care 
providers was included, providing a detailed and comprehensive insight in health care 
utilization in SSc.
In conclusion, health care use in SSc in the Netherlands is substantial and involves a 
range of care providers. The involvement of a greater number of different disciplines in 
the care of SSc was associated with less patient satisfaction in terms of communication 
among health care providers and care coordination. This implies that, for patients with 
a complex disease who receive care from multiple providers, attention should be given 
to the coordination of care, including communication among health care providers and 
synchronization of treatments.
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aBSTraCT
Objective
To describe the non-pharmacological care in systemic sclerosis (SSc) provided by 
European health professionals (HPs) including referrals, treatment targets, interventions, 
and educational needs.
Methods
In this observational study, European HPs working in SSc care were invited to complete 
an online survey through announcements by EUSTAR (European League Against 
Rheumatism (EULAR) Scleroderma Trials and Research) and FESCA (Federation of 
European Scleroderma Associations), the EULAR HPs’ newsletter, websites of national 
patient and HP associations, and by personal invitation.
Results
In total, 56 HPs, from 14 different European countries and 7 different disciplines, 
responded to the survey. In total, 133 specific indications for referral were reported, 
72% of which could be linked to the International Classification of Functioning, 
Disability and Health domain “body functions and structures”. Of the 681 reported 
treatment targets 45% was related to “body functions and structures”. In total, 105 
different interventions were reported as being used to address these treatment targets. 
Almost all (98%) respondents reported having educational needs, with the topics of 
management of stiffness (67%), pain (60%), and impaired hand function (56%) being 
mentioned most frequently.
Conclusions
Non-pharmacological care in SSc varies in Europe with respect to the content of 
interventions, reasons for referral, and treatment targets. Reasons for referral to HPs 
are not well-aligned to HPs subsequent treatment targets in SSc care suggesting 
suboptimal communication between physicians and HPs. The wide variations reported 
indicate a need to consolidate geographically disparate expertise within countries and 
to develop and improve standards of non-pharmacological care in SSc.
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iNTrOduCTiON
Systemic sclerosis (SSc, scleroderma) is a relatively uncommon and complex autoimmune 
connective tissue disease of unknown origin with clinically heterogeneous manifestations 
[1]. The disease is characterised by thickening and fibrosis of the skin and internal organs 
[2]. Currently, there is no cure available for SSc, and medical treatment focuses primarily 
on minimising internal organ involvement and symptom reduction for related organ, 
skin and musculoskeletal manifestations. Despite optimal pharmacological management 
and as a consequence of the complexity of the disease, the majority of patients with 
SSc experience a broad range of symptoms [3,4] including impairments in both physical 
and mental health-related quality of life (HRQL) [5]. Non-pharmacological treatment is 
often needed therefore as an adjunct to pharmacological treatment.
Research so far has shown that multiple non-physician health professionals can be 
involved in the care for patients with SSc. The physiotherapist is the most frequently 
contacted health professional and the proportion of patients that yearly contact a 
physiotherapist ranges between 31 - 61% [6-9]. In addition, a considerable proportion 
of patients visit other health professionals such as occupational therapists (13 - 34%) 
[7-9], dieticians (9 - 28%) [6,8,9],  social workers (4 - 20%) [8,9], nurse specialists (13 - 15%) 
[8,9], and psychologists (3 - 7%) [8,9]. The variety of health professionals who can be 
involved in the care for patients with SSc, reflects the broad range of symptoms that the 
majority of patients with SSc experience [3,4] and that can be targeted in interventions 
by health professionals.
There appears to be considerable national variation in access to different non-
physician  professions, in the types of interventions patients with SSc receive and which 
targets are set for treatment. The EULAR Scleroderma Health Professionals Network 
(EUSHNet) was established in 2011 with the goal of improving the quality of non-
pharmacological care in SSc by developing standards of care, reducing the variations in 
expertise, accessibility, and dissemination of knowledge within and among professions 
in Europe [10]. The aim of the current study was to provide an initial description of 
the non-pharmacological care provided by European health professionals who treat 
patients with SSc in terms of the content of referrals, targets of treatment, interventions, 
and educational needs.
maTErialS aNd mEThOdS
Participants and procedure
Participants were European health professionals, such as dieticians, nurses, occupational 
therapists, physiotherapists, podiatrists, psychologists, and social workers who are 
involved in the non-pharmacological care of people with SSc with sufficient knowledge 
of the English language. Health professionals working directly in clinical patient care 
or rehabilitation in the last five years and treating at least three patients with SSc in the 
last year were included in this study.
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European health professionals were invited in several ways to complete an online 
survey in English. First, an announcement of the survey including a hyperlink was 
placed in the European League Against Rheumatism (EULAR) health professionals’ 
newsletter. Second, EUSTAR (EULAR Scleroderma Trials and Research) members 
were emailed about the survey including a request to forward the email to 
health professionals working with patients with SSc. Third, announcements were 
placed on a range of relevant rheumatology websites, including the Federation 
of European Scleroderma Associations (FESCA) website, websites of 18 national 
patient associations, and websites of national health professionals associations. 
Fourth, a systematic literature search was conducted [11] and was used to identify 
from authorship listings, health professionals who had published research in fields 
related to the effectiveness of non-pharmacological care in SSc. The corresponding 
author received a personal invitation by email. The snowball propagation method 
was also used and participants were asked to send the email about the survey to 
health professional colleagues. The online survey was active between June 2012 
and June 2013.
survey
The electronic survey was conducted through the NetQuestionnaires website and 
developed by consensus between the members of the EUSHNet Steering Group (n = 9) 
and gathered information about: (1) participant characteristics; (2) the clinical setting 
and source of and reasons for referral to care provided by a health professional; (3) the 
targets of treatment; (4) interventions; and (5) educational needs.
Participant characteristics assessed were: gender, country, highest academic 
qualification (certificate/diploma, bachelor’s degree, master’s degree, postgraduate 
research, professor), year of graduation, and type of health professional.
Questions about clinical setting and referrals consisted mainly of closed-ended 
items asking health professionals about their work setting (hospital, ambulatory/
outpatient clinic, primary care, nursing home, home care, school/university, public 
health), the category of work (clinical patient care/rehabilitation, research, education, 
management), clinical experience (years), working in clinical practice in last 5 years 
(yes/no), and, if applicable, number of treated patients with SSc in the last year, the 
frequency of referrals from eight different sources, and an estimation regarding the 
three most common reasons for referral (open-ended question).
Targets of treatment in SSc care were assessed by providing participants with a list 
of 30 items of potential targets based on the concepts that were identified by Stamm 
et al. [12] and linked to the domains of the International Classification of Functioning, 
Disability and Health (ICF), including body functions and structures, activities and 
participation, and environmental and personal factors. Participants were required to 
tick the box(es) for those targets of treatment they felt were applicable to their own 
practice and they were also able to add up to two additional items per domain.
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To identify types of treatment interventions that were used, a list of 69 non-
pharmacological interventions was created from a literature search of reported non-
pharmacological treatment modalities employed by health professionals [11,13-19]. 
For each intervention on the list, participants were asked how frequently they used 
it (never, in some patients, in most/all patients) and they had the opportunity to add 
additional treatment interventions to the existing list. For brevity, only interventions 
provided by > 50% of health professionals in a profession and used in most/all patients 
are reported here.
Educational characteristics and needs were assessed by the following questions: 
post-graduate specialised training or education (yes/no), health professionals’ 
confidence about their knowledge of current research in SSc (1 = not at all confident 
to 4 = very confident), usefulness of further education (1 = not at all useful to 4 = very 
useful), preferred mode of deliverance of education (internet/e-learning, face-to-face 
sessions during conferences, written material), and a list of 22 potential topics based 
on the ICF for additional education (including three options to add other topics). 
Participants had to tick the box(es) only when they were interested in additional 
education on the topic.
The survey was pilot-tested by the members of the EUSHNet Steering Group, and 
was revised based on their feedback. A copy of the survey can be obtained from the 
first author.
Data analysis
Two researchers (LMW, NC) independently linked the most common reasons for 
referral to the ICF domains using established ICF linking rules [20]. If an item could 
not be mapped to the ICF classification, this item was assigned as “not covered”. 
Disagreements between the two researchers were discussed until consensus was 
achieved. Data were then analysed descriptively, and are presented as percentages for 
categorical variables. Analyses were conducted using Stata/IC 10.1 software (StataCorp 
LP, College Station, TX).
rESulTS
sample characteristics
In total 206 people viewed the survey on the website, of whom 102 completed at least 
part of the survey. Five duplicate response sets were identified and excluded from the 
analysis. Of the 97 unique response sets, 41 were excluded from the current analysis 
for not meeting the inclusion criteria: two (5%) did not work in Europe; 19 (46%) were 
not active in clinical patient care or rehabilitation in the last five years; two (5%) were 
medical doctors; 16 (39%) treated less than three patients with SSc in the last year; 
and two (5%) completed only the demographic and work setting characteristics. As a 
result, a total of 56 respondents were included in the analysis.
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The demographic characteristics of the 56 respondents are presented in Table 1. The 
majority of the responding health professionals were women (n = 49; 88%). Occupational 
therapists (n = 16; 29%), specialist nurses (n = 15; 27%) and physiotherapists (n = 14; 
25%) were the three most common professional groups represented. The majority 
worked in a hospital setting (n = 52; 93%) and had worked more than 10 years as a 
health professional (n = 40; 71%). Three quarters of respondents reported treating 
more than seven patients with SSc in the past year.
Table 1. Sample characteristics of 56 European health professionals working with patients with systemic 
sclerosis (SSc). (Continued)
Characteristics n (%)
Female 49 (87.5)
Country
   Netherlands 11 (19.6)
   United Kingdom 11 (19.6)
   Belgium 5 (8.9)
   Sweden 5 (8.9)
   Switzerland 5 (8.9)
   Austria 4 (7.1)
   Italy 4 (7.1)
   Denmark 2 (3.6)
   Germany 2 (3.6)
   Norway 2 (3.6)
   Spain 2 (3.6)
   Croatia 1 (1.8)
   Hungary 1 (1.8)
   Portugal 1 (1.8)
Profession
   Occupational therapist 16 (28.6)
   Specialist nurse 15 (26.8)
   Physiotherapist 14 (25.0)
   Podiatrist 7 (12.5)
   Psychologist 2 (3.6)
   Dietician 1 (1.8)
   Social worker 1 (1.8)
Highest academic qualification*
   Diploma 16 (29.6)
   Bachelor degree 18 (33.3)
   Master degree 17 (31.5)
   Postgraduate research (PhD) 1 (1.9)
   Professor 2 (3.7)
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Table 1. Sample characteristics of 56 European health professionals working with patients with systemic 
sclerosis (SSc). (Continued)
Characteristics n (%)
Practice setting†
   Hospital 52 (92.9)
   Ambulatory/ outpatient clinic 21 (37.5)
   School/ university 7 (12.5)
   Public health 3 (5.4)
   Primary care 3 (5.4)
   Home care 1 (1.8)
Category of work in last 5 years†
   Clinical patient care/ rehabilitation 56 (100)
   Research 21 (37.5)
   Education 19 (33.9)
   Management 7 (12.5)
   Other 1 (1.8)
Years worked in clinical practice as a health professional
   Less than 2 years 1 (1.8)
   2-10 years 15 (26.8)
   More than 10 years 40 (71.4)
Number of patients with SSc worked with in last year, more than 7 patients 43 (76.8)
* 2 missings; † multiple answers possible
Referrals
Referrals to health professionals were most frequently made by a rheumatologist (see 
Table 2). Table 3 presents the reasons for referral linked to ICF codes. In total, 164 reasons 
for referral were identified and subsequently linked to 133 ICF-codes, comprising 41 
unique ICF categories. Eight reasons for referral were linked to two ICF-codes and 39 
reasons for referral, such as “therapy” or “advice”, could not be classified and were 
assigned to the category “not covered”. Of the 133 ICF-codes, the majority were related 
to “body functions and body structures”(n = 96; 72%) with “protective functions of the 
skin” (b810) and “functions of the joints and bones, other specified and unspecified” 
(b729) arising as the most frequent ICF-codes. “Carrying out daily routine”(d230) was 
reported by 13 health professionals and was therefore the most frequent ICF-code 
describing referral within the domain of “activities and participation”.
Targets for treatment
Table 4 shows targets on which health professionals focus during treatment in the majority 
of their patients with SSc. In total, health professionals reported an average of thirteen 
treatment targets in the care for people with SSc. The majority of the reported 681 targets 
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Table 2. Frequency of referrals from different sources (n = 56).
n (%)
Never/not 
applicable
some of the 
patients
Most/all of the 
patients
General practitioners 41 (73.2) 13 (23.2) 2 (3.6)
Rheumatologists 4 (7.1) 4 (7.1) 48 (85.7)
Dermatologists 38 (67.9) 14 (25.0) 4 (7.1)
Other physician specialists 41 (73.2) 15 (26.8) 0 (0)
Non-physician health professionals 40 (71.4) 13 (23.2) 3 (5.4)
Self-referral 42 (75.0) 11 (19.6) 3 (5.4)
Other 54 (96.4) 1 (1.8) 1 (1.8)
Table 3. Reasons for referral expressed as ICF codes (n = 133) mentioned by 56 health professionals.
Reasons for referral n (%)
Body functions and structures 96 (72.2)
   Mental functions 5
   Sensory functions and pain 11
   Functions of the cardiovascular, haematological, immunological, and   
   respiratory systems
22
   Functions of the digestive, metabolic and endocrine systems 5
   Neuromusculoskeletal and movement-related functions 26
   Functions of the skin and related structures 21
   Other 2 
   Structures related to movement 4
Activities and participation 27 (20.3)
   General tasks and demands 14
   Mobility 5
   Self-care 5
   Major life areas 3
Environmental factors 10 (7.5)
   Products and technology 5
   Services, systems and policies 2
   Other 3
of treatment were linked to the ICF domains “body functions and body structures” 
(n = 303; 45%) with pain and stiffness mentioned by more than three quarters of the 
health professionals. One-third of the treatment targets are related to the ICF domain 
“environmental and personal factors”, and a quarter to “activities and participation”.
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Table 4. Health professionals’ targets of treatment in the care for patients with systemic sclerosis (n = 
681) mentioned by 53 health professionals.
Targets of treatment n (%)
Body functions and structures 303 (44.5)
   Pain 47 
   Stiffness, cramps, calcification 41 
   Fatigue 35 
   Blood vessels functions, Raynaud’s phenomenon 34 
   Emotional issues 32 
   Body image and appearance, including weight maintenance/loss 22 
   Skin 20 
   Lung function, bronchiae 19 
   Sleeping 19 
   Dry mucous membranes, dry mouth, eyes, nose 18 
   Ingestion functions 14 
   Other 2 
Activities and participation 161 (23.6)
   Household activities 39 
   Impaired hand function 37 
   Paid work and productive activities 36 
   Eating and drinking 26 
   Impaired foot function 17 
   Other 6 
Environmental and personal factors 217 (31.9)
   Coldness 39 
   Coping with the disease 37 
   Support from others 33 
   Non-pharmacological treatment 30 
   Experiences with healthcare institutions 23 
   Counselling 21 
   Footwear 20 
   Drugs and side effects 13 
   Other 1 
Interventions
Interventions frequently utilised in the treatment of people with SSc are detailed in 
Table 5. In total 105 different interventions were identified of which 34 were provided 
by > 50% of health professionals in a profession and used in most/all people with 
SSc. Of these 34 frequently provided interventions, nine were provided by at least 
two professional groups. The intervention “self-management” was reported by four 
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Table 5. Interventions used in the treatment of most/all patients with SSc by > 50% of health 
professionals (n = 53).
PT
n=14
Nurse
n=14
OT
n=14
Podiatrist
n=7
PsY
n=2
Dietician
n=1
sW
n=1
Assessment of body functions/structures/activities X X X
Physical activity promotion X
Posture training X
Manual therapy X
Training of upper extremity X X
Training of the hand X X
Training of the trunk X
Skin elasticity mouth X
Skin elasticity hand X X
Training of household activities X
Training of personal care activities X
Training of eating activities X
Training of leisure activities X
Training of work-related activities X
Thermotherapy X
Advice lifestyle X X
Advice illness and treatment X X
Advice physical activity X X X
Advice medication adherence X
Advice nutritional X
Advice energy conservation X
Advice joint protection X X
Advice splints X
Advice foot-care X
Advice footwear X
Advice assisstive devices X
Advice environment modifications X
Self-management X X X X
Cognitive restructuring X
Motivational Interviewing X
Support patient/family X
Supplement fluid X
Monitor nutritional status X
Health promotion X X X
pt = physiotherapist; Ot = occupational therapist; pSY = psychologist; SW = social worker
professional groups, including occupational therapists, psychologists, one dietician, 
and one social worker.
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diSCuSSiON
This was the first study to investigate the current non-pharmacological care in clinical 
practice provided by European health professionals who treat people with SSc. This 
study shows that non-pharmacological care in SSc is variable in Europe with respect 
to the content of interventions, reasons for referral, and targets of treatment. Most 
referrals concerned body functions and structures. There is an apparent discrepancy 
between the reasons for referral given by physicians and the subsequent targets of 
treatment set by health professionals, and it seems therefore, that expectations for 
non-pharmacological care are not well aligned between medical and non-physician 
health professionals caring for people with SSc. We acknowledge the relatively small 
Table 6. Educational needs of 52 European health professionals (HPs) working in systemic sclerosis 
care (n = 52).
Areas of educational need n (%) of HPs Areas of educational need n (%) of HPs
Understanding stiffness 35 (67.3) Respiratory function 19 (36.5)
Pain 31 (59.6) Digestive functions 16 (30.8)
Hand function 29 (55.8) Physical modalities 15 (28.9)
Fatigue 24 (46.2) Sexual function 15 (28.9)
Circulatory problems 24 (46.2) Functions and structures of cardiovascular system 14 (26.9)
Foot problems 24 (46.2) Dry mucous membranes 14 (26.9)
Face problems 23 (44.2) Ingestion functions 13 (25.0)
Emotional functions 23 (44.2) Nutrition intervention 11 (21.2)
Psychosocial functions 22 (42.3) Sleep 11 (21.2)
Physical functions 21 (40.4) Other 6 (11.5)
Educational needs among health professionals
Approximately one-third of the health professionals (n = 20; 39%) had participated 
in post-graduate specialised training, education or a course specifically about SSc. 
Although the majority of health professionals were either moderately confident or very 
confident that their knowledge of current research evidence about health professional 
practice in SSc care was up to date (n = 44; 85%), further training would be moderately 
or very useful according to most participants (n = 47; 90%). Specific educational 
needs were reported by 51 (98%) of the responding health professionals. A median 
of seven (interquartile range = 4-9) educational needs were reported, with further 
education about helping patients to manage stiffness, pain, and hand function cited 
most frequently as priority areas (Table 6). The preferred mode of education delivery 
reported was a combination of internet/e-learning (n = 38; 73%), face-to-face sessions 
during conferences (n = 33; 64%), and written material (n = 31; 60%).
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proportion of the total population of European health professionals completing the 
survey, which might reflect the fragmented expertise about non-pharmacological care 
for people with SSc.
Of note, there was a marked discrepancy between the reasons for referral to health 
professionals and the health professionals’ own targets for treatment as reported in 
our study. Reasons for referral primarily focused on body functions and structures 
in referring people with SSc to health professionals, while targets of treatment were 
more often reported in the domain of environmental and personal factors. The finding 
that physicians in making referral decisions mainly focus on functions and structures 
might indicate a lack of knowledge regarding the range of available treatment options 
that health professionals can deliver for people with SSc. This is likely to be due to 
suboptimal communication between physicians and health professionals. A tool that 
screens limitations in activities and participation problems and the patient-need for 
advice or therapy that can be addressed by a health professional, can help guide and 
optimize referrals for patients, such as the Perceived Limitations in Activities and Needs 
Questionnaire [21].
In our study we found that health professionals use a wide variety of non-
pharmacological interventions in treating people with SSc. In addition, we found 
some overlap in the interventions provided across the different professions. It is not 
uncommon that roles of health professionals partly overlap [22] and this can lead to both 
synergy and complimentary input for patients as well as to contradictory advice and 
conflicting treatment plans [23]. Considering the diversity in interventions, the number 
of disciplines potentially involved, and the limited evidence for the effectiveness of many 
non-pharmacological interventions in SSc [11], practice-based recommendations based 
on a broad consensus are highly warranted to improve the accessibility and inequity 
of care for people with SSc and to ensure consistency in approach between different 
professions. International consensus on a limited number of treatment targets and 
the content of a limited number of non-pharmacological interventions could provide 
a focus for both clinical practice and research. Agreement on core elements of non-
pharmacological care could increase transparency and enhance communication among 
different professional groups. Furthermore, a clear focus could facilitate international 
collaborative efforts to initiate randomized controlled trials with sufficient power to 
contribute meaningfully to the body of knowledge. These are important steps in 
establishing standards of non-pharmacological care for SSc.
Nearly all health professionals reported educational needs, although one-third of 
the health professionals in our study participated in post-graduate specialised training 
or education specifically about SSc and the majority of the health professionals were 
confident that their knowledge about current research in SSc was up to date. These 
educational needs were broadly in line with the most common symptoms experienced 
by patients with SSc [3,4], i.e. education in helping patients to manage stiffness, 
pain, and impaired hand function. The European network of health professionals 
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working in SSc care, EUSHNet, aims to combine the existing expertise among 
health professionals and to provide a platform to exchange knowledge and these 
results provides starting points for EUSHNet to develop educational courses and 
education material.
Our study has limitations that must be acknowledged. We noted previously that 
the sample reflects only a small proportion of the health professionals in the EULAR 
countries, especially in Eastern European countries. Furthermore, only half the health 
professionals that viewed the survey and read the explanatory notes on the website 
went on to complete the survey. This suggests that the health professionals who did not 
start filling in the survey may not have been confident about their expertise regarding 
the care for people with SSc. Alternatively, the relatively low number of respondents 
might also be explained by a lack of interest or the difficulty in responding using 
English language.
In conclusion, the complexity of SSc is reflected in the wide variety of targets for 
treatment and the breadth of interventions that health professionals use in the treatment 
of SSc. The reasons for referral by medical colleagues and subsequent treatment 
targets are not well aligned in SSc care, suggesting suboptimal communication 
between physicians and health professionals. Educational needs were identified in 
nearly every health professional responding. The self-reported expertise among health 
professionals in the  non-pharmacological care of SSc appears varied and a first step 
towards developing and improving standards of care in SSc may be to provide guidance 
and a framework for standardisation in education and practice through EULAR or 
similar organisations.
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aBSTraCT
Objective
To systematically and comprehensively document the effectiveness of non-
pharmacological interventions on physical functioning and psychological well-being 
in patients with systemic sclerosis (SSc).
Methods
Multiple electronic databases were searched for studies on the effectiveness of non-
pharmacological interventions in SSc. Randomized clinical trials (RCTs), controlled 
clinical trials (CCTs), and observational designs (ODs) with ≥ 10 participants were 
included. Two reviewers independently assessed methodological quality using the 
Downs & Black checklist.
Results
Twenty-three studies (9 RCTs, 4 CCTs, 10 ODs) were included. Studies assessing 
comparable interventions were grouped, resulting in data for sixteen different 
interventions. The total number of patients included per study ranged from 10 to 53. 
Seventeen different outcome domains were assessed, with hand function, limitations 
in activities, and quality of life being assessed most frequently. Three studies, all 
RCTs, were rated as ‘high quality’. These RCTs reported that i) a multi-faceted oral 
health intervention improves mouth hygiene and additional orofacial exercises did not 
improve mouth opening, ii) a multidisciplinary team care program improves limitations 
in activities, mouth opening, and hand grip strength, and iii) manual lymph drainage 
improves hand function, limitations in activities, and quality of life.
Conclusions
The body of knowledge regarding non-pharmacological care in SSc is very limited due 
to the wide variety in studied interventions and outcomes in the relatively uncommon 
but highly disabling disease. To structure and focus future research, an international 
consensus should be established to prioritize primary targets for non-pharmacological 
treatment, the content of interventions, and to agree on a core set of outcome measures.
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iNTrOduCTiON
Systemic sclerosis (SSc) is a rare and complex systemic autoimmune disease of unknown 
cause that affects the skin and multiple organs due to fibrosis [1]. SSc is a clinically 
heterogeneous disease, since patients can experience a broad range of symptoms, 
such as fatigue, pain, impaired hand function, dry mouth, and sleeping difficulties [2-6]. 
These symptoms are commonly associated with a considerable impact on the ability 
to carry out everyday activities [2,3], and the majority of patients report impairments 
in their physical as well as mental health-related quality of life (HRQL) [7-9].
Comprehensive care in chronic diseases, including SSc, involves a combination of 
both pharmacological and non-pharmacological interventions [10]. Because there is 
no cure, non-pharmacological treatment, including psychological, educational, and 
rehabilitation interventions may be provided as an adjunct to medical treatment in SSc. 
Non-pharmacological care aims to attenuate disability and support patients in coping 
with the disease [11]. Non-pharmacological care can target a broad range of symptoms 
simultaneously, depending on the needs expressed by patients. To help guide medical 
care for patients with SSc, the European League against Rheumatism (EULAR) and the 
EULAR Scleroderma Trials and Research group (EUSTAR) have developed evidence-
based, consensus-derived recommendations for the pharmacological treatment of 
SSc [12]. The authors of these guidelines also emphasized the potential importance of 
psychosocial and rehabilitation interventions in disease management, but could not 
make recommendations for or against these types of interventions. To contribute to 
developing such guidelines, an overview of the effectiveness of non-pharmacological 
interventions in patients with SSc is needed.
To date, three reviews have been published concerning non-pharmacological care 
in SSc. Poole [13] reviewed the evidence for the efficacy of rehabilitation techniques 
for musculoskeletal impairments in persons with SSc; Casale et al. [14] summarized 
the current management of skin, joints, tendons, muscles, pain, ergonomics, and 
working interventions in SSc; and Alantar et al. [15] reviewed preventive and curative 
treatments for oral and dental involvement in patients with SSc. These reviews did not 
utilize a systematic approach to identify and synthesize evidence however, did not 
assess the quality of included studies, and had a narrow scope of non-pharmacological 
interventions and outcome measures to be included in the review. The objective of 
this study was therefore, to systematically and comprehensively review the evidence 
on the effectiveness of non-pharmacological interventions on physical functioning and 
psychological well-being in patients with SSc.
mEThOdS
An expert panel consisting of two physical therapists (CHME, CB), an epidemiologist 
(TPMVV), two occupational therapists (TAS, JLP), three psychologists (LK, JEV, LMW), 
and a rheumatologist (AAS) developed the review protocol, including the eligibility 
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criteria for studies to be included, the methods of selection of studies, assessment of 
methodological quality, summarizing the evidence, and the interpretation of the results.
search strategy
The MEDLINE, EMBASE, CINAHL, PsycINFO, Cochrane Library, and Web of Science 
databases were searched from 1990 to March 2014. The broad computerized search 
strategy consisted of the combination of two main components (see supplementary 
Table S1 for the detailed search strategy); (1) the identification of studies involving 
patients with SSc, using key words and free text words ‘systemic scleroderma,’ 
‘diffuse scleroderma,’ ‘limited scleroderma,’ ‘systemic sclerosis,’ ‘scleroderma’; and 
(2) the identification of studies on non-pharmacological interventions, including more 
than 50 search terms that reflected types of interventions (e.g., ‘rehabilitation,’ ‘non-
pharmacological treatment,’ ‘physical therapy modalities,’ ‘exercises,’ ‘massage,’ 
‘stretching,’ ‘behaviour therapy,’ ‘occupational therapy,’ ‘splints,’ ‘activities of daily 
living,’ ‘nutrition therapy,’ ‘dental hygiene’).
To ensure a broad search, neither search terms for the identification of outcome 
measures nor for study design were applied. The search strategy was formulated in 
MEDLINE and was adapted for use in the other databases. Additionally, the reference 
lists of relevant articles and review articles were hand-searched for additional relevant 
studies.
Inclusion criteria and procedure
Studies were eligible for inclusion in the review if: (1) the study was published in 
English, German, French, Spanish or Dutch, since these languages are mastered by 
the authors and there was no budget available to consult translators; (2) the study 
was published in a full-length article or full written report; (3) the publication date 
was between 1990 and 2014; (4) the study sample consisted of patients ≥ 18 years of 
age with SSc; (5) outcomes for patients with SSc were reported separately in case of 
studies with a mixed patient sample; (6) the effectiveness was assessed of at least one 
non-pharmacological intervention defined as an intervention fitting in the domain 
of physical therapy, psychological therapy, occupational therapy, nursing, nutrition 
therapy, podiatry, and oral/ dental hygiene therapy, excluding medication, surgery or 
combined interventions with injections; (7) at least one outcome domain was assessed 
representing physical functioning or psychological well-being; and (8) at least 10 study 
participants were included.
The procedure for inclusion of the studies was based on the recommendations of van 
Tulder et al. [16]. The first selection, based on titles and abstracts and in consideration 
of the inclusion criteria, were independently performed by two reviewers (LMW, JEV). 
If either deemed an article potentially eligible based on title/abstract review, then a 
full-text review was completed. The second step of inclusion was performed by the 
same two reviewers, who independently considered the criteria described above using 
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full-text articles. Disagreements after full-text review were resolved by consensus. A 
third reviewer (CHME) was consulted when agreement was not achieved.
Quality assessment
To evaluate the quality of both randomized and non-randomized studies, the Downs 
and Black checklist was used [17], consisting of 27 criteria representing five domains: 
study reporting, external validity, internal validity- bias, internal validity- confounding, 
and power. The Cochrane Musculoskeletal Group has rated the Downs and Black 
checklist in the top six quality assessment tools that are potentially useful for systematic 
reviews including non-randomized studies [18-20]. Item 27 of the checklist was slightly 
modified (see supplementary Table 2) [21,22]. For each study, a total quality score was 
computed by adding up all item scores, resulting in a maximum possible score of 28 
(item 5: 0 = no, 1 = partially, 2 = yes). The checklist does not provide a classification 
for distinguishing between low and high quality studies. Consequently, we arbitrarily 
defined a priori that a study with a score ≥ 19 was considered of high quality, reflecting 
two-third of the maximum score.
The methodological quality of all included studies was assessed independently by 
one reviewer (LMW), and two reviewers each assessed half of the dataset (JEV, CHME). 
The three reviewers pilot-tested the checklist for three studies that were not included 
in the current review. Disagreement was resolved by consensus. If consensus could not 
be reached, a third reviewer (CHME or JEV) was consulted. The inter-rater reliability 
was examined using Cohen’s kappa.
Data analysis
Data were extracted for intervention characteristics, patient characteristics, outcome 
measures, study methods, and study results. One reviewer (LMW) extracted the data 
and entered data items into a standardized spreadsheet.
It was considered inappropriate to perform a meta-analysis due to the heterogeneity 
of the included studies with regard to intervention content, mode of delivery, duration, 
and outcome measures. Considering the heterogeneity of outcome measures, we 
decided pragmatically to categorize the outcome measures in outcome domains on the 
basis of consensus among CHME, JEV, and LMW, and sorted the domains according to 
the International Classification of Functioning, Disability, and Health (ICF). A list of 17 
relevant outcome domains was compiled including hand function/ dexterity, Raynaud’s 
phenomenon, aerobic capacity, muscle strength, fatigue, pain, mood, skin problems 
(e.g. skin thickness, elasticity, stiffness), mouth function, mouth hygiene, face function, 
gastrointestinal problems, limitations in activities, quality of life, cognitions, coping, 
and need for education. When outcome measures were related to a specific body part, 
the outcome domain was classified according to the localization. For example hand 
pain and hand skin score were classified as hand function, rather than as pain or skin 
problems, respectively.
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For each outcome domain included in a study, the reported effect was scored as 
positive (‘+’) or negative (‘-’) when results were statistically significant, and no effect 
(‘0’) when results were not statistically significant. Results with a p-value ≤ 0.05 were 
considered to be statistically significant. A number of decision rules were defined to 
score the effectiveness transparently. First, when multiple outcome measures and/or 
multiple subscales were used to assess the same outcome domain within a study, then 
> 50% of the outcome measures or subscales used needed to be effective to score 
a ‘+’. Second, when total scores were provided, those scores were preferred over the 
results of subscales scores.
The authors of  the high quality studies were contacted to request for additional data 
to calculate effect sizes (ES) and its 95% confidence intervals (CI). Where possible, the ES 
was calculated using the difference between the means of the intervention and control 
group on the post measurement divided by the pooled standard deviations. A positive 
effect size indicated that the intervention was successful, whereas a negative effect size 
indicated that the control group had been superior. The values of the ES were interpreted 
as small (0.20 ≤ ES < 0.50), medium (0.50 ≤ ES < 0.80), and large (ES ≥ 0.80) [23].
rESulTS
search results
The electronic database search yielded 2295 unique publications for screening of 
title and abstract, of which 35 articles were obtained for full-text review (see Figure 1). 
Twenty-four articles, reporting on 23 studies, met our inclusion criteria. In one study the 
intervention of orofacial exercises were nested in a broader oral health intervention and 
the results of these articles were considered together for the purpose of the present 
study [24,25].
Characteristics of included studies
The characteristics of the included studies are presented in Table 1. Of these studies, 
nine were randomized clinical trials (RCTs), four were controlled clinical trials (CCTs), 
and ten were observational designs (ODs). Two CCTs included healthy controls, and in 
one CCT and one RCT the non-treated hand/arm of the patient served as control. The 
total number of participants included in the studies varied from n = 10 to n = 53, the 
average age ranged from 44 to 57 years, the proportion of women ranged from 65% 
to 100%, and the mean disease duration ranged from 5 to 11 years.
The effectiveness of the following interventions was assessed: education [26], 
oral therapy [24,25,27,28], comprehensive rehabilitation program for physical and/
or psychological functioning [29,30], self-management [31,32], comprehensive 
rehabilitation for the hands and/or face [33-36], aerobic training [37], stretching [38], 
paraffin treatment [39,40], carbon dioxide baths [41], manual lymph drainage [42], 
ultrasound [43], extracorporeal shock wave therapy [44], biofeedback [45], deep 
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3404 records identified through 
database searching 
1 additional record identified by 
hand-search 
2295 records after duplicates 
removed 
2295 records screened on title and 
abstract 2259 records excluded 
36 full-text articles assessed for 
eligibility 
13 full-text articles excluded: 
   No pre-post measurement: 5 
   Case report: 3 
   Less than 10 participants: 2 
   No full-text article: 1 
   Wrong study population: 2 
23 eligible articles 
24 articles included 
Figure 1. Flow diagram of inclusion procedure. 
figure 1. Flow diagram of inclusion procedure.
oscillation [45], transcutaneous electrical nerve stimulation (TENS) [46], and home 
total parenteral nutrition [47]. The most frequently examined interventions were aimed 
(amongst other treatment targets) to improve hand function [33-35,38-40,42-45] and the 
function of the mouth and face [24,25,27,28,34,36]. The intervention duration ranged 
from two days [26] to one year [38]. Of the included studies, nine were home-based 
interventions [24,25,28,31,32,38-40,46,47], five were clinic/hospital-based interventions 
[26,30,34,37,42], five were combined home/hospital-based interventions [27,29,33,35,36], 
and four studies did not report the setting of the intervention [41,43-45].
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Table 1. Study design, description of the study interventions, patient characteristics, and outcome 
measures. (Continued)
First Author,
Year,
Country
study 
Design Intervention group
Post 
intervention 
assessment
Control 
Group
Number of 
Patients 
Mean Age 
(Years) Females (%)
Mean disease 
duration
(Years)
Primary 
outcome
Outcome domain 
(outcome measure)3
Patient Education
Pai, 2010, Taiwan 
[26]
OD Standardized nursing instruction about steroid pulse 
therapy both verbal and written, individualized to the 
patient. Minimum of 10 minutes each day for 2 days.
2 days N/A Tx: 20
Control: 
N/A
NR NR NR NR Need for education (questionnaire need 
for nursing instruction)
Oral therapy
Poole, 2010, USA 
[27]
OD Dental examination and cleaning by a dental 
hygienist. A structured home program consisting 
of patient education on brushing and flossing 
techniques, hand exercises 3 sets of 5 stretches once 
a day, facial exercises 5 stretches for 3-5 seconds once 
a day, individualized adapted dental appliances, and 
a 6-month supply of dental products. Once or twice a 
day for 6 months.
6 months N/A Tx: 17
Control: 
N/A
54 88 11 NR Hand function (Keitel Function Test, grip 
strength, timed button test, Grooved 
Pegboard) 
Mouth function (lip aperture, teeth 
aperture) 
Mouth hygiene (patient hygiene 
performance index, xerostomia)
Pizzo, 2003, Italy 
[28]
OD Mouth stretching exercises for at least 15 minutes, 
twice a day and oral augmentation exercise with a 
stick of soft wood daily during 18 weeks.
18 weeks N/A Tx: 10
Control: 
N/A
57 100 NR Maximal 
mouth 
opening
Mouth function (maximal mouth opening)
Yuen, 2011, USA 
[24] & Yuen, 2012, 
USA [25]
RCT Multi-faceted oral health intervention: adaptive oral 
hygiene devices, instruction and demonstration on the 
use of the devices. Brush teeth for 2 minutes and floss 
twice a day for 6 months.
Subgroup
Orofacial exercises including manual mouth-stretching 
and oral-augmentation exercises with a wooden stick 
(oral aperture < 40 mm), twice a day for 6 months.
6 months
Subgroup
6 months
Usual dental 
care
Tx: 26
Control: 22
Subgroup
Tx: 13
Control: 15
Tx: 52 
Control: 49
Subgroup
Tx: 52
Control: 51
Tx: 81
Control: 77 
Subgroup
Tx: 85
Control: 73
Tx: 8
Control: 7 
Subgroup 
Tx: 11
Control: 6
Löe-Silness 
gingival 
index 
Subgroup
Maximal 
mouth 
opening
Mouth hygiene (Löe-Silness gingival 
index)
Subgroup
Mouth function (maximum oral aperture)
Comprehensive rehabilitation for physical and/or psychological functioning
Schouffoer, 2011, 
the Netherlands 
[29]
RCT Multidisciplinary team care program with individual 
treatment goals once a week for 12 weeks, including 
general exercises, hand/mouth exercises, and 
educational sessions. Individual supervised exercises 
provided by a local physical therapist and a home-
based exercise program at least 6 days a week for 12 
weeks. 
12 weeks Usual care Tx: 28
Control: 25
Tx: 54
Control: 52
Tx: 68
Control: 84
Median 
disease 
duration
Tx: 7 Control: 
8
NR Aerobic capacity (VO2max) 
Fatigue (CIS-20) 
Hand function (HAMIS, grip strength) 
Limitations in activities (6MWT, SHAQ) 
Mouth function (maximal mouth opening) 
Pain (VAS pain) 
Quality of life (SF-36)
Kwakkenbos, 
2011, the 
Netherlands [30]
OD Psycho-educational group program with the following 
topics: goal setting and evaluation, education 
about the disease, education about joint protection 
and energy conservation, discussing psychosocial 
aspects of the disease, and education about benefits 
of exercise. An introduction lesson of Tai Chi was 
provided. Modules of 1.5 hour each, covering 13 
different topics, scheduled over 3 weekends.
6 weeks N/A Tx: 41
Control: 
N/A
53 83 10 NR Cognitions (ICQ acceptance, ICQ 
helplessness, ALS)
Coping (UCL)
Fatigue (VAS fatigue)
Limitations in activities (HAQ-DI) 
Mood (IRGL depressed mood)
Pain (VAS pain)
self-management
Poole, 2013, USA 
[31]
OD Mail-delivered self-management program. The 
program consisted of a workbook and face, mouth, 
hand, arm, and leg exercises on DVD. Participants 
were expected to complete the program in 3 to 4 
months.
4 to 6 
weeks after 
program 
completion
N/A Tx: 49
Control: 
N/A
54 92 7 NR Coping (ASES)
Fatigue (MAF)
Hand function (SFAQ)
Limitations in activities (HAQ)
Mood (CES-D)
Pain (VAS)
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Table 1. Study design, description of the study interventions, patient characteristics, and outcome 
measures. (Continued)
First Author,
Year,
Country
study 
Design Intervention group
Post 
intervention 
assessment
Control 
Group
Number of 
Patients 
Mean Age 
(Years) Females (%)
Mean disease 
duration
(Years)
Primary 
outcome
Outcome domain 
(outcome measure)3
Patient Education
Pai, 2010, Taiwan 
[26]
OD Standardized nursing instruction about steroid pulse 
therapy both verbal and written, individualized to the 
patient. Minimum of 10 minutes each day for 2 days.
2 days N/A Tx: 20
Control: 
N/A
NR NR NR NR Need for education (questionnaire need 
for nursing instruction)
Oral therapy
Poole, 2010, USA 
[27]
OD Dental examination and cleaning by a dental 
hygienist. A structured home program consisting 
of patient education on brushing and flossing 
techniques, hand exercises 3 sets of 5 stretches once 
a day, facial exercises 5 stretches for 3-5 seconds once 
a day, individualized adapted dental appliances, and 
a 6-month supply of dental products. Once or twice a 
day for 6 months.
6 months N/A Tx: 17
Control: 
N/A
54 88 11 NR Hand function (Keitel Function Test, grip 
strength, timed button test, Grooved 
Pegboard) 
Mouth function (lip aperture, teeth 
aperture) 
Mouth hygiene (patient hygiene 
performance index, xerostomia)
Pizzo, 2003, Italy 
[28]
OD Mouth stretching exercises for at least 15 minutes, 
twice a day and oral augmentation exercise with a 
stick of soft wood daily during 18 weeks.
18 weeks N/A Tx: 10
Control: 
N/A
57 100 NR Maximal 
mouth 
opening
Mouth function (maximal mouth opening)
Yuen, 2011, USA 
[24] & Yuen, 2012, 
USA [25]
RCT Multi-faceted oral health intervention: adaptive oral 
hygiene devices, instruction and demonstration on the 
use of the devices. Brush teeth for 2 minutes and floss 
twice a day for 6 months.
Subgroup
Orofacial exercises including manual mouth-stretching 
and oral-augmentation exercises with a wooden stick 
(oral aperture < 40 mm), twice a day for 6 months.
6 months
Subgroup
6 months
Usual dental 
care
Tx: 26
Control: 22
Subgroup
Tx: 13
Control: 15
Tx: 52 
Control: 49
Subgroup
Tx: 52
Control: 51
Tx: 81
Control: 77 
Subgroup
Tx: 85
Control: 73
Tx: 8
Control: 7 
Subgroup 
Tx: 11
Control: 6
Löe-Silness 
gingival 
index 
Subgroup
Maximal 
mouth 
opening
Mouth hygiene (Löe-Silness gingival 
index)
Subgroup
Mouth function (maximum oral aperture)
Comprehensive rehabilitation for physical and/or psychological functioning
Schouffoer, 2011, 
the Netherlands 
[29]
RCT Multidisciplinary team care program with individual 
treatment goals once a week for 12 weeks, including 
general exercises, hand/mouth exercises, and 
educational sessions. Individual supervised exercises 
provided by a local physical therapist and a home-
based exercise program at least 6 days a week for 12 
weeks. 
12 weeks Usual care Tx: 28
Control: 25
Tx: 54
Control: 52
Tx: 68
Control: 84
Median 
disease 
duration
Tx: 7 Control: 
8
NR Aerobic capacity (VO2max) 
Fatigue (CIS-20) 
Hand function (HAMIS, grip strength) 
Limitations in activities (6MWT, SHAQ) 
Mouth function (maximal mouth opening) 
Pain (VAS pain) 
Quality of life (SF-36)
Kwakkenbos, 
2011, the 
Netherlands [30]
OD Psycho-educational group program with the following 
topics: goal setting and evaluation, education 
about the disease, education about joint protection 
and energy conservation, discussing psychosocial 
aspects of the disease, and education about benefits 
of exercise. An introduction lesson of Tai Chi was 
provided. Modules of 1.5 hour each, covering 13 
different topics, scheduled over 3 weekends.
6 weeks N/A Tx: 41
Control: 
N/A
53 83 10 NR Cognitions (ICQ acceptance, ICQ 
helplessness, ALS)
Coping (UCL)
Fatigue (VAS fatigue)
Limitations in activities (HAQ-DI) 
Mood (IRGL depressed mood)
Pain (VAS pain)
self-management
Poole, 2013, USA 
[31]
OD Mail-delivered self-management program. The 
program consisted of a workbook and face, mouth, 
hand, arm, and leg exercises on DVD. Participants 
were expected to complete the program in 3 to 4 
months.
4 to 6 
weeks after 
program 
completion
N/A Tx: 49
Control: 
N/A
54 92 7 NR Coping (ASES)
Fatigue (MAF)
Hand function (SFAQ)
Limitations in activities (HAQ)
Mood (CES-D)
Pain (VAS)
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Table 1. Study design, description of the study interventions, patient characteristics, and outcome 
measures. (Continued)
First Author,
Year,
Country
study 
Design Intervention group
Post 
intervention 
assessment
Control 
Group
Number of 
Patients 
Mean Age 
(Years) Females (%)
Mean disease 
duration
(Years)
Primary 
outcome
Outcome domain 
(outcome measure)3
Poole, 2014,
USA [32]
OD Interactive internet-based self-management 
program. The program consisted of 10 modules 
(e.g. self-advocacy, fatigue and energy conservation, 
coping and body image/appearance ), an exercise 
video, learning activities, worksheets, and resources. 
Participants proceeded through the modules at their 
own pace over 10 weeks.
10 weeks N/A Tx: 16
Control: 
N/A
52 88 8 NR Cognitions (PAM)
Coping (SE Scale, heiQ)
Fatigue (VAS fatigue)
Limitations in activities (HAQ-DI)
Mood (CES-D)
Pain (VAS pain)
Quality of life (self-rated health)
Comprehensive rehabilitation for hands and/or face
Antonioli, 2009, 
Italy [33]
CCT Rehabilitation program consisted of warm-up and 
cool-down exercises, training of motor functions, 
diaphragmatic breathing, controlled coughing 
exercises, treadmill, free-walking, finger stretching 
and occupational therapy for 2 weeks daily 30-minute 
sessions (10 sessions in total). Physiotherapy was 
prescribed when necessary. At-home exercise 
programme was prescribed on days when the 
programme was terminated.
2 months Usual care Tx: 16
Control: 17
Median 
age:
Tx: 67
Control: 57
Tx: 100
Control: 94
Median 
disease 
duration:
Tx: 15
Control: 9
NR Aerobic capacity (modified Borg 
Dyspnoea Scale, VAS dyspnoea, lung 
function test: FVC and DLCO)
Hand function (HAMIS)
Limitations in activities (HAQ-DI, 6MWT)
Quality of life (SF-36, Saint George’s 
Respiratory Questionnaire)
Skin problems (mRSS)
Maddali-Bongi, 
2009, Italy [34]
RCT Rehabilitation program for the  hands and face. 
Hand involvement was treated with a combination 
of connective tissue massage and Mc Mennell joint 
manipulation. Manual lymph drainage if patients had 
edematous hands. Face involvement was treated with 
a combination of Kabat’s method, connective tissue 
massage, and kinesitherapy. Hydrokinesytherapy (for 
patients without ulcers) or land-based rehabilitation 
(for patients with ulcers), and respiratory rehabilitation 
exercises.  One or two sessions  per week for 9 weeks.
9 weeks Continue 
current care
Tx: 10
Control: 10
Tx: 58
Control: 56
Tx: 60
Control: 70
Tx: 9
Control: 9
NR Face function (VAS face)
Hand function (HAMIS, Duruoz scale, 
hand opening, fist closure, water 
volumetric test)
Limitations in activities (HAQ-DI)
Mouth function (mouth opening)
Quality of life (SF-36)
Maddali-Bongi, 
2009, Italy [35]
RCT Combined rehabilitation treatment of connective 
tissue massage and Mc Mennell joint manipulation 
for1 hour, twice per week for 9 weeks. Home exercise 
programme for the hands daily 20 minutes for 9 
weeks.
9 weeks Home 
exercise 
programme 
for the 
hands daily 
20 minutes 
for 9 weeks
Tx: 20
Control: 20
Tx: 56
Control: 58
Tx: 80
Control: 70
Tx: 9
Control: 9
NR Hand function (HAMIS, Cochin hand 
functional disability scale, hand opening, 
fist closure)
Limitations in activities (HAQ-DI)
Quality of life (SF-36)
Maddali-Bongi, 
2010, Italy [36]
RCT Rehabilitation program for the face with a combined 
four-step procedure of connective tissue massage 
(10 min), Kabat’s method (15 min), kinesitherapy (15 
min), relaxing exercise (20 min). In total, 1 hour, twice 
per week for 9 weeks. A home programme of mimic 
exercises daily for 18 weeks.
18 weeks Home 
programme 
of mimic 
exercises 
only
Tx: 20
Control: 20
Tx: 57
Control: 57
Tx: 90
Control: 80
Tx: 10
Control: 9
NR Limitations in activities (HAQ-DI)
Mouth  function (MHISS, mouth opening)
Quality of life (SF-36)
Skin problems (mRSS)
Aerobic training
Pinto, 2011, Brazil 
[37]
OD Supervized concurrent training session consisted 
of treadmill warm-up (5 min) followed by resistance 
training (30 min), treadmill aerobic training (20 min), 
and stretching exercises (5 min). Resistance training 
included 5 exercises for the main muscle groups: 
bench press, leg press, lat pull down, leg extension, 
and seated row. 1 hour sessions, twice per week for 
12 weeks.
12 weeks N/A Tx: 11
Control: 
N/A
44 100 7 NR Aerobic capacity (VO2 peak, AT, RCP, 
heart rate rest, heart rate peak exercise)
Hand function (hand grip)
Muscle strength (leg press, bench press, 
low back strength, timed up and go, 
timed stands)
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Table 1. Study design, description of the study interventions, patient characteristics, and outcome 
measures. (Continued)
First Author,
Year,
Country
study 
Design Intervention group
Post 
intervention 
assessment
Control 
Group
Number of 
Patients 
Mean Age 
(Years) Females (%)
Mean disease 
duration
(Years)
Primary 
outcome
Outcome domain 
(outcome measure)3
Poole, 2014,
USA [32]
OD Interactive internet-based self-management 
program. The program consisted of 10 modules 
(e.g. self-advocacy, fatigue and energy conservation, 
coping and body image/appearance ), an exercise 
video, learning activities, worksheets, and resources. 
Participants proceeded through the modules at their 
own pace over 10 weeks.
10 weeks N/A Tx: 16
Control: 
N/A
52 88 8 NR Cognitions (PAM)
Coping (SE Scale, heiQ)
Fatigue (VAS fatigue)
Limitations in activities (HAQ-DI)
Mood (CES-D)
Pain (VAS pain)
Quality of life (self-rated health)
Comprehensive rehabilitation for hands and/or face
Antonioli, 2009, 
Italy [33]
CCT Rehabilitation program consisted of warm-up and 
cool-down exercises, training of motor functions, 
diaphragmatic breathing, controlled coughing 
exercises, treadmill, free-walking, finger stretching 
and occupational therapy for 2 weeks daily 30-minute 
sessions (10 sessions in total). Physiotherapy was 
prescribed when necessary. At-home exercise 
programme was prescribed on days when the 
programme was terminated.
2 months Usual care Tx: 16
Control: 17
Median 
age:
Tx: 67
Control: 57
Tx: 100
Control: 94
Median 
disease 
duration:
Tx: 15
Control: 9
NR Aerobic capacity (modified Borg 
Dyspnoea Scale, VAS dyspnoea, lung 
function test: FVC and DLCO)
Hand function (HAMIS)
Limitations in activities (HAQ-DI, 6MWT)
Quality of life (SF-36, Saint George’s 
Respiratory Questionnaire)
Skin problems (mRSS)
Maddali-Bongi, 
2009, Italy [34]
RCT Rehabilitation program for the  hands and face. 
Hand involvement was treated with a combination 
of connective tissue massage and Mc Mennell joint 
manipulation. Manual lymph drainage if patients had 
edematous hands. Face involvement was treated with 
a combination of Kabat’s method, connective tissue 
massage, and kinesitherapy. Hydrokinesytherapy (for 
patients without ulcers) or land-based rehabilitation 
(for patients with ulcers), and respiratory rehabilitation 
exercises.  One or two sessions  per week for 9 weeks.
9 weeks Continue 
current care
Tx: 10
Control: 10
Tx: 58
Control: 56
Tx: 60
Control: 70
Tx: 9
Control: 9
NR Face function (VAS face)
Hand function (HAMIS, Duruoz scale, 
hand opening, fist closure, water 
volumetric test)
Limitations in activities (HAQ-DI)
Mouth function (mouth opening)
Quality of life (SF-36)
Maddali-Bongi, 
2009, Italy [35]
RCT Combined rehabilitation treatment of connective 
tissue massage and Mc Mennell joint manipulation 
for1 hour, twice per week for 9 weeks. Home exercise 
programme for the hands daily 20 minutes for 9 
weeks.
9 weeks Home 
exercise 
programme 
for the 
hands daily 
20 minutes 
for 9 weeks
Tx: 20
Control: 20
Tx: 56
Control: 58
Tx: 80
Control: 70
Tx: 9
Control: 9
NR Hand function (HAMIS, Cochin hand 
functional disability scale, hand opening, 
fist closure)
Limitations in activities (HAQ-DI)
Quality of life (SF-36)
Maddali-Bongi, 
2010, Italy [36]
RCT Rehabilitation program for the face with a combined 
four-step procedure of connective tissue massage 
(10 min), Kabat’s method (15 min), kinesitherapy (15 
min), relaxing exercise (20 min). In total, 1 hour, twice 
per week for 9 weeks. A home programme of mimic 
exercises daily for 18 weeks.
18 weeks Home 
programme 
of mimic 
exercises 
only
Tx: 20
Control: 20
Tx: 57
Control: 57
Tx: 90
Control: 80
Tx: 10
Control: 9
NR Limitations in activities (HAQ-DI)
Mouth  function (MHISS, mouth opening)
Quality of life (SF-36)
Skin problems (mRSS)
Aerobic training
Pinto, 2011, Brazil 
[37]
OD Supervized concurrent training session consisted 
of treadmill warm-up (5 min) followed by resistance 
training (30 min), treadmill aerobic training (20 min), 
and stretching exercises (5 min). Resistance training 
included 5 exercises for the main muscle groups: 
bench press, leg press, lat pull down, leg extension, 
and seated row. 1 hour sessions, twice per week for 
12 weeks.
12 weeks N/A Tx: 11
Control: 
N/A
44 100 7 NR Aerobic capacity (VO2 peak, AT, RCP, 
heart rate rest, heart rate peak exercise)
Hand function (hand grip)
Muscle strength (leg press, bench press, 
low back strength, timed up and go, 
timed stands)
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Table 1. Study design, description of the study interventions, patient characteristics, and outcome 
measures. (Continued)
First Author,
Year,
Country
study 
Design Intervention group
Post 
intervention 
assessment
Control 
Group
Number of 
Patients 
Mean Age 
(Years) Females (%)
Mean disease 
duration
(Years)
Primary 
outcome
Outcome domain 
(outcome measure)3
stretching
Mugii, 2006, 
Japan [38]
OD Home program self-administered exercises for finger 
stretching (3-10 repetitions, each stretch held 10 
seconds). Daily for 1 year.
1 year N/A Tx: 45
Control: 
N/A
49 87 5 NR Hand function (finger passive ROM test, 
hand skin score)
Limitations in activities (HAQ-DI)
Skin problems (mRSS)
Paraffin treatment
Sandqvist, 2004, 
Sweden [39]
RCT2 Randomly selected hand treated with paraffin bath 
once a day. Immediately after the paraffin bath 
treatment hand exercises were performed (isolated 
finger flexion, finger extension, finger abduction, and 
thumb abduction). Daily for 1 month. 
1 month Other hand 
treated 
with hand 
exercises 
only
Tx: 17
Control: 17
Median 
age:
53
88 Median 
disease 
duration:
6
NR Hand function (ROM, HAMIS, grip force)
Pain (VAS pain)
Skin problems (VAS stiffness, VAS skin 
elasticity)
Pils, 1991, Austria 
[40]
RCT Paraffin wax treatments once a day for 3 months. 3 months Paraffin wax 
treatments 
once a day 
for 12 days
Tx: 8
Control: 8
Overall:
54
Overall:
69
NR NR Hand function (grip strength, palmar 
pinch, flexion/mobility, maximal 
abduction, hand skin induration)
Carbon dioxide baths
Werner, 1996, 
Germany [41]
CCT1 Carbon dioxide baths. NR Healthy 
controls 
received 
the same 
treatment 
as the 
intervention 
group
Tx: 18
Control: 16
Tx: 46
Control: NR
Tx: 61
Control: NR
NR NR Skin problems (microcirculation of skin)
Manual lymph drainage
Maddali-Bongi, 
2011, Italy [42]
RCT Manual lymph drainage of the hands. One session a 
week lasting 1 hour for 5 weeks.
5 weeks Waiting list Tx: 20
Control: 15
Tx: 57
Control: 57
Tx: 100
Control: 
100
Tx: 8
Control: 8
NR Hand function (water volumetric test, 
HAMIS, VAS hand edema, VAS hand 
pain)
Limitations in activities (HAQ, VAS 
interference edema, VAS interference 
pain)
Quality of life (SF-36)
ultrasound
Uhlemann, 1990, 
Germany [43]
OD Ultrasound therapy of the hands with an intensity of  
0.6W/cm2, 6 minutes per region, 3 times a day during 
6 days.
6 days N/A Tx: 24
Control: 
N/A
NR 75 NR NR Hand function (hand strength)
Extracorporeal shock wave therapy
Tinazzi, 2011, Italy 
[44]
CCT2 Extracorporeal shock wave therapy of the arm and 
hand of one arm consisting of 3 sittings. Defocused 
energy applied was 0.20/0.25 mJ/mm2. 
7 days after 
treatment
Other 
arm no 
treatment
Tx: 30
Control: 30
56 97 7 NR Skin problems (mRSS, VAS skin welness, 
skin thickness, skin vascularity)
Biofeedback
Sporbeck, 2012, 
Germany [45]
RCT Biofeedback (5-200 Hz) 3 times per week for 4 weeks. 4 weeks Waiting list Tx: 8
Control: 10
Tx:50
Control: 59
Tx: 88
Control: 90
Median 
disease 
duration
Tx: 6
Control: 2
Scleroderma 
VAS for RP
Raynaud’s phenomenon (scleroderma 
VAS RP)
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Table 1. Study design, description of the study interventions, patient characteristics, and outcome 
measures. (Continued)
First Author,
Year,
Country
study 
Design Intervention group
Post 
intervention 
assessment
Control 
Group
Number of 
Patients 
Mean Age 
(Years) Females (%)
Mean disease 
duration
(Years)
Primary 
outcome
Outcome domain 
(outcome measure)3
stretching
Mugii, 2006, 
Japan [38]
OD Home program self-administered exercises for finger 
stretching (3-10 repetitions, each stretch held 10 
seconds). Daily for 1 year.
1 year N/A Tx: 45
Control: 
N/A
49 87 5 NR Hand function (finger passive ROM test, 
hand skin score)
Limitations in activities (HAQ-DI)
Skin problems (mRSS)
Paraffin treatment
Sandqvist, 2004, 
Sweden [39]
RCT2 Randomly selected hand treated with paraffin bath 
once a day. Immediately after the paraffin bath 
treatment hand exercises were performed (isolated 
finger flexion, finger extension, finger abduction, and 
thumb abduction). Daily for 1 month. 
1 month Other hand 
treated 
with hand 
exercises 
only
Tx: 17
Control: 17
Median 
age:
53
88 Median 
disease 
duration:
6
NR Hand function (ROM, HAMIS, grip force)
Pain (VAS pain)
Skin problems (VAS stiffness, VAS skin 
elasticity)
Pils, 1991, Austria 
[40]
RCT Paraffin wax treatments once a day for 3 months. 3 months Paraffin wax 
treatments 
once a day 
for 12 days
Tx: 8
Control: 8
Overall:
54
Overall:
69
NR NR Hand function (grip strength, palmar 
pinch, flexion/mobility, maximal 
abduction, hand skin induration)
Carbon dioxide baths
Werner, 1996, 
Germany [41]
CCT1 Carbon dioxide baths. NR Healthy 
controls 
received 
the same 
treatment 
as the 
intervention 
group
Tx: 18
Control: 16
Tx: 46
Control: NR
Tx: 61
Control: NR
NR NR Skin problems (microcirculation of skin)
Manual lymph drainage
Maddali-Bongi, 
2011, Italy [42]
RCT Manual lymph drainage of the hands. One session a 
week lasting 1 hour for 5 weeks.
5 weeks Waiting list Tx: 20
Control: 15
Tx: 57
Control: 57
Tx: 100
Control: 
100
Tx: 8
Control: 8
NR Hand function (water volumetric test, 
HAMIS, VAS hand edema, VAS hand 
pain)
Limitations in activities (HAQ, VAS 
interference edema, VAS interference 
pain)
Quality of life (SF-36)
ultrasound
Uhlemann, 1990, 
Germany [43]
OD Ultrasound therapy of the hands with an intensity of  
0.6W/cm2, 6 minutes per region, 3 times a day during 
6 days.
6 days N/A Tx: 24
Control: 
N/A
NR 75 NR NR Hand function (hand strength)
Extracorporeal shock wave therapy
Tinazzi, 2011, Italy 
[44]
CCT2 Extracorporeal shock wave therapy of the arm and 
hand of one arm consisting of 3 sittings. Defocused 
energy applied was 0.20/0.25 mJ/mm2. 
7 days after 
treatment
Other 
arm no 
treatment
Tx: 30
Control: 30
56 97 7 NR Skin problems (mRSS, VAS skin welness, 
skin thickness, skin vascularity)
Biofeedback
Sporbeck, 2012, 
Germany [45]
RCT Biofeedback (5-200 Hz) 3 times per week for 4 weeks. 4 weeks Waiting list Tx: 8
Control: 10
Tx:50
Control: 59
Tx: 88
Control: 90
Median 
disease 
duration
Tx: 6
Control: 2
Scleroderma 
VAS for RP
Raynaud’s phenomenon (scleroderma 
VAS RP)
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Table 1. Study design, description of the study interventions, patient characteristics, and outcome 
measures. (Continued)
First Author,
Year,
Country
study 
Design Intervention group
Post 
intervention 
assessment
Control 
Group
Number of 
Patients 
Mean Age 
(Years) Females (%)
Mean disease 
duration
(Years)
Primary 
outcome
Outcome domain 
(outcome measure)3
Deep oscillation
Sporbeck, 2012, 
Germany [45]
RCT Deep oscillation (5-200 Hz) 3 times per week for 4 
weeks.
4 weeks Waiting list Tx: 10
Control: 10
Tx: 53
Control: 59
Tx: 80
Control: 90
Median 
disease 
duration
Tx: 4
Control: 2
Scleroderma 
VAS for RP
Raynaud’s phenomenon (scleroderma 
VAS RP)
Transcutaneous electrical nerve stimulation
Sallam, 2007, USA 
[46]
CCT1 Home use transcutaneous electrical nerve stimulation 
(TENS) application on two GI acupoints (ST36 Zusanli 
and PC6 Neiguan) after an instruction session. 30 
minutes, twice  a day for 2 weeks.  
2 weeks Healthy 
controls 
received 
only one 
30 minutes 
session with 
TENS
Tx: 17
Control: 9
Tx: 57
Control: 35
Tx: 82
Control: 33
Tx: NR
Control: N/A
NR Aerobic capacity (sympathovagal 
balance)
Gastrointestinal (GI questionnaire)
Quality of life (SF-36)
Home total parenteral nutrition
Jawa, 2012, 
Canada [47]
OD Home total parenteral nutrition (HTPN) as long as 
required.
12 months N/A Tx: 12
Control: 
N/A
49 75 NR NR Gastrointestinal (BMI, weight)
abbreviations: OD = observational design; rCt = randomised controlled trial; CCt = controlled clinical trial; 
tx = treatment; N/a = not applicable; Nr = not reported; aCr = american College of rheumatology; ara = 
american rheumatism association; rp = raynaud’s phenomenon; VO2 = oxygen uptake; CIS-20 = Checklist 
Individual Strength 20; haMIS = hand  Mobility in Scleroderma; 6MWt = 6-minute walking test; ShaQ = 
Scleroderma health assessment Questionnaire; VaS = visual analogue scale; SF-36 = Short Form 36;  ICQ = 
Illness Cognition Questionnaire; aLS = acceptance Limitations Scale; UCL = Utrechtse Coping List; haQ-DI 
= health assessment Questionnaire Disability Index; IrGL = Impact of rheumatic Diseases on General 
health and Lifestyle; aSeS = arthritis Self-efficacy Scale; MaF = Multidimensional assessment of Fatigue; 
SFaQ = Scleroderma Functional assessment Questionnaire; CeS-D = Center for epidemiologic Studies 
Depression Scale; paM = patient activation Measure; Se Scale = Chronic Disease Self-efficacy Scale; heiQ 
= health education Impact questionnaire; FVC =  forced vital capacity ; DLCO = diffusion lung capacity for 
carbon monoxide; mrSS = modified rodnan skin score; MhISS = Mouth handicap in Systemic Sclerosis; at = 
anaerobic threshold; rCp = respiratory compensation point; WhOQOL-bref = the World health Organization 
Quality of Life; rOM = range of motion; GI = gastrointestinal; BMI = body mass index.
1 healthy controls; 2 Other hand/ arm considered as control; 3 the outcome measures are reported when a 
p-value was provided in the results-section.
A primary outcome measure for the intervention was specified in three (13%) studies. 
In addition, a variety of outcome measures were used across studies to assess a specific 
outcome domain. For instance, the outcome domain “hand function” was assessed by 
in total 18 different performance based and self-reported outcome measures across 
the selected reports.
Methodological quality
Initially, there was disagreement on quality ratings between the reviewers for 116 
(19%) of the 621 (23 x 27) items scored. The inter-rater reliability of the methodological 
quality assessment was 82.1%, with a Cohen’s kappa of 0.64 for JEV and LMW, and 
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Table 1. Study design, description of the study interventions, patient characteristics, and outcome 
measures. (Continued)
First Author,
Year,
Country
study 
Design Intervention group
Post 
intervention 
assessment
Control 
Group
Number of 
Patients 
Mean Age 
(Years) Females (%)
Mean disease 
duration
(Years)
Primary 
outcome
Outcome domain 
(outcome measure)3
Deep oscillation
Sporbeck, 2012, 
Germany [45]
RCT Deep oscillation (5-200 Hz) 3 times per week for 4 
weeks.
4 weeks Waiting list Tx: 10
Control: 10
Tx: 53
Control: 59
Tx: 80
Control: 90
Median 
disease 
duration
Tx: 4
Control: 2
Scleroderma 
VAS for RP
Raynaud’s phenomenon (scleroderma 
VAS RP)
Transcutaneous electrical nerve stimulation
Sallam, 2007, USA 
[46]
CCT1 Home use transcutaneous electrical nerve stimulation 
(TENS) application on two GI acupoints (ST36 Zusanli 
and PC6 Neiguan) after an instruction session. 30 
minutes, twice  a day for 2 weeks.  
2 weeks Healthy 
controls 
received 
only one 
30 minutes 
session with 
TENS
Tx: 17
Control: 9
Tx: 57
Control: 35
Tx: 82
Control: 33
Tx: NR
Control: N/A
NR Aerobic capacity (sympathovagal 
balance)
Gastrointestinal (GI questionnaire)
Quality of life (SF-36)
Home total parenteral nutrition
Jawa, 2012, 
Canada [47]
OD Home total parenteral nutrition (HTPN) as long as 
required.
12 months N/A Tx: 12
Control: 
N/A
49 75 NR NR Gastrointestinal (BMI, weight)
abbreviations: OD = observational design; rCt = randomised controlled trial; CCt = controlled clinical trial; 
tx = treatment; N/a = not applicable; Nr = not reported; aCr = american College of rheumatology; ara = 
american rheumatism association; rp = raynaud’s phenomenon; VO2 = oxygen uptake; CIS-20 = Checklist 
Individual Strength 20; haMIS = hand  Mobility in Scleroderma; 6MWt = 6-minute walking test; ShaQ = 
Scleroderma health assessment Questionnaire; VaS = visual analogue scale; SF-36 = Short Form 36;  ICQ = 
Illness Cognition Questionnaire; aLS = acceptance Limitations Scale; UCL = Utrechtse Coping List; haQ-DI 
= health assessment Questionnaire Disability Index; IrGL = Impact of rheumatic Diseases on General 
health and Lifestyle; aSeS = arthritis Self-efficacy Scale; MaF = Multidimensional assessment of Fatigue; 
SFaQ = Scleroderma Functional assessment Questionnaire; CeS-D = Center for epidemiologic Studies 
Depression Scale; paM = patient activation Measure; Se Scale = Chronic Disease Self-efficacy Scale; heiQ 
= health education Impact questionnaire; FVC =  forced vital capacity ; DLCO = diffusion lung capacity for 
carbon monoxide; mrSS = modified rodnan skin score; MhISS = Mouth handicap in Systemic Sclerosis; at = 
anaerobic threshold; rCp = respiratory compensation point; WhOQOL-bref = the World health Organization 
Quality of Life; rOM = range of motion; GI = gastrointestinal; BMI = body mass index.
1 healthy controls; 2 Other hand/ arm considered as control; 3 the outcome measures are reported when a 
p-value was provided in the results-section.
80.4% with a Cohen’s kappa of 0.61 for CHME and LMW, both indicating substantial 
agreement [48].
Three studies, all RCTs, met the predefined score for ‘high quality’ (see Table 2) 
[24,25,29,42]. At least half of the ‘study reporting’ items were met in 87% (n = 20) of the 
studies, with item 8 relating reporting of important adverse events being scored less 
frequently (n = 4). Regarding external validity, both criteria on the representativeness 
of study sample were met in three studies. Item 14 relating to the blinding of study 
subjects reflecting internal validity- bias was not met by a single study, and item 15 
relating to the blinding of assessors was met by three studies. The criteria for assignment 
concealment and power calculation were met in two and three studies, respectively.
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Table 2. Results of quality assessment.
First author Reporting
External 
validity
Internal validity- 
bias
Internal validity- 
confounding Power
Quality 
scorea
Schouffoer [29]b 1, 2, 3, 4, 5, 6, 7, 8, 
9, 10
11, 12, 13 15, 16, 17, 18, 19, 20 21, 22, 23, 25, 26 27 25
Yuen [24,25]b 1, 2, 3, 4, 5, 6, 9, 10 11, 12 15, 16, 17, 18, 19, 20 21, 23, 24, 25, 26 21
Maddali-Bongi 
[42]b
1, 2, 3, 4, 5, 6, 7, 9 13 15, 16, 17, 18, 20 21, 23, 25, 26 27 19
Maddali-Bongi 
[35]
1, 2, 4, 5, 6, 7, 9, 10 13 16, 17, 18, 20 21, 23, 25, 26 17
Pizzo [28] 1, 2, 4, 5, 6, 7, 8, 9, 10 13 16, 17, 18, 19, 20 22, 26 17
Maddali-Bongi 
[36]
2, 3, 4, 5, 6, 7, 9 13 16, 17, 18, 20 21, 23, 25, 26 16
Pinto [37] 1, 2, 3, 4, 6, 7, 8, 9, 10 11, 13 16, 17, 18, 20 26 16
Antoniolo [33] 1, 2, 3, 6, 7, 9, 10 11, 12 16, 17, 18, 20 21, 26 15
Mugii [38] 1, 2, 4, 6, 7, 9 13 16, 17, 18, 20 21, 22, 25, 26 15
Kwakkenbos 
[30]
1, 2, 4, 6, 7, 9, 10 13 16, 17, 18, 20 22, 26 14
Sandqvist [39] 1, 2, 3, 5, 7, 9 13 16, 17, 20 21, 22, 23, 26 14
Sporbeck [45] 1, 2, 5, 6, 10 16, 17, 18, 20 22, 23, 24, 25 14
Jawa [47] 1, 3, 6, 7, 9, 10 13 17, 18, 19, 20 22, 26 13
Maddali-Bongi 
[34]
2, 4, 5, 6, 7, 9 13 16, 20 21, 23, 25, 26 13
Poole [31] 2, 3, 5, 6, 7, 8, 9, 10 13 16, 17, 20 26 13
Tinazzi [44] 1, 2, 4, 6, 7, 9 16, 17, 18, 19, 20 22, 26 13
Pai [26] 1, 2, 6, 7, 9, 10 13 16, 17, 18 26 27 12
Poole [27] 1, 2, 3, 4, 6, 7, 9 16, 17, 18, 20 26 12
Poole [32] 1, 2, 3, 4, 6, 7, 9, 10 13 16, 17, 20 12
Sallam [46] 1, 2, 4, 7, 10 16, 18, 19 8
Uhlemann [43] 1, 4, 9 16, 17, 19 26 7
Pils [40] 7, 10 16, 17, 18 5
Werner [41] 1, 2, 9 16 26 5
a quality score = sum of ‘+’; b = studies of high quality (quality score ≥ 19)
Only the fulfilled criteria are reported. For detailed information about items methodological quality see 
supplement table 2.
Effectiveness of non-pharmacological interventions
The effect sizes  for the three studies that met criteria for ‘high quality’ are presented 
in Table 3 and are discussed below. Detailed information about reported treatment 
effects of all the included studies are only presented in supplementary Tables S3 and 
S4, because the heterogeneity of the interventions and outcome domains does not 
allow meaningful summarizing of the results across studies.
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Table 3. Effect sizes and its confidence intervals (CI) of the between group results of three high quality 
randomized clinical trials that evaluated the effectiveness of a non-pharmacological intervention in 
systemic sclerosis.
Outcome domains and 
outcome measures
Yuen, 2011 [24] & 
Yuen, 2012 [25]
schouffoer,  
2011 [29]1
Maddali-Bongi,  
2011 [42]
Effect size 
(95% CI)
Effect size 
(95% CI)
Effect size 
(95% CI)
Hand function
   HAMIS 0.48 (-0.14, 1.07)
   HAMIS right hand 0.99 (0.26, 1.67)*
   HAMIS left hand 1.09 (0.35, 1.77)*
   Grip strength 1.08 (0.42, 1.70)*
   Water volumetric test 0.70 (-0.01, 1.37)
   VAS hand edema 2.31 (1.41, 3.11)*
   VAS hand pain 1.01 (0.28, 1.70)*
Aerobic capacity
   VO2 max 0.41 (-0.19, 1.00)
Fatigue
   CIS-20 0.27 (-0.36, 0.90)
Pain
   VAS pain 0.56 (-0.10, 1.20)
Mouth function
   Maximal mouth opening 0.46 (-0.43, 1.31) 0.73 (0.12, 1.31)*
Mouth hygiene  
   Loë-Silness gingival index 1.54 (0.79, 2.22)*
Limitations in activities
   6MWT 0.75 (0.14, 1.35)*
   HAQ 0.89 (0.22, 1.52)* 0.81 (0.10, 1.49)*
   VAS interference edema 1.07 (0.34, 1.76)*
   VAS interference pain 0.90 (0.18, 1.58)*
Quality of life
   SF-36 PCS 0.33 (-0.31, 0.95) 0.74 (0.03, 1.41)*
   SF-36 MCS -0.08 (-0.71, 0.55) 0.85 (0.13, 1.53)*
abbreviations: haMIS = hand  Mobility in Scleroderma; VaS = visual analogue scale; VO2 = oxygen uptake; 
CIS-20 = Checklist Individual Strength 20; 6MWt = 6-minute walking test; haQ = health assessment 
Questionnaire; SF-36 = Short Form 36; pSI = physical component summary; MCS = mental component 
summary.
1 effect sizes calculated with change scores; * p ≤ 0.05.
The three high quality RCTs investigated four different non-pharmacological 
interventions. Yuen et al. reported that a multi-faceted oral health intervention had a 
large positive effect on mouth hygiene after six months compared with dental care as 
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usual [24] (Table 3). However, orofacial exercises for those with an oral aperture size of 
less than 40 mm had no statistically significant effect on maximal mouth opening after 
six months compared with the no-exercise group [25].
Schouffoer et al. [29] reported that a 12 week multidisciplinary team care program 
compared to usual outpatient care resulted in medium to large significant positive 
effects in limitations in activities measured with the 6-minute walking test and the 
Scleroderma Health Assessment Questionnaire, medium effects on maximal mouth 
opening, and large effect on grip strength.
Maddali-Bongi et al. [42] reported that the experimental treatment of 1 hour 
manual lymph drainage for 5 weeks was superior to the waiting list group and 
significantly improved hand function with medium to large effects (hand volume, 
the Hand Mobility in Scleroderma, VAS hand oedema, and VAS hand pain). Large 
effects were also observed for limitations in activities measured with the Health 
Assessment Questionnaire, VAS interference oedema, and VAS interference hand 
pain. Furthermore, medium to large effects for quality of life measured with the Short 
Form 36- Physical Component Summary and Short Form 36- Mental Component 
Summary were observed.
diSCuSSiON
Our study is the first that comprehensively and systematically documented the 
effectiveness of non-pharmacological interventions in patients with SSc. Twenty-
three studies were identified, but the wide variety in the content of interventions and 
outcome measures prevented a meaningful synthesis of results across studies. Three 
studies, all RCTs, met criteria for ‘methodological high quality’. These RCTs reported 
that a multi-faceted oral health intervention is effective in improving mouth hygiene and 
that orofacial exercises are effective in improving maximal mouth opening [24,25], that 
a multidisciplinary team care program is effective in improving limitations in activities, 
maximal mouth opening, and hand grip strength [29], and that manual lymph drainage 
is effective in improving hand function, limitations in activities, and quality of life [42]. 
Findings should be interpreted with caution, however, given that only a single RCT was 
conducted for each intervention, each having a small sample size, and there was a lack 
of predefined primary outcome measures.
Besides the heterogeneity in interventions and outcome measures, the low 
methodological quality and the small sample sizes impeded summarization of results. 
Most studies were lacking external validity and internal validity with regard to adjustment 
for confounding, randomization, and allocation concealment. In addition, the study with 
the largest sample size included only 53 participants in total, which is even fewer than 
the recommended lower limit of 35 participants in the smallest group for inclusion of 
trials in meta-analyses [49,50]. An important barrier to conducting adequately powered 
RCTs of non-pharmacological interventions in SSc is the small number of people with 
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the disease at any single centre. International collaborations should be established 
therefore, to overcome this barrier and to conduct well-designed and sufficiently large 
RCTs to facilitate the establishment of evidence-based recommendations for non-
pharmacological interventions.
As the majority of patients with SSc experience a broad range of symptoms [2,3,51] 
that could be targeted by non-pharmacological treatment, it is not surprising that 
single-component interventions focusing on one symptom such as improving hand 
function, as well as multimodal interventions targeting a range of symptoms were 
represented in the review. This could also explain, that only 3 out of 23 studies included 
in our review defined a primary outcome measure. Defining a primary outcome 
measure a priori is highly recommended [52,53], as a way to reduce the influence 
of reporting biases on the evidence base, and failing to do so hampers conclusions 
that can be drawn about the effectiveness of an intervention [54]. However, defining 
a single primary outcome measure for multimodal interventions, targeting multiple 
symptoms simultaneously, is a challenge. To tackle this problem, a possible solution 
might be to use a patient-specific outcome as the primary outcome, such as the 
patient specific complaints questionnaire [55]. Another solution might be to provide 
a combined score of different outcome domains that are targeted in an intervention, 
similar to the OMERACT-OARSI Responder Criteria [56]. For example, Hoogeboom et 
al. [57] defined adapted responder criteria for their non-pharmacological intervention 
and considered patients as responders if at least 3 of the 6 targeted areas (i.e. physical 
functioning, pain, fatigue, physical activity, acceptance, and patient global assessment) 
improved ≥ 20%.
The results of our review do not allow the formulation of evidence-based 
recommendations for the non-pharmacological care in SSc. Considering the high clinical 
burden of SSc however, an international research agenda is warranted to prioritize 
and focus future research. This research agenda should be based on an international 
consensus on a limited number of clearly defined non-pharmacological interventions 
and outcome measures. Symptoms that are commonly experienced by patients with 
SSc and have a major impact on carrying out everyday activities, like fatigue, pain, 
limitations in hand function, and decreased mobility [2,3] need to be considered as 
primary targets for interventions. In addition, the characteristics and results of studies 
documented in this review could be a starting point to initiate discussion among 
international experts on the optimal content of interventions.
In conclusion, the strength of evidence on the effectiveness of non-pharmacological 
interventions in SSc is limited due to the great variety in interventions and the low 
methodological quality of studies in this area. To increase the body of knowledge 
international collaboration following an international research agenda is needed. To 
focus future research on the effectiveness of non-pharmacological care for SSc, an 
international consensus on a limited number of treatment targets, interventions and 
outcome measures is warranted.
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SupplEmENTary TaBlES S1-S4
Table S1. Search strategy Pubmed. (Continued)
#1 systemic sclerosis[Mesh]
#2 diffuse scleroderma[Mesh]
#3 limited scleroderma[Mesh]
#4 “systemic sclerosis”
#5 scleroderma 
#6 1 or 2 or 3 or 4 or 5 
#7 “non pharmacological intervention*”
#8 “non pharmacological treatment*”
#9 rehabilitation[Majr] or rehabilitation[subheading] or rehabilitation
#10 “multidisciplinary treatment*” or “multicomponent treatment*” or “interdisciplinary treatment*” or 
“multimodal treatment
#11 “multidisciplinary intervention*” or “multicomponent intervention*” or “interdisciplinary intervention*” 
or “multimodal intervention
#12 7 or 8 or 9 or 10 or 11
#13 physical therapy modalities[Mesh] or “physical modalities”
#14 exercise therapy[Mesh] or exercise*
#15 hydrotherapy[Mesh] or hydrotherapy
#16 balneology[Mesh] or balneotherapy
#17 range of motion, articular[Mesh] or “range of motion”
#18 “physical therapy” or “physical therapies” or physiotherapy
#19 massage or “connective tissue massage”
#20 mobilization or “skin mobilization”
#21 training
#22 thermotherapy
#23 stretching
#24 “paraffin wax”
#25 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
#26 cognitive therapy[Mesh] 
#27 behavior therapy[Mesh]
#28 psychotherapy[Mesh]
#29 counseling[Mesh] or counseling or counselling
#30 vocational rehabilitation[Mesh] or “vocational rehabilitation”
#31 health education[Mesh]
#32 self care[Mesh]
#33 “cognitive behaviour therapy” or “cognitive behavior therapy” or “cognitive behaviour therapies” or  
“cognitive behavior therapies” or CBT
#34 “patient education”
#35 education
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Table S1. Search strategy Pubmed. (Continued)
#36 “self management”
#37 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
#38 occupational therapy[Mesh] or “occupational therapy” or “occupational therapies”
#39 splints[Mesh]
#40 leisure activities[Mesh] or “leisure activities”
#41 activities of daily living[Mesh] or “activities of daily living”
#42 self help device[Mesh] or “self-help device*”
#43 orthotics or orthotic*
#44 “joint protection”
#45 “activity pacing”
#46 “energy conservation”
#47 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46
#48 rehabilitation nursing[Mesh] or “rehabilitation nursing”
#49 nutrition therapy[Mesh]
#50 nutritional support[Mesh]
#51 nutrition
#52 49 or 50 or 51
#53 podiatry[Mesh] or podiatry
#54 “foot care”
#55 53 or 54
#56 oral hygiene[Mesh] or “oral hygiene”
#57 dental hygiene[Mesh] or “dental hygiene”
#58 56 or 57
#59 12 or 25 or 37 or 47 or 48 or 52 or 55 or 58
#60 6 and 59
#61 60 Limits: Humans, English, French, German, Spanish, Dutch, date 1990-current
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Table S2. Modified Downs & Black checklist for measuring study quality. (Continued)
Quality items specification of items
Reporting
1. Is the hypothesis/aim/objective of the study 
clearly described?
yes 1
no 0
Studies must report on what outcome domain(s) the 
intervention aims to be effective. 
2. Are the (main) outcomes to be measured clearly 
described in the Introduction or Methods section?
yes 1
no 0
If the main outcomes are first mentioned in the Results 
section, the question should be answered no. 
3. Are the characteristics of the patients included in 
the study clearly described?
yes 1
no 0
In cohort studies and trials, inclusion and/or exclusion 
criteria should be given. In case-control studies, a case-
definition and the source for controls should be given. 
4. Are the interventions of interest clearly described?
yes 1
no 0
Treatments and placebo (where relevant) that are to 
be compared should be clearly described (including 
duration and frequency). 
5. Are the distributions of principal confounders 
in each group of subjects to be compared clearly 
described?
yes 2
partially 1
no 0
A list of principal confounders is provided. In the 
Methods section it must be explicitly mentioned that 
confounders were taken into account. When baseline 
comparison between groups are present, this should 
be answered partially.
6. Are the (main) findings of the study clearly 
described?
yes 1
no 0
Simple outcome data (including denominators and 
numerators) should be reported for all major findings 
so that the reader can check the major analyses and 
conclusions. (This question does not cover statistical 
tests which are considered below). 
7. Does the study provide estimates of the random 
variability in the data for the main outcomes?
yes 1
no 0
In non-normally distributed data the inter-quartile 
range of results should be reported. In normally 
distributed data the standard error, standard deviation 
or confidence intervals should be reported. If the 
distribution of the data is not described, it must be 
assumed that the estimates used were appropriate and 
the question should be answered yes. If not applicable, 
this should be answered no. 
8. Have all important adverse events that may be a 
consequence of the intervention been reported?
yes 1
no 0
In the Methods section it must be mentioned that 
adverse events were assessed.
9. Have the characteristics of patients lost to 
follow-up been described?
yes 1
no 0
This should be answered yes where there were no losses 
to follow-up or where losses to follow-up were so small 
that findings would be unaffected by their inclusion. 
This should be answered no where a study does not 
report the number of patients lost to follow-up.
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Table S2. Modified Downs & Black checklist for measuring study quality. (Continued)
Quality items specification of items
10. Have actual probability values been reported 
(e.g. 0.035 rather than <0.05) for the (main) 
outcomes except where the probability value is less 
than 0.001?
yes 1
no 0
In table or text. 
External validity
11. Were the subjects asked to participate in the 
study representative of the entire population from 
which they were recruited?
yes 1
no 0
unable to determine 0
The study must identify the source population for 
patients and describe how the patients were selected. 
Patients would be representative if they comprised 
the entire source population, an unselected sample of 
consecutive patients, or a random sample. Random 
sampling is only feasible where a list of all members of 
the relevant population exists. Where a study does not 
report the proportion of the source population from 
which the patients are derived, the question should be 
answered as unable to determine. 
12. Were those subjects who were prepared to 
participate representative of the entire population 
from which they were recruited?
yes 1
no 0
unable to determine 0
The proportion of those asked who agreed should be 
stated. Validation that the sample was representative 
would include demonstrating that the distribution of 
the main confounding factors was the same in the study 
sample and the source population. 
13. Were the staff, places, and facilities where 
the patients were treated, representative of the 
treatment the majority of patients receive?
yes 1
no 0
unable to determine 0
The question should be answered no if, for example, 
the intervention was undertaken in a specialist centre 
unrepresentative of the hospitals most of the source 
population would attend. 
Internal validity- bias
14. Was an attempt made to blind study subjects to 
the intervention they have received?
yes 1
no 0
unable to determine 0
For studies where the patients would have no way of 
knowing which intervention they received, this should 
be answered yes. Cohort/ observational studies should 
be answered no.
15. Was an attempt made to blind those measuring 
the (main) outcomes of the intervention?
yes 1
no 0
unable to determine 0
Cohort/ observational studies should be answered no.
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Table S2. Modified Downs & Black checklist for measuring study quality. (Continued)
Quality items specification of items
16. If any of the results of the study were based on 
“data dredging”, was this made clear?
yes 1
no 0
unable to determine 0
Any outcome analyses that had not been planned at 
the outset of the study should be clearly indicated. If 
no retrospective unplanned subgroup analyses were 
reported, then answer yes. 
17. In trials and cohort studies, do the analyses 
adjust for different lengths of follow-up of patients, 
or in case-control studies, is the time period 
between the intervention and outcome the same for 
cases and controls?
yes 1
no 0
unable to determine 0
Where follow-up was the same for all study patients the 
answer should be yes. If different lengths of follow-up 
were adjusted for by, for example, survival analysis the 
answer should be yes. Studies where differences in 
follow-up are ignored should be answered no.  
18. Were the statistical tests used to assess the 
(main) outcomes appropriate?
yes 1
no 0
unable to determine 0
The statistical techniques used must be appropriate to 
the data. For example non-parametric methods should 
be used for small sample sizes. Where little statistical 
analysis has been undertaken but where there was no 
evidence of bias, the question should be answered 
yes. If the distribution of the data (normal or not) is not 
described it must be assumed that the estimates used 
were appropriate and the question should be answered 
yes. 
19. Was compliance with the intervention/s reliable?
yes 1
no 0
unable to determine 0
Where there was non-compliance with the allocated 
treatment or where there was contamination of one 
group, the question should be answered no. For 
studies where the effect of any misclassification was 
likely to bias any association to the null, the question 
should be answered yes. 
20. Were the (main) outcome measures used 
accurate (valid and reliable)?
yes 1
no 0
unable to determine 0
For studies where the outcome measures are clearly 
described, the question should be answered yes. For 
studies which refer to other work or that demonstrates 
the outcome measures are accurate or widely accepted 
in rheumatic diseases, the question should be 
answered yes. 
Internal validity- confounding 
21. Were the patients in different intervention 
groups (trials and cohort studies) or were the cases 
and controls (case-control studies) recruited from the 
same population?
yes 1
no 0
unable to determine 0
For example, patients for all comparison groups should 
be selected from the same hospital. The question 
should be answered unable to determine for cohort 
and case-control studies where there is no information 
concerning the source of patients included in the study. 
Cohort/ observational studies should be answered no.
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Table S2. Modified Downs & Black checklist for measuring study quality. (Continued)
Quality items specification of items
22. Were study subjects in different intervention 
groups (trials and cohort studies) or were the cases 
and controls (case-control studies) recruited over the 
same period of time?
yes 1
no 0
unable to determine 0
For the study which does not specify the time period 
over which patients were recruited, the question should 
be answered as unable to determine. 
23. Were study subjects randomised to intervention 
groups?
yes 1
no 0
unable to determine 0
Studies which state that subjects were randomised 
should be answered yes except where method of 
randomisation would not ensure random allocation. For 
example alternate allocation would score no because it 
is predictable. 
24. Was the randomised intervention assignment 
concealed from both patients and health care staff 
until recruitment was complete and irrevocable? 
y
yes 1
no 0
unable to determine 0
All non-randomised studies should be answered no. If 
assignment was concealed from patients but not from 
staff, it should be answered no. 
25. Was there adequate adjustment for confounding 
in the analyses from which the (main) findings were 
drawn?
yes 1
no 0
unable to determine 0
This question should be answered no for trials if: 
the main conclusions of the study were based on 
analyses of treatment rather than intention to treat; 
the distribution of known confounders in the different 
treatment groups was not described; or the distribution 
of known confounders differed between the treatment 
groups but was not taken into account in the analyses. 
In non-randomised studies if the effect of the main 
confounders was not investigated or confounding was 
demonstrated but no adjustment was made in the final 
analyses the question should be answered as no. 
26. Were losses of patients to follow-up taken into 
account?
yes 1
no 0
unable to determine 0
If the numbers of patients lost to follow-up are not 
reported, the question should be answered as unable 
to determine. If the proportion lost to follow-up was 
too small to affect the main findings, the question 
should be answered yes (< 20% lost to follow-up). 
Power
27. Did the study included a power analysis?
yes 1
no 0
When a power analysis is conducted this question 
should be answered yes. 
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Table S4. Reported within (between) group treatment effects of non-pharmacological interventions on 
outcome domains regarding activities and participation, and personal factors.
study domain/
Intervention
Limitations  
in activities
Quality  
of life Cognitions Coping
Need for 
education 
Education [26] 0
Oral therapy [27/28/24,25]
Comprehensive rehabilitation for physical  
and/or psychological functioning [29/30]
+(+)/0 0(0)/
NA
NA/+ NA/0
Self-management [31/32] 0/0 NA/0 NA/+ 0/0
Comprehensive rehabilitation for hands  
and/or face [33/34/35/36]
0/+/+/0 0/+/+/0
Aerobic training [37]
Stretching [38] 0 dSSc
NR lSSc
Paraffin treatment [39/40]
Carbon dioxide baths [41]
MLD [42] + +
Ultrasound [43]
ESWT [44]
Biofeedback [45]
Deep oscillation [45]
TENS [46] 0
HTPN [47] 
abbreviations: MLD = manual lymph drainage; eSWt = extra-corporeal shock wave therapy; teNS = 
transcutaneous electrical nerve stimulation; htpN = home total parenteral nutrition; rp = raynaud’s 
phenomenon; GI = gastrointestinal; Na = not applicable; dSSc = diffuse systemic sclerosis; lSSc = limited 
systemic sclerosis.
0 = no statistically significant effect; + = statistically significant effect; underlined = randomised clinical trial; 
bold parentheses = result of between group analysis.
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Summary
The treatment of patients with systemic sclerosis (SSc) is a challenge for health 
care providers due to the broad range of symptoms that patients may experience. 
Because there is no cure available for SSc, treatment focuses on reducing symptoms 
and disability, and improving patients’ health-related quality of life. Apart from 
pharmacological treatment, non-pharmacological care provided by health professionals 
(i.e.,  physiotherapists, occupational therapists, nurses, dieticians, podiatrists, 
psychologists, social workers) is therefore considered to be a cornerstone in the 
management of SSc [1]. However, there is a lack of knowledge about the problems that 
patients with SSc experience, the non-pharmacological care they receive from health 
professionals, and the evidence regarding the effectiveness of non-pharmacological 
care. This thesis describes key elements of the non-pharmacological care in patients 
with SSc, with the aim to provide recommendations for future research and clinical 
practice: a first step towards better non-pharmacological management of SSc. In this 
final chapter, the results of the studies are summarised and methodological issues, as 
well as implications for clinical practice and future research are discussed.
The study described in Chapter 2 examined the frequency and impact of 40 
symptoms associated with SSc by means of an online survey that was distributed 
by patient associations in 5 European countries. In total, 537 patients with SSc were 
included in the study, originating from France (n = 111), the Netherlands (n = 229), Spain 
(n = 61), Switzerland (n = 50) and the United Kingdom (n = 86). The symptoms that 
were experienced by ≥ 70% of patients in every country included fatigue, Raynaud’s 
phenomenon, joint and muscle pain. Furthermore, amongst all countries, we found that 
more than half of the patients experienced at least 20 out of 40 symptoms in the past 
year, and 30 symptoms had at least a moderate impact on daily activities. Significant 
differences among countries were found for the prevalence of 17 out of 40 symptoms, 
and significant differences in the proportions of patients reporting an impact of a 
specific symptom on everyday activities were observed for 24 out of 40 symptoms. 
These results suggest that European patients with SSc experience a broad range 
of symptoms that have an impact on everyday activities. We concluded that future 
international research initiatives should target common SSc symptoms cooperatively.
In Chapter 3, the cross-language measurement equivalence of the English, French, 
and Dutch versions of the Functional Assessment of Chronic Illness Therapy –Fatigue 
(FACIT-F) questionnaire was assessed in patients with SSc. International multi-centre 
collaborations, with patients who complete questionnaires in different languages, are 
frequently utilized in SSc. In order to pool or compare outcomes, it should be proved that 
instruments are equivalent metrically across cultural or linguistic groups. The FACIT-F 
was completed by 871 English-speaking Canadian, 238 French-speaking Canadian, 
and 230 Dutch patients with SSc. Confirmatory factor analysis was used to assess the 
factor structure in the three samples. The Multiple-Indicator Multiple-Cause (MIMIC) 
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model was utilised to assess differential item functioning (DIF), comparing English 
versus French and English versus Dutch patient responses separately. A unidimensional 
factor model showed good fit in all samples. There was statistically significant DIF in 
several items, but the overall effect on fatigue scores was minimal. We concluded that 
the English, French, and Dutch versions of the FACIT-F can be reasonably treated as 
having equivalent scoring metrics.
Chapter 4 presents a longitudinal study that aimed to identify and characterise 
homogeneous subgroups with distinct 3-year trajectories of disability and fatigue, 
separately. A 3-year cohort study of 215 patients with SSc was conducted. Two disability 
classes were identified: a ‘low’ group (n = 133) with low baseline HAQ-DI scores (intercept 
= 0.48) and slight, statistically non-significant deterioration over time (increase of HAQ-DI 
score of 0.01 per 6 months), and a ‘high’ group (n = 82) with high baseline HAQ-DI 
scores (intercept = 1.63) and also slight, statistically non-significant deterioration over 
time (increase of HAQ-DI score of 0.01 per 6 months). Patients in the high disability 
group were more likely to be female, have higher fatigue, more helplessness, and less 
emotion-focused coping. Two fatigue classes were identified: an ‘average’ group (n = 99) 
with average baseline SF-36 Vitality scores (intercept = 53.9) and slight, statistically non-
significant deterioration over time (decrease in SF-36 Vitality score of 0.23 per 6 months, 
indicating more fatigue), and a ‘high’ fatigue group (n = 116) with low baseline SF-36 
Vitality scores (intercept = 39.8) and also slight, but non-significant deterioration over 
time (decrease in SF-36 Vitality score of 0.15 per 6 months). Patients in the high fatigue 
group were more likely to be female, report more impact of lung involvement, and less 
acceptance. One-third of the patients (n = 66) belonged to both the high disability and 
high fatigue groups. There was a statistically significant association between the disability 
subgroups and the fatigue subgroups (p<0.01). Our results suggest that limitations in 
physical functioning and fatigue are relatively stable consequences of the disease over 
time. More than half of the patients with SSc in our sample were relatively little affected 
in daily functioning, whereas the vast majority of patients were consistently impacted 
by fatigue. In addition, our findings may imply that psychosocial factors as coping and 
cognitions could be considered as targets for treatment in particular in those patients 
who experience severe limitations in daily functioning and high levels of fatigue.
Research about health care utilisation in SSc is scarce, in particular regarding the use 
of nonmedical care services. In Chapter 5 a cross-sectional study examined health care 
utilisation and patients’ perceptions on quality of health care in SSc. An anonymised 
survey on health care utilisation, quality of care, and quality of life was completed by 
198 patients with SSc, recruited through the Dutch patient organisation for systemic 
autoimmune diseases (NVLE). We found that, in the last 12 months, 95% of patients 
had had contact with at least one medical specialist and two-thirds had contacted 
at least one health professional, mostly a physiotherapist. The median numbers of 
visits to medical specialists and health professionals during the last year were 7 and 
7.5, respectively. Patients had had contact with a median of eight different health 
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professionals since the onset of SSc, and four in the last 12 months. Having a partner 
and reduced physical health status were significantly associated with more visits to 
medical specialists and health professionals. Patients with less fatigue contacted more 
disciplines, as did patients with more pain. The involvement of a higher number of 
disciplines was significantly associated with less satisfaction with cooperation and 
alignment of care. We concluded that health care use in Dutch patients with SSc is 
substantial, as is reflected in the high number of visits and the number of different 
disciplines involved in the care of patients, and that having more disciplines involved 
in the care was associated with lower patients’ rating of care coordination. This may 
imply that, in particular for patients with a complex disease who receive care from 
multiple care providers, attention should be given to the coordination of care, including 
communication among health care providers.
In Chapter 6, we used an online survey to provide a description of the non-pharmacological 
care delivered by European health professionals who treat patients with SSc. The survey 
consisted of closed-ended questions about the discipline of referring physicians, a 
predefined list to identify treatment targets and educational needs. Furthermore, a list 
of 69 interventions with the opportunity to add interventions was administered. Finally, 
an open-ended question was used to make an inventory of reasons for referral which 
were subsequently linked to the International Classification of Functioning, Disability and 
Health (ICF). Fifty-six health professionals from fourteen different European countries and 
seven different disciplines responded to the survey. Participants reported 133 specific 
indications for referral, 72% of which could be linked to the ICF domain “body functions 
and structures”, whereas, of the 681 reported treatment targets, only 45% was related 
to “body functions and structures”. In total, 105 different interventions were reported as 
being used to address these treatment targets. Almost all (98%) respondents reported 
having educational needs to help them in caring for people with SSc, with the management 
of stiffness (67%), pain (60%), and impaired hand function (56%) being mentioned most 
frequently. We concluded that in Europe the care provided by health professionals for 
patients with SSc is heterogeneous regarding the reasons for referral, treatment targets 
and content of interventions. The reasons for referral to health professionals and the health 
professionals’ subsequent treatment targets are not well aligned in SSc care, suggesting 
suboptimal communication between physicians and health professionals.
Chapter 7 comprises a systematic and comprehensive overview of the evidence 
regarding the effectiveness of non-pharmacological interventions regarding physical 
functioning and psychological well-being in patients with SSc. Twenty-three studies were 
included in the review, of which nine were randomised clinical trials (RCT), four controlled 
clinical trials, and ten studies with an observational design. The methodological quality 
of the studies was assessed with the Downs & Black Checklist and was found to be high 
in 3 of 23 studies, all of which were RCTs. However, all study samples were small and 
ranged from 10 to 53 participants. In total, the studies evaluated sixteen different non-
pharmacological interventions with respect to seventeen different outcome domains. 
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Hand function, limitations in activities, and quality of life were assessed most frequently. 
There was insufficient evidence regarding the effectiveness of non-pharmacological 
interventions in SSc due to the low methodological quality of the studies, the small 
sample sizes, and the wide variety in interventions and outcome domains. To increase 
knowledge of the effectiveness of non-pharmacological interventions in SSc, and to 
structure and focus future research endeavours, international consensus should be 
reached to prioritise primary targets for non-pharmacological treatment, the content 
of interventions, and to agree on a core set of outcome measures. Furthermore, we 
recommend that international collaborations should be established to conduct well-
designed and sufficiently large RCTs that will facilitate the development of evidence-
based guidelines for the non-pharmacological care in SSc.
mEThOdOlOgiCal iSSuES
There are some limitations related to outcome measurement and patient selection that 
should be considered in interpreting the results of the studies described in this thesis.
Validity of results
In most studies in this thesis, questionnaires were used to collect data from patients 
and health care providers. Questionnaires are relatively quick, inexpensive, and easy to 
administer but have important limitations [2]. A major problem is recall bias. Information 
obtained by retrospective self-reports may be biased due to poor recall of past events. 
For example, in Chapter 5, health care services’ use in the last year and since the onset 
of the disease was assessed with retrospective self-reports. According to the literature 
[3,4], self-reported physician visits in the last year are less precise than computerised 
medical records and are less accurate due to underreporting, which is likely to increase 
as the number of visits increases. Thus, although our results are comparable to another 
Dutch study on health care utilisation in SSc [5], it is conceivable that health care use 
in SSc might be even higher than described in our study.
Another limitation is that questionnaires that do not provide open-ended response 
options might result in a lack of information [2]. In Chapter 2 we used a predefined list 
of 40 SSc symptoms to gain more insight into the range of problems patients with SSc 
experience and did not provide open-ended response options to explore additional 
problems. This format might have failed to offer an appropriate set of alternative 
responses, or might have discouraged respondents from giving spontaneous responses. 
Additional open-ended response options might have elicited other common or 
burdensome symptoms. Several patients with SSc were involved in the development of 
the questionnaire, however, and the questionnaire was based on the most common and 
most burdensome symptoms of the 69 SSc symptoms assessed in a Canadian study, 
which may have helped capture the most commonly experienced SSc symptoms [6].
Sample bias might also influence results when online questionnaires are used. 
A relatively small number of European health professionals completed the online 
146
8SU
M
M
A
R
Y
 A
N
D
 G
E
N
E
R
A
L D
ISC
U
SSIO
N
survey regarding non-pharmacological care in SSc described in Chapter 6 and we 
lack information on those who decided not to participate. The generalizability of the 
results could therefore be limited. This study, however, was of explorative nature and 
clearly demonstrated the heterogeneity of the provided non-pharmacological care.
In the studies described in Chapter 2, 3, and 5 we invited members of patient 
organisations to complete an online anonymous questionnaire. Patient organisation-
based samples may not be representative for the whole patient population, since 
members of a patient organisation differ in some aspects from non-members. It has 
been found that members of patient organisations in cancer are more likely highly 
educated, be more agreeable, employ more active coping strategies, and feel more 
control over their disease [7-9]. Furthermore, members of patient organisations were 
found to be more anxious and distressed compared to non-members [9]. In addition, as 
a result of the anonymous nature of the questionnaire, it was not possible to verify the 
patient-reported diagnosis and medical information. However, patients rarely report 
a diagnosis that is incompatible with their clinical diagnosis [10] and considering that 
patients in our study were comparable to another large and well-described Dutch 
sample of patients with SSc [11] it unlikely that this biased our results.
TOWardS BETTEr CarE fOr paTiENTS WiTh SSC: 
impliCaTiONS aNd rECOmmENdaTiONS fOr rESEarCh 
aNd CliNiCal praCTiCE
The studies described in this thesis were set up to contribute to a better understanding 
of the content, targets, and effectiveness of non-pharmacological care in SSc. Based 
on the findings of this thesis, directions for future research and recommendations 
for clinical practice can be made, as a first step towards better non-pharmacological 
management of SSc.
Tailoring care
In Chapter 2 we showed that patients with SSc have a high clinical burden considering 
the broad range of symptoms that have an impact on their ability to carry out everyday 
activities. In addition, in Chapter 4 we showed that the proportion of patients 
experiencing stable, yet relatively high levels of fatigue or disability is substantial. 
Interventions provided by health care professionals could contribute to reducing the 
impact of such consequences of the disease. However, the content and intensity of care 
that is required might differ among patients. Therefore, care delivered by health care 
professionals should be targeted to the specific needs of patients with SSc in those 
who are most likely to benefit. Considering the lack of evidence on the effectiveness 
of non-pharmacological interventions for SSc a pragmatic approach to structure the 
non-pharmacological care for SSc patients is warranted.
A stepped-care model might be a good strategy to match interventions of varying 
intensities to patient needs in SSc. Generally, stepped care starts off with the simplest, 
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least intrusive intervention and proceeds to more intense treatment approaches as 
necessary [12]. Self-help programs and patient education can be a very useful first step 
towards improving outcomes, such as health-related quality of life. Other low-intensity 
strategies, such as self-management programs and support groups are effective to 
improve coping with the consequences of common chronic diseases [13-15], and may 
be readily available to many patients with SSc.
In addition to tailoring care to the severity of the consequences of SSc, health 
care providers should also take into consideration whether patients are able to travel 
or have enough energy to undergo treatment, since the disease has a significant 
impact on functioning and quality of life in most patients. A number of patients are 
treated at secondary or tertiary care centres. However, non-pharmacological care 
can also be provided in primary care and is less time-consuming and energy-saving, 
because treatment is provided in outpatient clinics within a close geographical range 
or at home. On the other hand, due to the relatively rarity of the disease, primary 
care providers are usually less experienced in treating patients with SSc compared 
to secondary care providers in specialised centres. Exchange of knowledge and 
facilitating communication between primary and specialised secondary care 
providers is needed to improve quality and access to care in SSc. Health care 
providers that are experienced in the treatment of patients with SSc should coach 
non-specialised care providers. Furthermore, educational courses specifically about 
SSc and its non-pharmacological treatment could increase the knowledge of health 
care providers.
The physician, together with the nurse specialist, need to take into account which 
patients are at risk and require non-pharmacological treatment and should therefore 
be referred to a health care provider. To achieve appropriate referral both the patient 
and the referring physician need to be well-informed about the range of available 
treatment options that health professionals can deliver to people with SSc. Although, 
in the Netherlands the role of the nurse specialist is increasingly recognised, access is 
limited. In Chapter 5 we showed that only 45% of the Dutch patients had contact with 
a nurse specialist since the onset of the disease and 15% in the last 12 months. This 
problem likely exists in other countries as well.
Research agenda
Due to the broad range of symptoms patients with SSc experience simultaneously, 
it is not remarkable that we found in both the literature and in clinical practice a 
considerable variety of non-pharmacological interventions in SSc that were studied 
and provided (Chapter 6 and 7). This variation hampers results from being synthesised, 
which in turn decreases the level of evidence for or against the investigated intervention 
and prevents formulating evidence-based recommendations [16]. Therefore, a research 
agenda that prioritise targets for non-pharmacological treatment in SSc is needed to 
structure future research.
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In 2010 a consensus research agenda was developed through a panel of 
internationally-recognised experts in behavioural and psychological health in SSc, 
patients and patient advocates [17]. However, this research agenda focused mainly 
on a group of psychological and behavioural aspects of SSc including depression, 
fatigue, pain, pruritus, body image distress, sexual functioning, and sleep disturbance. 
Furthermore, this research agenda was, due to pragmatic reasons, restricted 
to “automated” e-health interventions without the involvement of health care 
professionals. To optimise efficient disease management, topics for the research 
agenda should be in accordance with disease burden [18]. In Chapter 2 we found 
that fatigue, limitations in hand function, and decreased mobility were frequently 
experienced by a vast majority of SSc patients and had a major impact on daily 
life. Therefore, we would suggest that the existing research agenda should include 
limitations in hand function and decreased mobility as primary targets for the 
development and evaluation of non-pharmacological interventions as well. Besides 
consensus on prioritising targets of treatment in SSc research, consensus on a clear 
description of the indication, timing, content and mode of delivery of these treatments 
is also needed to reduce clinical heterogeneity and increase the reproducibility of 
non-pharmacological interventions in SSc.
Outcome measures
The systematic review in Chapter 7 showed that in research on effectiveness of non-
pharmacological interventions in SSc a large variety of outcome measures covering 
multiple domains of health status is used. As this variation hampers comparisons and 
statistical pooling of effects, the usage of a core set of outcome measures for this type 
of research is highly recommended. Such a core set will facilitate the standardisation, 
conduct, reporting, interpretation, and comparison of clinical trials and will lessen 
the ambiguity associated with the presentation of multiple test statistics. In SSc, a 
standardised core set of measures was developed for the assessment of disease 
activity and severity in clinical trials using a structured Delphi exercise [19]. The core 
set consisted of 31 items for the following 11 domains: skin, musculoskeletal, cardiac, 
pulmonary, gastrointestinal, renal, Raynaud phenomenon, digital ulcers, health-related 
quality of life and function, global health, and biomarkers. Elements of this core set 
could also be used for studies evaluating non-pharmacological interventions in SSc, 
since they also focus on improving quality of life and function. In order to make the 
core set suitable for evaluating non-pharmacological interventions in SSc, measures of 
important targets of non-pharmacological care should be included in the core set, such 
as a measure for fatigue and hand function. However, when this core set of measures is 
used internationally, the cross-cultural validity must have been proved. The importance 
of cross-cultural validity of health-related patient-reported outcomes (HR-PRO) is 
addressed in Chapter 3. The results of a measure with equivalent scoring metrics across 
linguistic or cultural groups can be pooled among or used to compare results between 
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patients from different linguistic or cultural groups [20]. In addition, measures that can 
be used to make comparisons across diseases can facilitate research as well.
Another possible solution to narrow down the number of outcome measures 
presented in studies might be to develop a combined response score of the different 
outcome domains that are targeted in an intervention, similar to the OMERACT-
OARSI Responder Criteria for osteoarthritis [21]. An overall combined response index 
is currently being developed for SSc and will produce a single efficacy measure [22] 
for pharmacological interventions. Future research is needed to investigate whether 
a similar combined response score is suitable for evaluating non-pharmacological 
interventions in SSc.
Practice-based recommendations
Ultimately evidence-based recommendations are needed to direct care for patients 
with SSc. In the meantime, however, given the high clinical burden for patients living 
with SSc, and the high need for education amongst health professionals, practice-
based recommendations may help health professionals to better help patients with SSc 
in coping with everyday challenges related to living with the disease. Practice-based 
guidelines will improve the accessibility and inequity of care for people with SSc and 
ensure consistency in approach between different professions. According to Driever, 
[23] best practice is not a specific practice per se but rather a level of agreement about 
research-based knowledge and an integrative process of embedding this knowledge 
into the organisation and delivery of health care. Due to a lack of research evidence 
in SSc, best practice must be based on health professionals’ experiences in treating 
patients with SSc and interventions that have been proven to be effective in other 
chronic diseases. For instance, physical exercise and psychosocial interventions have 
proven to be promising approaches to address fatigue in patients with cancer [24,25] 
and rheumatoid arthritis [26], and could be considered as techniques to treat fatigue 
in patients with SSc as well.
In the Netherlands, the need for practice-based guidelines was recognised by 
the Dutch Society for Rheumatology (Nederlandse Vereniging voor Reumatologie; 
NVR). Initiated by the NVR and in collaboration with Dutch health professionals 
working with SSc, non-pharmacological best practice guidelines are currently 
developed to improve the quality of care in SSc by limiting practice variability. 
These guidelines will be available in the spring of 2015 and contain a core set of 
interventions based on research and health professionals’ experiences on how to treat 
symptoms that patients with SSc commonly experience, such as limitations in hand 
function, Raynaud’s phenomenon, decreased mouth opening, difficulty swallowing, 
depressive symptoms, fatigue, etc. Such practice-based guidelines could provide a 
starting point to structure and focus future research regarding the effectiveness of 
non-pharmacological interventions in SSc, but still need to be complemented with 
research evidence.
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Networks
The small number of people with SSc at any singe centre is an important barrier to 
conducting adequately powered clinical trials and to developing and retaining SSc 
specific interventions. Effective research in SSc, therefore, often requires successful 
national and international multicentre collaborations. To support research in SSc 
multiple collaborations are established, for instance the Scleroderma Clinical Trials 
Consortium [27] and the EULAR Scleroderma Trials and Research group [28] that 
routinely conduct multicentre drug trials. In addition to collaborations that support 
research regarding pharmacological interventions, the Scleroderma Patient-centered 
Intervention Network (SPIN), is an international collaboration of patient organisations, 
clinicians and researchers, organised to develop, test, and disseminate non-
pharmacological interventions in patients with SSc [29,30]. Researchers should join 
or establish national and international collaborations, to conduct sufficiently large 
clinical trials in SSc, facilitating the establishment of evidence-based guidelines for 
non-pharmacological interventions.
Furthermore, national and international patient or health professional organisations 
could also play an important role in making guidelines accessible for health professionals 
and patients once guidelines become available. Recently, a national network called 
“NVLE connect” for SSc health professionals all over the Netherlands was developed in 
collaboration with the Dutch patient organisation for patients with systemic autoimmune 
diseases (Nationale Vereniging voor Lupus, APS, Sclerodermie en MCTD; NVLE). 
This network provides a platform for exchanging experiences and knowledge, and 
could therefore be used to make the non-pharmacological practice-based guidelines 
developed by the NVR accessible to health care providers and patients.
Besides a national network of experienced SSc health professionals, recently an 
international network was established as well, called the EULAR Scleroderma Health 
Professionals Network (EUSHNet) [31]. EUSHNet is financially supported by EULAR and 
aims to improve non-pharmacological care and reduce inequality through building an 
interactive international network of health professionals working in SSc. This network 
is intended to raise standards of proficiency and consistency, and will help health 
professionals share research and best clinical practice examples.
Another important role of EUSHNet is helping to conduct research to improve non-
pharmacological care in SSc. The study described in Chapter 6 about a description of 
the non-pharmacological care delivered by European health professionals who treat 
patients with SSc was a EUSHNet initiative.
In summary, the studies described in this thesis contributed to the gap of knowledge 
regarding the non-pharmacological care for patients with SSc. In this thesis, we showed 
that patients with SSc experience a broad range of symptoms for which they receive 
care from multiple medical specialists and health professionals. The care provided 
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by health professionals is heterogeneous regarding referrals, treatment targets, and 
interventions. However, to date, the effectiveness of these non-pharmacological 
interventions is still not proven. National and international collaborations should be 
established in the future to provide practice and evidence-based recommendations 
to optimise non-pharmacological care for patients with SSc.
rEfErENCES
1. Schouffoer AA, Zirkzee EJ, Henquet SM, 
Caljouw MA, Steup-Beekman GM, van Laar 
JM, et al. Needs and preferences regarding 
health care delivery as perceived by patients 
with systemic sclerosis. Clin Rheumatol 
2011;30:815-24.
2. Wakley G. Questionnaires: paradigms and 
pitfalls. J Fam Plann Reprod Health Care 
2005;31:222-4.
3. Ritter PL, Stewart AL, Kaymaz H, Sobel DS, 
Block DA, Lorig KR. Self-reports of health care 
utilization compared to provider records. J 
Clin Epidemiol 2001;54:136-41.
4. Roberts RO, Bergstralh EJ, Schmidt L, 
Jacobsen SJ. Comparison of self-reported 
and medical record health care utilization 
measures. J Clin Epidemiol 1996;49:989-95.
5. Meijs J, Zirkzee EJ, Schouffoer AA, Henquet 
SM, Caljouw MA, Stijnen T, et al. Health-
care utilization in Dutch systemic sclerosis 
patients. Clin Rheumatol 2014;33:825-32.
6. Bassel M, Hudson M, Taillefer SS, Schieir O, 
Baron M, Thombs BD. Frequency and impact 
of symptoms experienced by patients with 
systemic sclerosis: results from a Canadian 
National Survey. Rheumatology (Oxford) 
2011;50:762-7.
7. Stevinson C, Lydon A, Amir Z. Cancer support 
group participation in the United Kingdom: 
a national survey. Support Care Cancer 
2011;19:675-83.
8. Sherman AC, Pennington J, Simonton S, 
Latif U, Arent L, Farley H. Determinants of 
participation in cancer support groups: 
the role of health beliefs. Int J Behav Med 
2008;15:92-100.
9. Grande GE, Myers LB, Sutton SR. How do 
patients who participate in cancer support 
groups dif fer from those who do not? 
Psychooncology 2006;15:321-34.
10. Rasooly I, Papageorgiou AC, Badley EM. 
Comparison of clinical and self reported 
diagnosis for rheumatology outpatients. Ann 
Rheum Dis 1995;54:850-2.
11. Vonk MC, Broers B, Heijdra YF, Ton E, Snijder 
R, van Dijk AP, et al. Systemic sclerosis and its 
pulmonary complications in The Netherlands: 
an epidemiological study. Ann Rheum Dis 
2009;68:961-5.
12. Bower P, Gilbody S. Stepped care in 
psychological therapies: access, effectiveness 
and efficiency. Narrative literature review. Br J 
Psychiatry 2005;186:11-7.
13. Foster G, Taylor SJ, Eldridge SE, Ramsay J, 
Griffiths CJ. Self-management education 
programmes by lay leaders for people with 
chronic conditions. Cochrane Database Syst 
Rev 2007;17:4:CD005108.
14. Kroon FP, van der Burg LR, Buchbinder 
R, Osborne RH, Johnston RV, Pitt V. Self-
management education programmes for 
osteoarthritis. Cochrane Database Syst Rev 
2014;1:CD008963.
15. Kennedy A, Reeves D, Bower P, Lee V, 
Middleton E, Richardson G, et al. The 
effectiveness and cost effectiveness of a 
national lay-led self care support programme 
for patients with long-term conditions: a 
pragmatic randomised controlled trial. J 
Epidemiol Community Health 2007;61:254-61.
16. van den Ende CHM, Steultjens EMJ, Bouter 
LM, Dekker J. Clinical heterogeneity was a 
common problem in Cochrane reviews of 
physiotherapy and occupational therapy. J 
Clin Epidemiol 2006;59:914-9.
17. Thombs BD, van Lankveld W, Bassel M, Baron 
M, Buzza R, Haslam S, et al. Psychological 
health and well-being in systemic sclerosis: 
state of the science and consensus research 
agenda. Arthritis Care Res 2010;62:1181-9.
18. Woolf SH, Stange KC. A sense of priorities 
for the healthcare commons. Am J Prev Med 
2006;31:99-102.
19. Khanna D, Lovell DJ, Giannini E, Clements PJ, 
Merkel PA, Seibold JR, et al. Development of 
152
8SU
M
M
A
R
Y
 A
N
D
 G
E
N
E
R
A
L D
ISC
U
SSIO
N
a provisional core set of response measures 
for clinical trials of systemic sclerosis. Ann 
Rheum Dis 2008;67:703-9.
20. Teresi JA. Different approaches to differential 
item functioning in health applications. 
Advantages, disadvantages and some 
neglected topics. Med Care 2006;44:S152-
70.
21. Pham T, van der Heijde D, Lassere M, Altman 
RD, Anderson JJ, Bellamy N, et al. Outcome 
variables for osteoarthritis clinical trials: The 
OMERACT-OARSI set of responder criteria. 
J Rheumatol 2003;30:1648-54.
22. Khanna D, Distler O, Avouac J, Behrens F, 
Clements PJ, Denton C, et al. Measures of 
response in clinical trials of systemic sclerosis: 
the Combined Response Index for Systemic 
Sclerosis (CRISS) and Outcome Measures 
in Pulmonary Arterial Hypertension related 
to Systemic Sclerosis (EPOSS). J Rheumatol 
2009;36:2356-61.
23. Driever MJ. Are evidenced-based practice 
and best practice the same? West J Nurs Res 
2002;24:591-7.
24. Cramp F, Byron-Daniel J. Exercise for the 
management of cancer-related fatigue 
in adults. Cochrane Database Syst Rev 
2012;11:CD006145.
25. Goedendorp MM, Gielissen MF, Verhagen 
CA, Bleijenberg G. Psychosocial interventions 
for reducing fatigue during cancer treatment 
in adults. Cochrane Database Syst Rev 
2009;1:CD006953.
26. Cramp F, Hewlett S, Almeida C, Kirwan 
JR, Choy EH, Chalder T, et al. Non-
pharmacological interventions for fatigue 
in rheumatoid arthritis. Cochrane Database 
Syst Rev 2013;8:CD008322.
27. Scleroderma Clinical Trials Consortium 
website. Available: http://sites.bu.edu/sctc/. 
Accessed 2015 Jan 23.
28. Tyndall A, Mueller-Ladner U, Matucci-Cerinic 
M. Systemic sclerosis in Europe: first report 
from the EULAR Scleroderma Trials And 
Research (EUSTAR) group database. Ann 
Rheum Dis 2005;64:1107.
29. Thombs BD, Jewett LR, Assassi S, Baron M, 
Bartlett SJ, Maia AC, et al. New directions 
for patient-centred care in scleroderma: the 
Scleroderma Patient-centred Intervention 
Network (SPIN). Clin Exp Rheumatol 
2012;30:S23-9.
30. Kwakkenbos L, Jewett LR, Baron M, 
Bartlett SJ, Furst D, Gottesman K, et al. The 
Scleroderma Patient-centered Intervention 
Network (SPIN) Cohort: protocol for a cohort 
multiple randomised controlled trial (cmRCT) 
design to support trials of psychosocial and 
rehabilitation interventions in a rare disease 
context. BMJ Open 2013;3:e003563.
31. Redmond A. EUSHNet- the EUL AR 
sc le roder ma hea l th p rofes s iona ls ’ 
network. EULAR HP news. http://www.
eular.org/myUploadData/f i les/HP%20
Newsletter_0212.pdf
153

Chapter
NEDERLANDsE sAMENVATTING 
(DuTCH suMMARY) 9

9N
E
D
E
R
LA
N
D
SE
 SA
M
E
N
VA
T
TIN
G
 (D
U
TC
H
 SU
M
M
A
R
Y
) 
iNlEidiNg
Systemische sclerose (SSc) ook wel sclerodermie genoemd, is een zeldzame, complexe, 
chronische aandoening van het bindweefsel met onbekende oorzaak. De aandoening 
wordt gekenmerkt door overmatige productie van het bindweefsel, met name door 
collageen, waardoor verharding en verstrakking van de huid ontstaat. Naast de huid, 
kunnen ook inwendige organen aangetast worden door een toename van bindweefsel, 
wat kan leiden tot een verminderde functie van de longen, het hart, de nieren en het 
maagdarmstelsel. Ruim 90% van de patiënten heeft het fenomeen van Raynaud, waarbij 
verminderde doorbloeding naar extremiteiten zoals handen en/of voeten zorgt voor 
een verkleuring van de huid bij blootstelling aan kou of emoties.
Systemische sclerose is niet te genezen en het ziektebeloop is wisselend en wordt 
bepaald door de mate van huidbetrokkenheid en orgaan manifestaties. Er zijn twee 
subtypes waarin systemische sclerose kan worden ingedeeld: gelimiteerde SSc waarbij 
de aantasting van de huid zich beperkt tot de onderarmen, onderbenen en het gelaat, 
en diffuse SSc, waarbij de huidverharding zich ook uitstrekt tot boven de ellenbogen 
en knieën. Over het algemeen is de prognose van mensen met gelimiteerde SSc 
gunstiger dan voor mensen met diffuse SSc. De mortaliteit van SSc is aanzienlijk 
vergeleken met andere reumatische aandoeningen, aangezien de levensverwachting 
over het algemeen verkort wordt met een mediaan van 11 jaar. Met name de inwendige 
orgaanbetrokkenheid, in het bijzonder de longen en het hart, is de belangrijkste 
oorzaak van overlijden als gevolg van SSc.
De prevalentie in Nederland wordt geschat op 8.9 per 100.000 volwassenen en 
een incidentie van 0.77 per 100.000 volwassenen per jaar. Hieruit blijkt dat er naar 
schatting 1500 mensen met SSc in Nederland zijn. De aandoening komt circa vijf maal 
vaker voor bij vrouwen dan bij mannen en manifesteert zich meestal tussen het 30e 
en 50e levensjaar.
Vooralsnog is er geen curatieve behandeling voor SSc. De behandeling is 
overwegend gericht op het beperken van de symptomen van de aandoening en het 
verbeteren van de kwaliteit van leven. Niet-medicamenteuze zorg is naast medische 
zorg een belangrijke hoeksteen in de behandeling van SSc. Meerdere paramedische 
zorgverleners kunnen betrokken zijn bij de zorg voor mensen met SSc. Paramedici, zoals 
fysiotherapeuten, ergotherapeuten, verpleegkundige, diëtisten, podotherapeuten, 
maatschappelijk werkers en psychologen ondersteunen patiënten in het omgaan met 
de gevolgen van de aandoening en helpen hen om een actieve rol te spelen in de 
management van hun aandoening. Dit proefschrift heeft tot doel inzicht te verwerven 
in de aard van de niet-medicamenteuze zorg die geleverd wordt aan patiënten met SSc.
SamENVaTTiNg
Om inzicht te krijgen in de niet-medicamenteuze zorg bij SSc is het van belang om 
eerst helder te krijgen welke symptomen veel voorkomen en veel impact hebben bij 
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patiënten met SSc. Deze symptomen kunnen aangrijpingspunten voor de zorg zijn. In 
hoofdstuk 2 werd middels een internetvragenlijst onder leden van Europese patiënten 
verenigingen de prevalentie en de impact van een lijst van 40 symptomen van SSc 
onderzocht. In totaal werden er 537 patiënten met SSc geïncludeerd in de studie, 
afkomstig uit Frankrijk (n = 111), Nederland (n = 229), Spanje (n = 61), Zwitserland (n = 
50) en het Verenigd Koninkrijk (n = 86). In alle vijf de landen kwamen vermoeidheid, het 
fenomeen van Raynaud, gewrichts- en spierpijn bij meer dan 70% van de patiënten voor. 
Twintig van de veertig symptomen werden door meer dan de helft van de patiënten 
ervaren in het afgelopen jaar, terwijl 30 van de 40 symptomen impact hebben op het 
uitvoeren van dagelijkse activiteiten bij tenminste de helft van de patiënten. De impact 
op het dagelijks functioneren door problemen met lopen en/of handfunctie was in alle 
landen hoog. Er werden verschillen gevonden tussen landen in de prevalentie van 17 
van de 40 symptomen en in de impact van 24 van de 40 symptomen op het dagelijks 
functioneren. Het is echter onduidelijk waaraan deze verschillen toe te schrijven zijn. 
We concludeerden dat Europese patiënten met SSc een breed scala aan symptomen 
ervaren die impact hebben op het dagelijks functioneren.
Voor initiatieven ter verbetering van de zorg is vaak (internationale) samenwerking 
nodig, aangezien SSc relatief zeldzaam is. Dit houdt in, dat onderzoeksresultaten 
afkomstig uit verschillende landen en in verschillende talen samengevoegd 
worden. Onderzoeksresultaten kunnen echter pas samengevoegd worden als de 
meetequivalentie van uitkomstmaten goed is bevonden. Meetequivalentie betekent 
dat vragenlijsten taalkundig en conceptueel vergelijkbaar zijn waardoor individuen van 
verschillende groepen met hetzelfde niveau van een uitkomstmaat (bijv. depressie), 
ook gelijke scores behalen op de vragenlijst. Aangezien vermoeidheid veel voorkomt 
bij SSc, werd in de studie in hoofdstuk 3 de meet-equivalentie onderzocht van de 
Functional Assessment of Chronic Illness Therapy –Fatigue (FACIT-F) vragenlijst tussen 
Engelstalige Canadese patiënten (n = 871), Franstalige Canadese patiënten (n = 238) 
en Nederlandse patiënten (n = 230) met SSc. Het Multiple-Indicator Multiple-Cause 
(MIMIC) model werd gebruikt om patiënt responses te vergelijken tussen Engels- versus 
Franstalige en Engels- versus Nederlandstalige. De resultaten lieten zien dat de FACIT-F 
scores van Engelstalige Canadese, Franstalige Canadese en Nederlandse patiënten 
met SSc vergeleken en samengevoegd kunnen worden, ondanks de aanwezigheid van 
een aantal individuele items met geringe culturele of linguïstische bias.
Zoals beschreven in hoofdstuk 2 zijn vermoeidheid en functionele beperkingen 
veel voorkomende gevolgen van SSc die aangrijpingspunten vormen voor de niet-
medicamenteuze behandeling. In hoofdstuk 4 werd door middel van een longitudinale 
studie met 215 patiënten met SSc onderzocht of er subgroepen te identificeren en 
karakteriseren zijn met een homogeen beloop van functionele beperkingen en 
vermoeidheid over een periode van 3 jaar. Ten aanzien van functionele beperkingen, 
gemeten met de Health Assessment Questionnaire –Disability Index (HAQ-DI), 
konden we 2 subgroepen onderscheiden; een groep met 133 patiënten met relatieve 
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geringe functionele beperkingen (gemiddelde HAQ score = 0.48) en een groep van 
82 patiënten met relatieve ernstige functionele beperkingen (gemiddelde = 1.63). In 
beide subgroepen observeerden we een geringe functionele achteruitgang over de 
tijd de heen; dit betekent dat in beide groepen de mate van functionele beperkingen 
redelijk stabiel in de tijd was. Patiënten in de groep met relatief ernstige beperkingen 
werden gekarakteriseerd door het vrouwelijk geslacht, meer vermoeidheid, meer 
hulpeloosheid en minder emotie-gerichte coping. Ook ten aanzien van vermoeidheid, 
gemeten met de vitaliteit subschaal van de Short Form 36 (SF-36) konden we 2 
subgroepen onderscheiden; een groep van 99 patiënten met een gemiddelde 
mate van vermoeidheid (gemiddelde SF-36 vitaliteit score = 53.9) en een groep van 
116 patiënten met relatieve ernstige vermoeidheid (gemiddelde = 39.8). In beide 
subgroepen observeerden we een geringe toename in vermoeidheid over de tijd heen; 
in beide groepen was de mate van vermoeidheid redelijk stabiel in de tijd. Patiënten 
in de groep met relatief ernstige vermoeidheid werden gekarakteriseerd door het 
vrouwelijk geslacht, rapporteerden meer impact van longbetrokkenheid en minder 
acceptatie. Meer dan de helft van de patiënten in onze studie hadden relatief weinig 
functionele beperkingen, terwijl de overgrote meerderheid van de patiënten last had 
van vermoeidheid. Een derde van de onderzoekspopulatie (n= 66) maakten zowel deel 
uit van de subgroep met ernstige functionele beperkingen als tot de subgroep met 
ernstige vermoeidheid. De bevindingen ten aanzien van de gevonden karakteristieken 
impliceren dat psychosociale factoren zoals coping en cognities overwogen dienen 
te worden als aangrijpingspunt van de behandeling in het bijzonder bij patiënten die 
ernstige functionele beperkingen en ernstige vermoeidheid ervaren.
In hoofdstuk 5 werd de aard en omvang van het zorggebruik en de kwaliteit van 
de zorg vanuit het patiëntperspectief onderzocht. Leden van de Nationale Vereniging 
voor lupus, APS, sclerodermie en MCTD (NVLE) met SSc werden gevraagd een 
anonieme vragenlijst in te vullen over zorggebruik, kwaliteit van de zorg, en kwaliteit 
van leven. Er namen 198 patiënten met SSc deel aan deze cross-sectionele studie, 
waarvan 95% aangaf tenminste met één medisch specialist contact te hebben gehad 
in de afgelopen 12 maanden en twee derde tenminste met één health professional. 
De mediaan van het aantal verschillende zorgverleners waarmee patiënten contact 
hebben gehad was 8 sinds de diagnose en 4 in het afgelopen jaar. De mediaan van 
het aantal bezoeken naar medisch specialisten en health professionals in de afgelopen 
12 maanden was respectievelijk 7 en 7.5. Patiënten met een partner, een slechtere 
fysieke gezondheid, die minder vermoeidheid rapporteerden en meer pijn, bezochten 
vaker een zorgverlener. De betrokkenheid van meer verschillende zorgverleners was 
geassocieerd met minder tevredenheid over de samenwerking en afstemming van de 
zorg. Geconcludeerd kon worden dat het zorggebruik van Nederlandse patiënten met 
SSc substantieel is. Dit blijkt zowel uit het aantal bezoeken als het aantal verschillende 
zorgverleners. Patiënten waren minder tevreden over de afstemming van de zorg als 
er meer verschillende zorgverleners bij de zorg betrokken waren. Dit impliceert dat, 
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in het bijzonder voor mensen met complexe aandoeningen die zorg ontvangen van 
meerdere zorgverleners, aandacht moet worden besteed aan de afstemming van de 
zorg, inclusief de communicatie tussen zorgverleners.
Om inzicht te krijgen in welke zorg paramedici in de praktijk verlenen aan patiënten 
met SSc werd in hoofdstuk 6 een internetvragenlijst onder Europese paramedici 
die patiënten met SSc behandelen afgenomen. De vragenlijst bestond uit gesloten 
vragen over doorverwijzingen, een vooraf gedefinieerde lijst met behandeldoelen 
en educatiebehoeften. Daarnaast werd een open vraag gebruikt om de redenen van 
doorverwijzing te inventariseren die vervolgens gecodeerd werden tot een domein van 
de Internationale Classificatie van Functioneren (ICF). Tenslotte, konden paramedici 
op een lijst met 69 interventies aangeven welke interventies zij toepassen bij patiënten 
met SSc, waarbij ze ook interventies aan de lijst toe konden voegen. De vragenlijst 
werd ingevuld door 56 paramedici uit veertien verschillende Europese landen en zeven 
verschillende disciplines. Participanten rapporteerden 133 redenen van doorverwijzing, 
waarvan 72% gelinkt kon worden aan het ICF domein “lichaamsfuncties en structuren”, 
terwijl van de 681 gerapporteerde behandeldoelen er slechts 45% toebehoorden 
aan dit domein. In totaal werden er 105 verschillende interventies gerapporteerd 
om deze behandeldoelen aan te pakken. Bijna alle participanten (98%) gaven aan 
educatiebehoeften te hebben, met name naar de behandeling van stijfheid, pijn en 
beperkte handfunctie; deze onderwerpen werden door meer dan de helft van de 
respondenten genoemd. De resultaten van deze studie toonden aan dat de zorg 
geleverd door Europese paramedici aan patiënten met SSc zeer heterogeen is met 
betrekking tot de redenen van verwijzing, behandeldoelstellingen en de inhoud van 
interventies. De redenen van verwijzing en de behandeldoelstellingen lijken niet goed 
op elkaar afgestemd; dit suggereert dat de communicatie tussen medici en paramedici 
niet optimaal is.
In hoofdstuk 7 werd door middel van een systematische review van de literatuur een 
overzicht gegeven over de bewijskracht van de effectiviteit van niet-medicamenteuze 
interventies op het fysiek functioneren en psychologisch welbevinden bij patiënten 
met SSc. Er werden 23 studies geïncludeerd in de review, waarvan 9 gerandomiseerde 
gecontroleerde trials (RCTs), 4 gecontroleerde trials en 10 studies met een 
observationeel design. Drie van de drieëntwintig studies bleek van hoge kwaliteit te 
zijn, allen waren RCTs. Alle studies hadden een kleine steekproefgrootte die varieerden 
van 10 tot 53 participanten. In totaal werden er 16 verschillende niet-medicamenteuze 
interventies onderzocht op 17 verschillende uitkomstdomeinen. Handfunctie, 
beperkingen in activiteiten en kwaliteit van leven waren de meest frequent gebruikte 
uitkomstmaten. Vanwege de lage methodologische kwaliteit van de studies, de kleine 
steekproefgroottes, en de variabiliteit aan interventies en uitkomstdomeinen, was er 
onvoldoende bewijs om onderbouwde uitspraken te kunnen doen over de effectiviteit 
van niet-medicamenteuze behandelingen bij SSc.
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Met de studies in deze thesis is een bijdrage geleverd aan de geringe kennis 
die bestond over de niet-medicamenteuze zorg bij patiënten met SSc. We hebben 
aangetoond dat patiënten met SSc een breed scala aan symptomen ervaren waardoor 
verscheidene medische en paramedische zorgverleners betrokken zijn bij de zorg. 
De niet-medicamenteuze zorg die geleverd wordt door Europese paramedici is zeer 
heterogeen met betrekking tot redenen van verwijzing, behandeldoelen en interventies. 
Er is echter onvoldoende bewijskracht voor de effectiviteit van niet-medicamenteuze 
interventies. Middels nationale en internationale samenwerkingsverbanden dient 
er gedegen onderzoek te komen naar de effectiviteit van niet-medicamenteuze 
behandelingen zodat er in de toekomst evidence-based richtlijnen voor deze vorm 
van zorg opgesteld kunnen worden. Zolang daar nog geen sprake van is, dienen deze 
samenwerkingsverbanden ook een belangrijke rol te hebben in het ontwikkelen van 
practice-based richtlijnen voor de niet-medicamenteuze zorg, zodat de kwaliteit van 
de niet-medicamenteuze zorg voor patiënten met SSc geborgd is.
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Eindelijk kan ik zeggen ‘mijn proefschrift is af!’ Aangezien ik erg op zag tegen het 
schrijven van mijn master thesis, had ik nooit gedacht dat ik in het onderzoek zou 
belanden, laat staan een proefschrift zou schrijven. Dit heb ik dan ook aan veel mensen 
te danken. Ik wil graag iedereen bedanken die een bijdrage heeft geleverd aan de 
totstandkoming van dit proefschrift. Zonder iemand tekort te willen doen, wil ik graag 
enkele mensen in het bijzonder bedanken.
Allereerst natuurlijk de patiënten met systemische sclerose en de zorgverleners die 
hebben deelgenomen aan de verschillende studies en die de tijd hebben genomen om 
alle vragenlijsten in te vullen. Zonder jullie bijdrage had dit proefschrift nooit geschreven 
kunnen worden. In het bijzonder wil ik de patiëntenvereniging NVLE bedanken voor de 
betrokkenheid en financiering van de verschillende projecten, met name Joep Welling, 
Marja Kruithof, Jessica Thonen-Velthuizen en Lisa Kamphuis. Jullie waren altijd zeer 
toegankelijk, enthousiast in het meedenken en ondanks jullie aandoening maakten jullie 
een bewuste keuze om energie te willen steken in de projecten. Dit maakt dat ik onze 
samenwerking altijd als zeer prettig heb ervaren en ontzettend waardeer.
Graag wil ik mijn beide promotoren: Prof. dr. FHJ van den Hoogen en Prof. dr. 
TPM Vliet Vlieland, bedanken voor hun inzet en begeleiding bij het volbrengen van 
mijn proefschrift. Beste Frank, bedankt voor je betrokkenheid bij mijn promotie. Je 
(medische) inbreng heb ik als zeer waardevol beschouwd en je passie om de zorg voor 
patiënten met systemische sclerose te verbeteren is ook op mij overgeslagen. Deze 
passie heeft ervoor gezorgd dat ik tegenslagen overwon en altijd met veel plezier 
aan mijn projecten heb gewerkt. Beste Thea, je duidelijke visie en vragen naar wat ik 
over wilde brengen, hebben mij vooral in het eindstadium van mijn promotietraject 
erg geholpen. Daarnaast heeft je kritische feedback ervoor gezorgd dat de artikelen 
steeds beter werden dank daarvoor.
Mijn dank gaat tevens uit naar mijn copromotoren: Dr. CHM van den Ende en 
Dr. L Kwakkenbos. Beste Els, jouw dagelijkse begeleiding zorgde ervoor dat ik het 
overzicht kon bewaren. Indien ik toch even de weg kwijt was of niet meer wist hoe 
ik verder moest, opende jij weer deuren die mij houvast en energie gaven om weer 
hard aan de slag te gaan. Dank voor je vertrouwen en de kansen die jij mij hebt 
geboden om mijzelf te ontplooien als onderzoeker. Hierdoor heb ik meer vertrouwen 
gekregen in mijn kunnen, ben ik (iets) geduldiger geworden en deins ik niet meer 
achteruit voor ingewikkelde statistiek. Beste Linda, ik bewonder je gedrevenheid in 
het onderzoek en je manier van begeleiding geven. Je opbouwende en concrete 
feedback werkte stimulerend voor mij en het was daarom erg prettig dat je gedurende 
de laatste loodjes van het proefschrift weer in Nederland was. Daarnaast vond ik het 
ontzettend fijn dat je voor mij een soort “vraagbaak” was zodat ik gebruik kon maken 
van zowel je inhoudelijke kennis over systemische sclerose als je kennis over statistiek 
en methodologie.
De co-auteurs met wie ik samen heb mogen werken wil ik graag bedanken voor 
hun kritische blik waardoor de studies in dit proefschrift verbeterd zijn. Daarnaast wil 
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ik de leden van de manuscriptcommissie: Prof. dr. ACH Geurts, Prof. dr. AE Voskuyl, 
en Dr. JWJ Repping-Wuts, bedanken voor het beoordelen van mijn manuscript.
Natuurlijk wil ik ook mijn collega’s bedanken. Nienke, wij zaten in hetzelfde schuitje 
aangezien onze promotietrajecten bijna gelijktijdig liepen. De laatste twee jaar hebben 
wij samen een werkkamer gedeeld en dit zorgde voor veel plezier in mijn werk. Naast 
hard werken, hebben we veel gelachen, gekletst en thee gedronken. Je bent een 
geweldige collega! Je proefschrift is prachtig geworden daar mag je trots op zijn. 
Ik wens je heel veel succes met je verdere loopbaan en hoop dat we onze gezellige 
etentjes samen met Agnes voort blijven zetten. Aniek, ik heb erg genoten van onze 
wandelingen op de berg waar we lekker een frisse neus haalden en naast werk ook 
privé zaken deelden. Ik heb veel bewondering voor je, met name hoe jij het weet bol 
te werken om alles draaiende te  houden met twee verschillende banen en de vele 
kilometers die je aflegt om naar Nijmegen te komen. Sinds kort is duidelijk geworden 
dat je start met een promotietraject, ik wil je hiermee veel succes en plezier wensen! 
Vera, Ellen, Michiel, Joke, Charlotte en oud-collega’s Mirelle, Agnes, Thomas, Hanneke 
en Dicky bedankt voor de gezellige lunches en fijne werksfeer.
Graag wil ik ook alle andere onderzoekers bedanken voor hun input tijdens 
werkoverleggen, kunst van het schrijven, de researchlunch en natuurlijk voor de 
gezelligheid bij de schrijfdagen en congressen. Daarnaast zijn er nog andere collega’s 
die ik graag bij naam wil noemen dat zijn Hanneke, Toon en Helma. Mijn loopbaan bij 
de Sint Maartenskliniek begon namelijk toen ik op het Ambulant Reumacentrum de 
gelegenheid kreeg om mijn masterstage te lopen. In een zeer veilige en stimulerende 
leeromgeving met jullie als geweldige rolmodellen, heb ik mezelf als psycholoog kunnen 
ontwikkelen en ben ik geënthousiasmeerd geraakt voor de medische psychologie. 
Hiervoor wil ik jullie in het bijzonder bedanken.
Zonder mijn familie en vrienden was het me niet gelukt om dit resultaat te bereiken. 
Mijn vriendinnen: Loes, sophie, Lonneke, Laura, Priscilla, Patty, Miep en Moniek, 
jullie partners en vele andere vrienden bedankt dat jullie voor de nodige ontspanning, 
gezellige feestjes, etentjes en carnaval- en kermisavonden hebben gezorgd. Paulie, 
op de middelbare school waren we onafscheidelijk. Wat is het fijn dat we al die jaren 
contact hebben gehouden en om te weten dat je er altijd voor me bent. Onze gezellige 
gesprekken, uitjes en etentjes zou ik voor geen goud willen missen. Marjolein, onze 
vriendschap gaat ook al ver terug. Wij leerden elkaar kennen bij ons bijbaantje. Naast 
het snijden van kaas en vleeswaren was er gelukkig voldoende ruimte om mee te zingen 
met de muziek, gek te doen in de koelcel en vooral veel te kletsen. Ik zou me geen 
betere vriendinnen kunnen wensen!
Mijn lieve familie, jullie steun en vertrouwen hebben er aan bijgedragen dat dit 
proefschrift er is. sonja en Inge, mijn lieve zusjes, ik ben blij dat we zo een ontzettend 
hechte band hebben. son, jij bent mijn grote zus tegen wie ik altijd op heb gekeken 
(en dat doe ik nog steeds), jij hebt me gestimuleerd om het beste uit mezelf te halen. 
Ik ben trots op jou als zus en paranimf. Pinkie ik ben ook heel trots op jou, jij bent 
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mijn kleine zusje en ik vind het heerlijk dat ik met jou lekker ongegeneerd gek kan 
doen. Ik kan met jullie alles delen en hoop dat dit nooit veranderd. Joost en Ivo jullie 
zijn de beste zwagers die ik me kan wensen! Mijn allerliefste neefjes siem en Pim, ik 
vind het heerlijk om op jullie op te passen, met jullie te spelen en mezelf voor schut 
te zetten om jullie aan het lachen te krijgen. Ik heb altijd gezegd ‘tante’ is de mooiste 
titel die ik heb! Pap en Mam, jullie kennen mij als geen ander en hebben mij zien 
ontwikkelen van een verlegen en onzeker meisje naar een zelfverzekerde jonge vrouw. 
Hierin hebben jullie een grote rol gespeeld. Bedankt dat jullie er altijd voor mij zijn, 
voor jullie vertrouwen, luisterend oor, onvoorwaardelijke steun en liefde. Een beter thuis 
kan ik me niet wensen. Ik hou van jullie! Pap, ik ben trots dat jij mijn paranimf wilt zijn. 
Gea, Roel en Esther, ik ben ontzettend blij met jullie als schoonfamilie.
De laatste regels wil ik graag richten aan mijn man Armin. Ik wil je bedanken voor je 
geduld, steun en begrip tijdens, maar met name tegen het eind van het promotietraject. 
Onze wittebroodsweken heb ik meer op het werk doorgebracht dan dat ik thuis 
aanwezig was doordat het eind van het promotietraject in zicht was. Ik ben trots dat ik 
vorig jaar je vrouw ben geworden en hoop op nog heel veel mooie jaren samen! 
          
       - Linda -
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Linda Eulen-Willems werd op 13 augustus 1987 geboren te Nijmegen. In 2005 behaalde 
zij haar VWO diploma aan het Lindenholt College te Nijmegen, tegenwoordig het 
Mondial College, waarna ze in datzelfde jaar begon met de opleiding psychologie, 
met afstudeerrichting klinische psychologie, aan de Radboud Universiteit Nijmegen. 
Van september 2008 tot en met februari 2009 liep zij haar klinische masterstage op het 
Ambulant Reumacentrum van de Sint Maartenskliniek te Nijmegen. Alwaar zij in 2009 
tot 2011 diverse vervangingstaken op zich heeft genomen (o.a. een ouderschapsverlof 
en een ziekteverlof). April 2010 rondde zij haar master thesis af en behaalde ze haar 
diploma. Naast de vervangingstaken op het Ambulant Reumacentrum, was Linda sinds 
juli 2010 ook werkzaam als onderzoeksassistent op de afdeling Reumaresearch in de 
Sint Maartenskliniek. Dit mondde uit in een promotietraject waarin zij begeleid werd 
door dr. Els van den Ende, dr. Linda Kwakkenbos, Prof. dr. Thea Vliet Vlieland en Prof. 
dr. Frank van den Hoogen, waarvan dit proefschrift het resultaat is. Linda Eulen-Willems 
woont in Ewijk en is getrouwd met Armin Eulen. 
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